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ABSTRACT 
FACILITATING AND ENHANCING BIOMEDICAL KNOWLEDGE 
TRANSLATION: AN IN SILICO APPROACH TO PATIENT-CENTERED  
PHARMACOGENOMIC OUTCOMES RESEARCH 
 
by 
 
Kourosh Ravvaz 
 
The University of Wisconsin-Milwaukee, 2015 
Under the Supervision of Professor Peter J Tonellato 
 
 
Current research paradigms such as traditional randomized control trials 
mostly rely on relatively narrow efficacy data which results in high internal 
validity and low external validity. Given this fact and the need to address 
many complex real-world healthcare questions in short periods of time, 
alternative research designs and approaches should be considered in 
translational research. In silico modeling studies, along with longitudinal 
observational studies, are considered as appropriate feasible means to 
address the slow pace of translational research. Taking into consideration this 
fact, there is a need for an approach that tests newly discovered gene 
variants, via an in silico enhanced translational research model (iS-TR) to 
conduct patient-centered outcomes research and comparative effectiveness 
research studies (PCOR CER). 
In this dissertation, it was hypothesized that retrospective EMR analysis and 
subsequent mathematical modeling and simulation prediction could facilitate 
and accelerate the process of generating and translating pharmacogenomic 
knowledge on comparative effectiveness of anticoagulation treatment plan(s) 
tailored to well defined target populations which eventually results in a 
decrease in overall adverse risk and improve individual and population 
iii 
 
outcomes. To test this hypothesis, a simulation modeling framework (iS-TR) 
was proposed which takes advantage of the value of longitudinal electronic 
medical records (EMRs) to provide an effective approach to translate 
pharmacogenomic anticoagulation knowledge and conduct PCOR CER 
studies. 
The accuracy of the model was demonstrated by reproducing the outcomes of 
two major randomized clinical trials for individualizing warfarin dosing. A 
substantial, hospital healthcare use case that demonstrates the value of iS-TR 
when addressing real world anticoagulation PCOR CER challenges was also 
presented. 
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1.1.) Statement of the Problem 
Translational research in genomics aims to move promising genomic 
applications to clinical and public health practice for population health benefit 
(Cleeren, 2011). Despite demonstrable health benefits of many new genomic 
discoveries, there remain large barriers between the explosive growth of 
healthcare related scientific discovery and dramatic improvements in 
technology and the implementation of this new knowledge and technology to 
improve health outcomes. There is great optimism that systematic 
translational research will address these gaps and remove these barriers 
while appropriately evolving patient-centered care practice to improve the 
health of individuals and populations (Glasgow, 2012; Waldman, 2010).   
A fifteen year study to evaluate predictors of and time required for the 
translation of highly promising basic research into clinical applications, 
showed that only about 5% of the basic science findings were licensed for 
clinical use and only 1% were extensively used for licensed indications 
(Contopoulos-Ioannidis, 2003). 
Since the completion of the Human Genome Project in 2003 (Collins, 2003), 
advances in genetic science discoveries have led to mounting expectations in 
regard to their impact on health care and disease prevention. Translating 
genetic discoveries into lab tests, improved individual care and ultimately into 
public health improvements, has emerged as an important, but difficult, 
objective in biomedical research. It is widely recognized that the current 
translational process is slow, very expensive and often results in an 
incomplete transfer of research findings into practice, and consequently failure 
of comparative effectiveness studies used to translate the findings into 
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substantial changes in patient care and health disparities (Khoury, 2007). 
Although pharmacogenomics is one of the first clinical applications of the new 
genomic era, so far, few human genomic discoveries have led to evidence-
based applications for medicine and public health and its implementation in 
clinical practice still involves significant challenges (Swen, 2007; Burke, 
2006). 
The delay in systematic use of the rapidly expanding collection of clinically 
valuable genomic discoveries is created by significant problems in the clinical 
research enterprise including the lack of clinical and biomedical informatic 
methods, tools and infrastructure required to facilitate the successful 
translation of the discoveries to practical clinical use. To date, the primary 
focus of initiatives is to improve the technology, clinical science collaboration 
and training, and methodologies supporting rapid discovery and regulatory 
approval of genetic, genomic, and biological markers, associations, and 
targets. However, efforts to translate discoveries and processes to generate 
and evaluate evidence in genomic areas (e.g., pharmacogenomics) require 
prohibitively expensive clinical trial and clinical study validation that are 
severely hindered by regulatory, technical and validation barriers not easily 
conducted using current clinical-research or clinical enterprise environments.  
As an example of these conundrum, highly-sensitive pharmacogenomic (PGx) 
tests that detect variant alleles combined with increasing genomic knowledge 
offer physicians the ability to individualize a patient’s drug treatment. If 
pharmacogenomic treatment is successful, one anticipates a large reduction 
in adverse drug reactions leading to improved patient care, improved 
outcomes, reduced treatment periods, and overall lower costs. 
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One notable case is the estimation of initial and managing the maintenance 
dose of warfarin, the most commonly prescribed oral anticoagulant for the 
treatment and prevention of thromboembolic events. Many studies have 
proven warfarin’s effectiveness for the prevention of recurrent stroke, 
ischemic stroke in patients with atrial fibrillation, thromboembolism in patients 
with mechanical prosthetic heart valves, and myocardial infarction in patients 
with coronary artery disease (Reynolds, 2007). Warfarin is also effective for 
the prevention of pulmonary embolism (PE) and deep venous 
thromboembolism (DVT) in patients requiring orthopedic surgery and in those 
with a history significant for venous or arterial thromboembolism. Although 
warfarin remains the therapy of choice, its narrow therapeutic index creates 
challenges for proper management of anticoagulation, as maintaining the 
balance of sufficient dosage to prevent thromboembolism while avoiding 
overdosing to prevent bleeding events is critical. The correct initial dose of 
warfarin differs widely between individuals with intra-individual variability 
contributions from factors including age, gender, race, body size, drug 
interactions, genetics (i.e., mainly VKORC1 and CYP2C9 genes) and 
compliance. The challenge of warfarin dosing and promise of 
pharmacogenomics (PGx) have resulted in tens of dosing algorithms including 
a large number of PGx-based warfarin dosing algorithms. 
To date, PGx-based dosing algorithms have not been adequately tested for 
their impact on clinical outcomes across large hospital diverse patient 
populations in prospective, controlled trials as it is extremely expensive and 
time-consuming to conduct the full array of clinical trials required to test and 
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identify the correct combination of genotypes, phenotypes, clinical and 
personal data necessary to accurately model drug response, test treatment 
options and produce the optimal protocol. For example, in most clinical trials 
the study population is dominated by a specific racial or sub-population group 
(e.g., about 95% of CoumaGen-I & II study populations were white) which 
leads to questions on the effectiveness of the PGx testing for different sub-
populations and also failure of comparative effectiveness studies and health 
disparities. Accordingly, there is insufficient evidence, at this time, to 
recommend for or against routine CYP2C9 and VKORC1 testing in patients 
under warfarin. Consequently, the use of PGx testing in clinical practices has 
remained limited. In short, the translation of pharmacogenomic knowledge to 
clinical practices is associated with challenges and no practical approach to 
identify the optimal anticoagulation treatment plan exists for large 
heterogeneous patient populations that accounts for individual risk factors, 
drug and protocol options, and achieves minimal risk to adverse reactions.  
1.2.) Translational Research, Patient-Centered Outcomes 
Research and Comparative Effectiveness 
As mentioned, translational research is designed to move knowledge gained 
from the basic sciences to its application into clinical and community settings 
thus improving healthcare outcomes. This process is usually described in 
phases of translation (i.e., "T-phases"). Recognizing that there are a number 
of ways to frame the phases, a 5-phase model of translational research 
process proceeds in iterative and bidirectional phases, research to identify a 
problem and the discovery of an opportunity or approach to tackle a health 
issue (T0), research involves basic genome-based discoveries to develop 
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promising applications such as tests and drugs (T1), research involves 
evaluating efficacy of such applications and developing evidence-based 
recommendations (T2), research includes investigations designed to increase 
uptake and implementation of evidence-based recommendations into practice 
and public health programs (T3), and research involves evaluation of the 
effectiveness and cost-effectiveness of genomic applications in the "real 
world" and in diverse populations (T4) (Khoury, 2012). The translation process 
is guided by ongoing and updated knowledge synthesis and translation that 
applies to all phases of translation (Khoury, 2010). 
Focusing on these phases, each of which addresses different issues and 
requires somewhat different methods, provides greater clarity about what is 
needed if evidence-based approaches are to be successfully implemented 
and sustained in real-world settings. One of the main methods used in almost 
all phases from T2 through T4 is conducting clinical trials. Given the 
complexity and cost of clinical trials, most funded and published genomic 
research remains in the early phases of translation (Schully, 2012). 
Consequently, the evidence base for genomics in practice remains limited.  
In the light of existing challenges in translating pharmacogenetic knowledge of 
anticoagulants and given the burden of managing anticoagulation therapy 
using medications with high and variable adverse event risks across diverse 
populations, there is a clear need for prospective clinical trials that provide 
direct evidence of the benefits, disadvantages, and costs associated with the 
genetic testing in the setting of warfarin dosing as well as patient-centered 
outcomes research and comparative effectiveness studies (PCOR CER). 
PCOR CER studies are to assist patients, clinicians, and other stakeholders in 
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making informed decisions by advancing the quality and relevance of 
evidence concerning the manner in which anticoagulation therapy can 
effectively and appropriately be managed through research and evidence 
synthesis that considers variations in patient subpopulations and the 
dissemination of research findings with respect to the relative health 
outcomes, clinical effectiveness, and appropriateness of the medical 
treatments.  
Comparative effectiveness research (CER), as a main practical approach to 
the PCOR, is defined by the Institute of Medicine as "the generation and 
synthesis of evidence that compares the benefits and harms of alternative 
methods to prevent, diagnose, treat, and monitor a clinical condition or to 
improve the delivery of care” (IOM, 2009). In the context of anticoagulation 
therapy, PCOR CER studies could address questions such as: "Given my 
personal characteristics, conditions and preferences, what should I expect 
from different anticoagulation therapy protocols?", "What are my 
anticoagulation therapy options and what are the potential benefits and harms 
of those options?", "What can I do to improve the outcomes of my 
anticoagulation therapy given my health condition?", and "How can clinicians 
and the care delivery systems they work in help me make the best decisions 
about my anticoagulation-related health?" (PCORI, 2014). 
1.3.) An In Silico Translational Research Model for 
Patient-Centered Outcomes Research and Comparative 
Effectiveness Studies 
Current research paradigms such as traditional randomized control trials 
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mostly rely on relatively narrow efficacy data which results in high internal 
validity (i.e., extent to which systematic error, bias, is minimized in clinical 
trials under optimal conditions) and low external validity (i.e., extent to which 
results of trials provide a correct basis for generalization to other 
circumstances) (Glasgow, 2012; Nelson, 2006; Juni, 2001; Kessler, 2011). 
Given this fact and the need to address many complex real-world healthcare 
questions in short periods of time, alternative research designs and 
approaches should be considered in translational research. In silico modeling 
studies, along with longitudinal observational studies, are considered as 
appropriate feasible means to address the slow pace of translational research 
(Glasgow, 2012). Taking into consideration this fact, there is a need for an 
approach that tests newly discovered genetic variants, via an in silico 
enhanced translational research model (iS-TR) to conduct patient-centered 
outcomes research and comparative effectiveness studies (Figure 1.1). 
 
 
9 
 
 
 
1.4.) Objective of this work: 
In this dissertation, we hypothesize that retrospective EMR analysis and 
subsequent mathematical modeling and simulation prediction can facilitate 
and accelerate the process of generating and translating pharmacogenomic 
knowledge on comparative effectiveness of anticoagulation treatment plan(s) 
tailored to well defined target populations which eventually results in a 
decrease in overall adverse risk and improve individual and population 
outcomes. To test this hypothesis, we present a simulation modeling 
framework, in silico enhanced model of translational research (iS-TR), which 
takes advantage of the value of longitudinal electronic medical records 
(EMRs) to provide an effective approach to translate pharmacogenomic 
anticoagulation knowledge and conduct PCOR CER studies. 
We, first, introduce “iS-TR”, a translational research model enhanced with in 
silico knowledge synthesis that expedites testing newly discovered genetic 
variants and eventually facilitates conducting PCOR CER studies (Figure 1.1). 
Second, we demonstrate the accuracy of the framework by reproducing the 
Figure 1.1. Conceptual framework of iS-TR: an iterative and 
bidirectional translational research framework enhanced 
with an in Silico knowledge synthesis platform to facilitate 
pharmacogenetic PCOR and CER studies. 
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outcomes of two major randomized and clinical effectiveness trials of 
CoumaGen I and II comparing pharmacogenetic algorithms and standard care 
for individualizing warfarin dosing. Third, we present a substantial, hospital 
healthcare Use Case that demonstrates that the value of iS-TR when 
addressing real world anticoagulation PCOR CER challenges.  
1.5.) Organization of the Dissertation 
This dissertation consists of 7 chapters. An introductory chapter presents the 
statement of problem and the objectives. 
Chapter 2 presents a background on models of translational research, our in 
silico enhanced model of translational research (iS-TR), anticoagulation and 
anticlotting, pharmacogenetics, in silico clinical trial studies, and application of 
the iS-TR to a patient-centered pharmacogenetic outcomes research problem, 
Chapter 3 describes the details of our in silico translational model of genetics 
testing in patient-centered anticoagulation outcomes research, 
Chapter 4 focuses on the details of development of an EMR-based 
longitudinal comparative effectiveness anticoagulation/anticlotting research 
database, 
Chapter 5 describes a few in silico translational research pharmacogenetic 
comparative effectiveness studies using iS-TR, 
Chapter 6 presents a PCOR CER study conducted using iS-TR and WiAD to 
address warfarin therapy differences in different subpopulations, 
Chapter 7 contains a summary of the important results and conclusions and it 
also discusses directions for future work in this area using in siIico 
translational research. 
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2.1.) Translational Research 
The progression of scientific knowledge that advances discoveries from 
“bench to bedside” occurs through a process called translation. The term 
“translation” which defines and describes the advancement of knowledge 
through multiple successive phases of research transformation from basic 
scientific discoveries to public health impact is a complex process that 
involves different resources and actions and requires both research (e.g., 
bench-work and clinical trials) and nonresearch activities (e.g., 
implementation) (Drolet, 2011). The application of findings derived in basic 
science to the development of new understanding of disease mechanisms, 
diagnoses, and therapeutics in humans is known as “Translational Research” 
(Nathan, 2002). Despite an ongoing discussion on the number and nature and 
stages of translational research, the general consensus is that translational 
research involves highly iterative and interrelated stages of research in 
advancing from scientific discoveries to population health (Glasgow, 2012).  
In this section, we review the current models and terminology of translation 
and translation research. We consider the widely adopted models of 
translational research that have been proposed for different areas of medicine 
and public health and investigate its applicability to genomic medicine using 
some examples.  
Although the gap between bench and bedside and knowledge translation 
have been discussed in the last few decades, the translation process has 
been at the center of attention in biomedical science for only last few years. 
The Institute of Medicine (IOM) acknowledged the difficulty and importance of 
translating basic scientific discoveries to clinical applications in its 2001 
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“Crossing the Quality Chasm” report (Institute of Medicine, 2001). In 2003, the 
National Institutes of Health (NIH) Roadmap was announced in which 
translation research was a prominent component (Zerhouni, 2003). Through 
the Roadmap, many significant programs and major grant efforts have been 
funded by the NIH to expedite the process and translation. In spite of billions 
of dollars invested by the NIH to fund basic science research each year, the 
rate of translation of the results of these research studies into clinical practice 
has been low and slow. The results of a study on the translation of basic 
science shows that less than 25% of highly promising biomedical discoveries 
resulted in at least one published positive randomized clinical trial and less 
than 5% were established in clinical practice within 20 years (Contopoulos-
Ioannidis, 2003). Only 14% of new scientific discoveries entered day-to-day 
practice and the translation took an average of 17 years (Westfall, 2007). For 
instance, one study showed that 15 years after successful clinical trials on 
beta blockers for patients recovering from myocardial infarction, these 
medications were prescribed for only 62% of patients (Lenfant, 2003). The low 
percentage of translation, long translational time periods, and low practical 
implementation would likely be reduced and improved if a known process and 
clear model of translation of basic science into clinical practice existed and 
was used. It is vital to identify the continuum of knowledge translation from the 
laboratory to the point of care. Without having enough understanding of this 
process, knowledge gets lost in translation and it is difficult to improve the 
quality of translation and therefore to reach public health gains. 
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2.1.1.) Models of Translational Research 
The IOM Translational Research Model: 
In 2003, the US Institute of Medicine (IOM) put forth the principles and a 
model for translational research. Their translation model (“Clinical Research 
Continuum”, CRC) consists of a two-phase process: 
1- From basic science to clinical science and 
2- From clinical science to public health impact. 
The CRC model is based on different perceptions of basic science 
researchers and public health agencies on translational research. The first 
group believes that translational research involves "the transfer of new 
understandings of disease mechanisms gained in the laboratory into the 
development of new methods for diagnosis, therapy, and prevention and their 
first testing in humans" (Sung, 2003). The second group tends to view 
translational research as "the translation of results from clinical studies into 
everyday clinical practice and health decision making" (Sung, 2003). IOM 
refers to the first phase as "T1" translational research (translation of basic 
Figure 2.1. The 2 Translational Blocks in the Clinical Research Continuum 
(Sung, 2003). 
17 
 
 
 
research into clinical application) and the second phase as "T2" research 
(clinical application to evidence-based practice guidelines).  
They also identified “Translational Blocks” acting as obstacles in the clinical 
research continuum in their framework (Figure 2.1). 
“Blue Highways” on the NIH Roadmap: 
While the standard NIH Roadmap for Medical Research included two major 
laboratories (bench and bedside) and two above translational steps, Westfall 
et al., in 2007, divided the second phase into two separate phases resulting in 
a three-phase translational research model (Figure 2.2) (Westfall, 2007): 
1- Basic science to clinical science (T1) 
2- Clinical practice (T2) 
3- Health improvement (T3) 
The following figure displaying this model includes examples of the types of 
research common in each research laboratory and translational step. 
As illustrated in the above figure, the proposed expansion of the NIH 
Roadmap (blue) consists of (1) an additional research paradigm (Practice-
based Research) and (2) a translational step (T3) to improve dissemination 
Figure 2.2. Expansion on the NIH Roadmap (Westfall, 2007). 
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and implementation of research discoveries into clinical practice as the 
endpoint of the process. 
The 3T's Road Map: 
Taking into consideration the need for expediting the process of translating 
and implementing discoveries into clinical settings, a three-phase model of 
translational research has been offered by Dougherty et al., which addresses 
the "how" of health care delivery (Figure 2.3) (Dougherty, 2008). 
This model moves from basic biomedical science to clinical efficacy 
knowledge (T1). Then, T2 translation focusing on outcomes and comparative 
effectiveness research results in clinical effectiveness, and patient-centered 
knowledge and evidence which helps develop individualized treatment plans, 
more effective "practice guidelines and tools for patients, clinicians and policy 
makers". 
T3 translation activities focus on how new evidence-based treatment, and 
prevention plans and other interventions are rapidly and reliably incorporated 
into day-to-day clinical practice and aligned across all levels of the health care 
system. This phase of translation aimed to improve the health of individuals 
and populations is accomplished by conducting research in domains such as 
Figure 2.3. The 3T's Road Map - Double-headed arrows represent the 
essential need for feedback loops between and across the phases of the 
translational research process (Dougherty, 2008). 
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measurements, dissemination, and implementation of interventions and 
healthcare delivery. Policy change is a major component of T3 activities 
required to enhance health outcomes. In this model, the translational steps 
T1, T2, and T3 built on each other proceed to improve healthcare delivery 
over time. This model also includes feedback loops (as represented by the 
bidirectional arrows in Figure 2.3) to explicitly emphasize on the importance of 
the bidirectional nature of translational research process.  
Biomedical Research Translation Continuum: 
Since Drolet et al. believed that none of the prior translation models was 
unambiguous and the terminology remained indistinct to both researchers and 
physicians, they proposed a model to define and solidify the concepts and 
terminology of translation. They called their model “the Biomedical Research 
Translation Continuum” (Figure 2.4) (Drolet, 2011). 
This model has 4 practical landmarks separated by gaps called "Translation 
Chasms". These chasms represent periods in which translation activities are 
required to fill the gaps between the phases of research continuum. In the 
illustration of the model (Figure 2.4), the "zone of translation" depicts the 
collection of translational tasks that have to be conducted to reach public 
health impact. 
The underlying idea for this model is that a biomedical translation research 
continuum starts with basic science discoveries that are supposed to be 
translated to create potential clinical uses. The initial step involves the first 
translation chasm (T1) in which the basic science discoveries are interpreted 
in the context of human medical applications. In most cases, addressing T1 
chasm requires in vitro laboratory studies and animal models. This is 
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especially the case for genetic scientific discoveries. So, any new basic 
discovery entering the continuum is going to be interpreted and translated to 
human medical applications. The other translation chasms are also bridged 
similarly. For the T2 chasm, potential human applications are followed by 
studies such as clinical trials on animal models and humans. In this phase, 
the safety and efficacy of the interventions based on the new medical 
applications are evaluated. The output of this phase is proven clinical 
applications which are going to be implemented and adopted in clinical 
practice through bridging the T3 chasm. The ultimate goal is to make positive 
impacts on public health.  
To see a complete picture of the translation continuum, they have brought up 
two examples to examine the entire translation continuum retrospectively. 
First, it is the example of aspirin for a specific medical application as a 
medication administered after myocardial infarction (MI) to decrease morbidity 
and mortality. In this case, initially basic science knowledge from laboratory 
discoveries (i.e., "acetylsalicylic acid inhibits prostaglandin synthesis") has to 
be translated to proven clinical practice (administration of aspirin after MI), 
and, eventually, to individual and public health impacts (decreased mortality). 
In this process, initially, basic science knowledge has to be translated to a 
medicine. It happens by bridging the T1 chasm. To cross the first translational 
chasm (T1), the potential human applications of the medication aspirin should 
be identified ("Aspirin inhibits platelet aggregation in vivo via inhibition of 
prostaglandin synthesis") and also biochemical mechanisms that the 
medication functions in vivo has to be studied in laboratory investigations.  
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The next step which comes after development of a human application (e.g., 
"Aspirin prevents post-MI thrombosis by inhibiting platelet aggregation") is to 
test the safety and efficacy of the medication by conducting clinical research 
studies such as clinical trials. This translational study crosses the second 
chasm (T2).   
Once the effectiveness of aspirin in decreasing post-MI thrombosis and 
mortality is demonstrated through clinical trial studies, the medication could be 
implemented and adopted in clinical practice by bridging the third translational 
chasm (T3). Then, through practice-based research studies, the public health 
impact of aspirin should be investigated to find out if administering this 
medication after MI reduces the rate of morbidity and mortality in the 
population. In this translational model also, the process of translation is 
bidirectional and “bedside to bench” feedback loops are considered as means 
to allow integration of new knowledge and also continual improvement of 
translation process.   
The second example is about the administration of beta blockers after MI 
which is well depicted in the following table (Table 2.1). 
 
Figure 2.4. Biomedical Research Translation Continuum (Drolet, 2011) 
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Table 2.1. Research Translation Continuum for the administration of beta 
blockers after MI (Drolet, 2011). 
 
The Continuum of Translation Research in Genomic Medicine: 
In the current omics era, it is believed that recent improvements and 
advances in human genomics and related fields would lead in the future to (1) 
accelerating the use of new biomarkers derived from gene expression, 
proteomic, and other omic technologies, and (2) more genomic applications 
for personalized medicine and disease prevention. Although, there is currently 
a high interest in evaluating genetic variants for their association with common 
chronic diseases, however, the rate of use of genetic tests in clinical practice 
and clinical research has increased at a slow pace in last few years (Pagon 
2006). To expedite moving genomic discoveries into practice and the delivery 
of population-level health benefit, Khoury et al. have proposed a translational 
model that classifies genomic translational research into the four following 
multidisciplinary phases of translation (Khoury, 2007): 
1- from gene discovery to candidate health applications (T1), 
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2- from health applications to evidence-based guidelines (T2), 
3- from evidence-based guidelines to health practice (T3), 
4- from practice to population health impact (T4). 
Their phase 4 (one more phase to the Westfall’s model) represents the 
population-level evaluation of health outcomes (Figure 2.5). 
Although the four phase-array of translational research proposed by Khoury et 
al. seems to be a linear process, however, this process takes advantage of 
feedback loops and it is likely that similar types of research (e.g., clinical trials, 
observational studies) are conducted in different phases.  
They have also offered the detailed definitions of some terms used in 
translational research models (Table 2.2). 
 
Figure 2.5. The continuum of translation research in genomic 
medicine. HuGE, human genome epidemiology; ACCE, analytic 
validity, clinical validity, clinical utility, ethical, legal, and social issues. 
(Khoury, 2007) 
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Translational Research and Knowledge Integration: 
Glasgow et al., in 2012, argued that although there are “significant advances 
in treatments, the public health benefits associated with these improved 
Table 2.2. Glossary of certain types of “translation research” 
involving multiple scientific disciplines (Khoury, 2007). 
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treatments tend to be modest because they are not widely implemented” 
(Glasgow, 2012). Accordingly, they believe there should be more focus on 
some aspects of dissemination and implementation research (rigor and 
relevance, efficiency, collaboration, improved capacity, and cumulative 
knowledge) to be able to accelerate and improve the appropriate integration 
of basic science and genomic discoveries into health care and disease 
prevention. Consequently, this prohibits incomplete classification of translation 
which might result in missing influential and in essence different tasks that 
have to be addressed in the later stages of translation, “dissemination” and 
“implementation”.  
To address this need, they have proposed a different translational research 
model with a more differentiated approach to the science of dissemination and 
implementation (Figure 2.6). Rather than a linear process of translating 
research findings into practice, they have framed the phases of translational 
research as a 5-phase model in which research moves into practice and 
policy. Having known that research in essence is not a one-way process, they 
also believe findings at any phase can impact the other phases and the 
translational process is a highly iterative cycle. These 5 overlapping, 
interrelated phases span a diverse array of research disciplines, methods and 
activities needed to move basic science discoveries to population health. 
Each phase moves to progressively broader settings over time and addresses 
different questions and requires somewhat different methods to successfully 
implement and sustain evidence-based approaches in real-world settings. 
Basically, this 5-phase model shows the complexity of translational research 
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and its inter- and transdisciplinary nature which requires collaboration among 
partners from basic, clinical, population sciences as well as communities.    
In the T0 phase, unaddressed health issues and opportunities and the 
potential scientific approaches to tackle them are identified. Basically, the 
scientific approaches and discoveries could be derived from multiple 
disciplines such as molecular, biological, genomic, behavioral, and 
epidemiological research studies. Then, it is followed by the T1 phase in 
which promising interventions (e.g., clinical tests, drugs, behavioral, and 
organizational interventions or policy changes) are tested. In the next phase 
(T2), the focus is on finding the effectiveness of the new developed 
interventions and whether they positively impact health outcomes. Different 
study designs (e.g., clinical trials) and analysis methods are used during this 
second research phase to create evidence-based recommendations, policies, 
and guidelines published by respective professional associations and groups. 
As mentioned in the earlier sections, NIH's primary focus has been on T1 and 
T2 research and it usually categorizes the activities during T3 and T4 
translational research phases under T2. In this model, the T3 phase includes 
research studies designed and conducted to scale up the implementation of 
evidence-based recommendations and guidelines into clinical practice 
settings. And finally, the T4 phase involves real-world evaluation of the 
population health outcomes of the interventions through different translational 
studies such as comparative effectiveness and cost effectiveness research 
studies. Glasgow et al. mainly focus on dissemination and implementation 
and highly believe in the importance of investigation and understanding of the 
processes involved in the adoption, implementation, and sustainability of 
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research. According to them, these translational processes and activities 
include “dissemination of interventions”, “decisions by healthcare practitioners 
or organizations to adopt or use the interventions”, “implementation of the 
interventions into standard practice or standard operating procedures of 
organizations”, and “maintenance of changes in health care practices by 
organizations, individual health care practitioners, and patients”. In their 
proposed cyclic model, the translational research process is fueled and 
directed by continuing and updated evidence and knowledge synthesis to 
guide dissemination and implementation research.    
2.2.) An In Silico Enhanced Model of Translational 
Research (iS-TR) 
Given the limitations of the other translational research models and the need 
to address many complex real-world healthcare questions in short period of 
Figure 2.6. 5-phase model of translational research guided by ongoing and 
updated knowledge synthesis and integration (Glasgow, 2012). 
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time, alternative research designs, approaches and models should be 
considered in translational research. In silico modeling studies, along with 
longitudinal observational studies, are considered as appropriate feasible 
means to address the slow pace of translational research (Glasgow, 2012). 
Taking into consideration this fact in the context of genomics and specifically 
pharmacogenomics, there is a need for an approach that tests newly 
discovered genetic variants, via an in silico enhanced translational research 
model (iS-TR) to conduct patient-centered outcomes research and 
comparative effectiveness studies (PCOR CER). Figure 2.7 depicts the 
conceptual framework of our proposed iS-TR which includes an iterative and 
bidirectional translational research framework enhanced with an in silico 
knowledge synthesis platform to facilitate pharmacogenetic PCOR and CER 
studies. Our model and its proposed applications are explained in the 
following sections. 
Figure 2.7. Conceptual framework of iS-TR  
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Based on the iS-TR model, we have developed an in silico translational 
research framework to facilitate and expedite the pharmacogenomic 
translational research. This framework consists of a few components including 
a longitudinal EMR-based anticoagulation research database, a database 
miner and analyzer, a population health knowledge base, an anticoagulation 
clinical trial simulator, and a CER Knowledge Base (Figure 2.8). In the 
following sections, the components of the framework are briefly described. 
Wisconsin Anticoagulation Database: WiAD  
To generate meaningful PCOR, researchers need high-quality data, including 
greater clinical detail, longitudinal follow-up, and linkages among data sets 
(Navathe, 2011). To advance research data infrastructure, University of 
Wisconsin-Milwaukee and Aurora Health Care Research Institute have 
collaborated on a multistage project to develop a retrospective EMR-based 
longitudinal anticoagulation clinical database (Wisconsin Anticoagulation 
Database: WiAD) being used for PCOR on most frequently prescribed 
Figure 2.8. In silico translational research framework: In Silico WiAD PCOR 
CER Framework. WiAD: Wisconsin Anticoagulation Database; ETL: Extract, 
Transform, Load. 
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anticoagulation agents such as Coumadin (Warfarin), Heparin, Ticlopidine 
(Ticlid), Clopidogrel (Plavix), Dipyridamole (Persantine), Abciximab (ReoPro), 
Eptifibatide (Integrilin), Tirofiban (Aggrastat), or and Dabigatran (Pradaxa). 
Aurora Health Care is the largest health care system in Wisconsin operating 
15 hospitals throughout the state with more than 3600 licensed beds, 172 
physician clinic facilities, and several other health care related entities. It 
serves about 1.2 million unique patients each year through 7.8 million patient 
encounters per year. So, such an anticoagulation research database 
representing Wisconsin State population has provided a powerful tool for 
conducting outcome research studies on anticoagulation dosing algorithms. 
The details of this database are described in chapter 4. 
WiAD-Miner and Analyzer: 
An interactive data profiling and population “segmentation” tool “WiAD-Miner 
and Analyzer” was developed and used to (a) facilitate the process of patient 
cohort selection using different demographic, clinical, temporal, and 
geographical inclusion criteria and (b) synthesize hypotheses. This tool also 
has some features which are specific to anticoagulation therapy such as a 
module which calculates the Time in Therapeutic Range (TTR) for each 
individual from the electronic medical record (EMR) data. WiAD-Miner’s 
details are covered in Chapter 4. 
Population Health Knowledge Base: 
WiAD is a database that includes data from a geographically widespread, 
diverse racial and demographic patient population across the state of 
Wisconsin. A knowledge base including health, demographic and 
socioeconomic characteristics of original populations of this patient population 
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provides a rich source of complementary information to be used in different 
ways for the EMR-based in silico PCOR CER studies such as (a) quality 
control and assurance in the process of transforming and integrating data into 
the WiAD, (b) generate more accurate virtual patients and patient populations 
by the clinical trial simulator, (c) generate more enriched hypothesis. The 
information in the knowledge base is provided from different sources such as 
the national, state, county and city census data, and state, county and city 
health reports. This details and usage of this knowledge base is demonstrated 
in chapters 5 and 6.    
Pharmacogenetic Clinical Trial Simulator:  
Our pharmacogenetic clinical trial simulator consists of the 5 following 
adjustable modeling components: 1) A Bayesian network model (BNM) to 
produce virtual patient population (“Clinical Avatars”) consistent with desired 
target populations, 2) A dose calculator which calculates an initial dose 
(clinical and PG-based) for each virtual patient, 3) An INR predictor which is 
based on pharmacokinetic/pharmacodynamics (PK/PD) model, 4) A dose 
adjuster which adjusts doses by using different protocols based on INRs, and 
5) An outcome calculator which measures the desired outcomes (e.g., TTR). 
The details of this simulator is described in detail in chapter 5. 
CER Knowledge Base: 
The outcomes of the simulations using the simulator will contribute to the CER 
knowledge base in comparing effectiveness of different anticoagulation 
therapy treatment plans and practices from which evidence-based information 
can be derived by patients, providers, policymakers, and other stakeholders. 
This knowledge is used as a basis for designing and testing different 
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population-based treatment plans in real clinical settings. This details and 
usage of this knowledge base is demonstrated in chapters 5 and 6.  
2.3.) Anticoagulation and Anticlotting 
The phenomenon of coagulation (thrombogenesis) is a crucial component of 
the body’s hemostasis. Through this process, blood creates clots. Coagulation 
disorders can result in different forms of bleeding (hemorrhage) and 
obstructive clotting (thrombosis). Blood coagulation (clotting) is a complex 
process involving many clotting factors which activates each other. The 
details of the process are depicted and explained in Figure 2.9.  
In brief, this process composes of the three following stages: 
- Formation of Prothrombinase 
Prothrombinase can be formed either through “intrinsic system” or “extrinsic 
system” which involves interactions between coagulation factors (e.g., Factor 
VIII, Factor IX).  
- Conversion of Prothrombin to Enzyme Thrombin 
In this stage, prothrombinase converts prothrombin to enzyme thrombin.   
-  Conversion of Fibrinogen to Fibrin (formation of clot) 
Then, thrombin converts fibrinogen into fibrin which forms a mesh to form 
clots. 
Various substances are required for the proper functioning of the coagulation 
cascade (Wikipedia Coagulation, 2014): 
- “Calcium and phospholipid (a platelet membrane constituent) are required 
for the tenase and prothrombinase complexes to function. Calcium mediates 
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the binding of the complexes via the terminal gamma-carboxy residues on 
FXa and FIXa to the phospholipid surfaces expressed by platelets, as well as 
procoagulant microparticles or microvesicles shed from them. Calcium is also 
required at other points in the coagulation cascade. 
Figure 2.9. The Coagulation and Fibrinolytic Pathways. The main coagulation 
reactions are divided into the intrinsic and extrinsic systems. Activation of factor 
XII on contact with a negatively charged surface initiates the intrinsic 
coagulation system. (The activated form of the factor is indicated by “a.”) The 
extrinsic coagulation system induces the formation of a complex composed of 
factor VII and tissue factor, which is released after tissue injury. Some of these 
reactions depend on calcium ions. Thrombin is formed by an enzyme complex 
called prothrombinase, composed of factor X, factor V, negatively charged 
phospholipids, and calcium ions. Intrinsic and extrinsic activation of the 
coagulation cascade leads to the generation of thrombin, the activation of 
fibrinogen, the release of fibrinopeptides, the formation of soluble fibrin, and 
finally, the formation of factor XIII–mediated, cross-linked, insoluble fibrin. The 
main fibrinolytic reactions involve the inhibition of fibrinolysis by plasminogen-
activator inhibitor type 1 (PAI-1) and a2-antiplasmin. Fibrinolysis is initiated by 
tissue plasminogen activator (t-PA), urinary-type plasminogen activator (u-PA), 
and plasmin. Plasmin bound to the surface of fibrin initiates the lysis of 
insoluble, cross-linked fibrin, with the subsequent generation of fibrin-
degradation products. Plasmin bound to the surface of fibrin is better protected 
from inhibition by a2-antiplasmin than is plasmin generated in the fluid phase 
(Kohler; 2000). 
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- Vitamin K is an essential factor to a hepatic gamma-glutamyl carboxylase 
that adds a carboxyl group to glutamic acid residues on factors II, VII, IX and 
X, as well as Protein S, Protein C and Protein Z. In adding the gamma-
carboxyl group to glutamate residues on the immature clotting factors Vitamin 
K is itself oxidized. Another enzyme, Vitamin K epoxide reductase, (VKORC) 
reduces vitamin K back to its active form. Vitamin K epoxide reductase is 
pharmacologically important as a target of anticoagulant drugs warfarin and 
related coumarins such as acenocoumarol, phenprocoumon, and dicumarol. 
These drugs create a deficiency of reduced vitamin K by blocking VKORC, 
thereby inhibiting maturation of clotting factors. Vitamin K deficiency from 
other causes (e.g., in malabsorption) or impaired vitamin K metabolism in 
disease (e.g., in hepatic failure) lead to the formation of PIVKAs (proteins 
formed in vitamin K absence) which are partially or totally non-gamma 
carboxylated, affecting the coagulation factors' ability to bind to phospholipid”. 
Anticoagulation Agents: 
Anticoagulation agents are a class of medications that are developed to 
prevent and reduce blood coagulation and clotting disorders (e.g., DVT: deep 
vein thrombosis, PE: pulmonary embolism, MI: myocardial infarction and 
IS:ischemic stroke). Anticoagulation agents are administered in different 
ways; oral, intravenous, or subcutaneous injection. Different anticoagulants 
interrupt the coagulation cascade at various points (Figure 2.10). Vitamin K 
antagonists, such as warfarin, typically work on and inhibit several calcium-
dependent clotting factors, including factors II, VII, IX, and X. Dabigatran 
directly inhibits factor IIa (thrombin). Apixaban, betrixaban, edoxaban, and 
rivaroxaban inhibit factor Xa. 
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For a few decades, vitamin K antagonists (VKAs) such as warfarin, the most 
commonly used VKA, have been used as the main agents for long term 
anticoagulation therapy (Steffel, 2006). Anticoagulation therapy using dose-
adjusted VKAs has been always an effective clinical option to prevent and 
treat thromboembolic diseases. However, long term management of VKAs is 
challenging as the intensity of anticoagulation represented by measurement of 
international normalized ration (INR) can be out of desired therapeutic ranges 
for a large amount of treatment period. Despite the widespread use of VKAs, 
they have some characteristics that make them difficult to manage, such as 
(a) a narrow therapeutic index/window outside of which there is a risk of 
bleeding events, or thromboembolism which demands regular frequent 
monitoring of INR, (b) a wide inter-individual variability in dose-response due 
Figure 2.10. Coagulation cascade and point of effect of the common 
oral anticoagulants. TF: tissue factor. (Makaryus, 2013) 
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to their pharmacokinetics affected by genetic and physiological factors, (c) 
different levels of interactions with other medications and foods (Hart, 2007; 
Guyatt, 2012).  
In addition to VKAs, there are other anticoagulant agents that can be 
applicable alternatives such as unfractionated heparin, the low molecular-
weight heparins (LMWHs), and indirect-acting factor Xa inhibitors (e.g., 
fondaparinux). However, they have some limitations too. The subcutaneous 
and parenteral route of administration make them time consuming and less 
convenient medications for patients under anticoagulation treatment. 
Furthermore, taking into consideration their specific pharmacokinetics, they 
need continuous intravenous infusion or daily dose adjustment. Some of them 
such as LMWHs have unstable bioavailability under some physiological 
circumstances such obesity or renal failure. 
Novel Oral Anticoagulants: 
These shortcomings and practical limitations of the VKAs and the intravenous 
anticoagulant medications have motivated scientists to develop alternative 
oral medications called novel oral anticoagulants (NOAs) with quick onset of 
action, predictable pharmacokinetics, less need for regular monitoring and 
interactions with other medications and foods. NOAs include direct thrombin 
inhibitors, such as dabigatran, and factor Xa inhibitors such as apixaban, 
edoxaban, and rivaroxaban (Makaryus, 2013).  
The VKAs and NOAs act differently in the body. The first group of 
medications, inhibit gamma-glutamyl carboxylation of coagulation factors II, 
VII, IX, X, and the coagulation inhibitor proteins C and S. On the other side, 
NOAs act on some different proteins in the coagulation cascade (Figure 2.10). 
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Although NOAs have some benefits over VKAs such as predictable 
pharmacokinetic mechanisms which facilitate their dosing without a need for 
routine monitoring, their use have not been popular as expected for some 
reasons such as their high cost versus VKAs and lack of strategies to rapidly 
quantify or reverse their anticoagulant effects (Harder, 2008; Brenner, 2011). 
2.4.) Pharmacogenetics 
Variability in response to medications creates a significant challenge for 
physicians, patients and pharmaceutical companies (Evans, 1999). Factors 
involving in the body’s response to a medication are multifold and complex 
(Table 2.3) (Ma, 2011). A large number of clinical studies have shown that 
variation in genetic make-up of individuals is an important factor affecting the 
medication response in the body. 
Different factors such as environmental effects, physiological factors (e.g., 
medical conditions) and genetic profile variations are involved in the variation. 
The field of pharmacogenetics studies the relationship between individual’s 
response variability to medications and genetic variations (Hewett, 2002). This 
field of study, especially in the light of the complete human genome 
sequence, has motivated many researchers to conduct pharmacogenetic 
studies at an accelerating rate in recent years on many medications which 
were previously recognized to have unpredictable outcomes and unintended 
side effects. 
The knowledge of pharmacogenetics helps to understand some of the 
underpinning causes of these challenges and also implement personalized 
medicine. The main questions asked in the field of pharmacogenetics are: 
what are the genes involved in a drug's mechanism of action? how are a 
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Table 2.3. Major factors affecting individual medication response (Ma, 2011) 
Factors Effects 
Genetic Factors 
     Therapeutic targets 
     Drug-metabolizing enzymes 
     Drug transporters 
     Targets of adverse drug reactions 
      
      Factors with indirect effects 
Major variables; stable and inherited 
     Drug efficacy (pharmacodynamics) 
     Drug metabolism (pharmacokinetics) 
     Drug disposition (pharmacokinetics) 
     Drug toxicity (pharmacokinetics and 
pharmacodynamics) 
     Drug efficacy, pharmacokinetics, and 
toxicity 
Other Factors 
     Environmental factors 
         
        Environmental chemicals, 
coadministered drugs, tobacco 
smoking, alcohol drinking, and 
dietary constituents 
     Physiological factors  
          Age, sex, disease state, pregnancy, 
exercise, circadian rhythm, and 
starvation 
Mostly transient 
     Drug efficacy, pharmacokinetics, and 
toxicity 
      
        
 
       Drug efficacy, pharmacokinetics, and 
toxicity 
 
drug's effects propagated through pathways? how can this information be 
applied to characterize "off-target" adverse events? How can 
pharmacogenomics information be utilized in prescription and dosing 
decisions? (Karczewski, 2012).    
In clinical settings, physicians mainly prescribe medications based on their 
clinical judgment and evidence resulting from clinical trials. They usually take 
into consideration clinical factors (e.g., age, weight, ongoing health condition) 
and behavioral characteristics of patients and genetic characteristics are not 
considered in many settings. This appears to be the case in anticoagulation 
therapy. For example, two groups of patients with similar clinical and 
backgrounds and presentations might undergo the same dosing regimen of 
anticoagulant clopidogrel (e.g., 75 mg/day) or warfarin (e.g., 5 mg/day). This 
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treatment approach might result in a good protection against thromboembolic 
events in one group and might cause side effects in the other group. 
Pharmacogenetic studies have revealed that the patients under clopidogrel 
and warfarin who experience inadequate protection are more likely the ones 
who are poor metabolizers of the medications owing to their variant alleles of 
genes CYP2C19 and CYP2C9 and VKORC1, respectively (Highashi, 2002; 
Aithal, 1999; Rieder, 2005; D'Andrea, 2005; Yuan, 2005; Aquilante 2006). In 
the case of warfarin, these findings have resulted in a sheer number of 
pharmacogenetic-based (PG-based) dosing algorithms explaining a 
significant proportion of the interindividual variability in warfarin dose 
requirement (e.g., Gage, 2008; Anderson, 2007; Klein 2009). 
After taking a medication, it has to go through different components of the 
body to reach its target tissues/cells, then it acts on its target, and eventually 
its metabolites and residues are eliminated from the body. The process of 
absorbing, distributing, metabolizing, and excretion/elimination are regulated 
by pharmacokinetic (PK) genes. Pharmacodynamic (PD) genes regulate the 
effect of medications on their targets. Genes regulating PK and PD processes 
can be involved and led to desired/intended effects by affecting target cells or 
contribute to undesired/side effects by affecting non-target cells. 
Pharmacogenetic researchers try to find the genes involved in both the PK 
and PD pathways that affect drug action in order to improve dosing and avoid 
adverse drug reactions (Karczewski, 2012). 
Different stakeholders such as patients, health care providers, pharmaceutical 
companies and academics can take advantage and are interested in 
pharmacogenetic knowledge. Patients and healthcare providers use 
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pharmacogenetic information to make more informed decisions and determine 
more accurate medication optimal doses. Using pharmacogenetic discoveries 
and knowledge, research teams and pharmaceutical companies are able to 
enhance and facilitate safer and target-oriented clinical trials. 
2.5.) In Silico Clinical Trial Studies 
In silico is a term which is used and referred to tasks performed on computer 
or through computer simulation. In silico techniques and methods have been 
widely used in different disciplines such as engineering, physics, astronomy, 
marketing and economics to foster the process of developing and testing the 
performance of systems. The application of simulation in these fields have 
resulted in reduction of costs and shorter development cycles.  
In last two decades, clinical trials modeling and simulation has gained a lot of 
attention. In silico approaches to conduct clinical trials which employ realistic 
virtual subjects and typical trial conditions, based on both experimentally 
informed disease progress and drug intervention models have been 
embraced by both pharmaceutical companies and also regulatory agencies 
(Kimko, 2003). It provides an opportunity for researchers to develop and test 
hypotheses virtually prior to real-world experiments. Many pharmaceutical 
companies use the clinical trials modeling and simulation techniques to 
facilitate the development of new drugs and make the drugs more efficient. 
Regulatory agencies such as US Food and Drug Administration (FDA) and 
European Medicines Agency have recognized the important role of clinical 
trials modeling and simulation and have advocated using it to support more 
evidence-based study designs and dosing protocols in different target 
subpopulations. FDA underscored clinical trial modeling and simulation in its 
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2004 Clinical Path Initiative as an opportunity which could improve 
predictability and efficiency along the critical path from laboratory concept to 
commercial product: “FDA scientists use, and are collaborating with others in 
the refinement of, quantitative clinical trial modeling using simulation software 
to improve trial design and to predict outcomes.” (FDA, 2004). 
From the perspective of European Medicines Agency, the modeling and 
simulation of clinical trials and PK/PD data contribute to the regulatory review 
process and also drug development because modeling and simulation 
(Jönssen, 2010): “allow more efficient utilization of collected clinical data”, 
“support informed decision making regarding future studies and study designs 
including dose selection”, are beneficial in time and cost savings. Accordingly, 
several European guidelines “recommend modeling and simulation as a 
useful tool to support dose selection and establish dose recommendations in 
special populations”.  
Peck et al. have provided the following detailed technical definition for the 
clinical trial simulation: “the generation of biomarker or clinical responses in 
virtual subjects that take into account (a) the trial design and execution, (b) 
pathophysiological changes in subjects during the trial (disease progress 
model), and (c) pharmacology (drug intervention model), using mathematical, 
statistical and numerical methods and models” (Peck, 2011). 
Components of a Clinical Trial Simulation:  
A clinical trial simulation generally is composed of three following components 
(Holford, 2000):  
1- The input–output model consists of submodels that incorporate the drug’s 
pharmacokinetics and pharmacodynamics, the disease progression during the 
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trial, the trial endpoints, and the residual variability. Some of these submodels 
may include covariate influences on model parameters, which comprise the 
covariate distribution model. Basically, the input–output models are functions 
that map the set of inputs to the set of outputs.  
2- The covariate distribution model describes the distribution of the covariates 
and their intercorrelations.  
3- The trial execution model consists of the study design elements, and 
potential submodels for compliance, protocol deviations, and missing data. 
2.6.) Application of the iS-TR to a Patient-Centered 
Pharmacogenetic Outcomes Research Problem 
Based on the Patient Protection and Affordable Care Act (PPACA, 2010), 
Comparative Effectiveness Research (CER) is a national research priority. 
Under this Act, the Patient-Centered Outcomes Research Institute (PCORI) is 
in charge of supporting the research that takes into account the potential for 
differences in the effectiveness of health care treatments, services, and items 
as used with various subpopulations, such as racial and ethnic minorities, 
women, age, and groups of individuals with different comorbidities, genetic 
and molecular sub-types, or quality of life preferences and include members 
of such subpopulations as subjects in the research as feasible and 
appropriate. Accordingly, PCORI has proposed priorities and research 
agenda with focus on CER studies providing opportunities to assess the 
benefits and risks of adopting genetic tests in patient subsets (PCORI, 2012). 
PCORI has recently published its “Methodology Report” introducing the 
PCORI Methodology Standards (PCORI, 2013). These are specific 
recommendations for researchers that designate the minimal requirements for 
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following PCOR best practices. Under the recommended methods related to 
Heterogeneity of Treatment Effect (HTE: a technical term for the fact that 
different people do not always respond the same way to the same treatment), 
it is recommended to develop methods to use simulation models to (a) 
address questions on heterogeneity of treatment effect, (b) address patient-
centered comparative effectiveness questions, and (c) to support guidance on 
adaptive trials’ complex design specific to PCOR.   
Accordingly, we use our iS-TR model and framework to generate robust, 
relevant, and timely evidence for patient-centered pharmacogenetic outcomes 
research questions. For instance, although the potential clinical value of most 
of the PG-based algorithms versus non PG-based “best practice” treatment 
plans was assessed through rigorous randomized controlled trials, their 
clinical applicability and effectiveness for different target populations have not 
been evaluated which leads to an opportunity for PCOR CER studies using 
our iS-TR framework. 
2.7.) Focus of this study 
As part of continuing effort to address health care challenges through patient-
centered outcomes research (PCOR), we introduce an in silico translational 
research model and framework supporting pharmacogenetic anticoagulation 
PCOR CER prediction and validation studies. This framework is designed to 
demonstrate how current access to large comprehensive electronic medical 
records (EMR) covering diverse patient populations, coupled with novel 
modeling and computational simulations could provide an unprecedented 
opportunity to conduct in silico identification, validation and comparison of 
treatment strategies.  
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3.1.) Patient Populations and Subpopulations 
As discussed in section 1.3, current research paradigms such as traditional 
randomized control trials mostly rely on relatively narrow efficacy data which 
results in high internal validity (i.e., extent to which systematic error, bias, is 
minimized in clinical trials under optimal conditions) and low external validity 
(i.e., extent to which results of trials provide a correct basis for generalization 
to other circumstances) (Glasgow, 2006; Juni, 2001; Kessler, 2011). The lack 
of comparability between trial participants and nonparticipants has resulted in 
a slow pace of translation of new genomic knowledge to clinical settings and 
public health. In almost all of the controlled trials, a small fraction of the total 
number of patients participate. The participants are usually dedicated 
individuals to trial studies who are selected based on strict inclusion and 
exclusion criteria. So, the interventions that are successful in trial patient 
cohorts may not necessarily translate well to the real-world clinical setting. 
This raises questions of the generalizability of the results of clinical trials 
which is one of the important and practical aspects of clinical trials (Elting, 
2006; Schulz, 2010). There are different approaches that can be taken to 
answer the questions, “How can trial results be applied to patients in clinical 
practice?” and “How different are the interventions/treatment plans resulted 
from a given trial study compared with the other available ones?” For 
example, (a) conducting large, population-based effectiveness trials to provide 
evidence on the generalizability of clinical trial results and the realistic benefits 
of treatments, (b) conducting effectiveness studies that examine how a 
therapy/intervention, that works effectively under certain circumstances, works 
in clinical practice, (c) developing trials that fit patients seen in practice and 
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their participants share the same characteristics as the majority of patients, 
and (d) another approach is the development of trials that are targeted and 
appropriate to the needs of special populations. Accordingly, continued 
investigation is needed to see how results of clinical trials are translated into 
nontrial care, to facilitate the dissemination of clinical trials findings, and to 
identify ways to achieve faster and more generalizable clinical trial findings. 
This has been the case for pharmacogenomics in the last decade too. 
Enormous number of clinical trials have been conducted or are currently 
under way to test the accuracy of previous dosing algorithms, construct new 
dosing algorithms, or test the value of genetic tests in warfarin dosing, with 
equivocal results. Several clinical trial studies have shown that PG-based 
dosing lead to superior control of warfarin anticoagulation (e.g., Gage, 2008; 
Anderson, 2012), whereas a number of prospective studies and controlled 
clinical trials have failed to show that genotyping improves warfarin dosing 
and anticoagulation control (e.g., Anderson, 2007; Kimmel, 2013). Although in 
those clinical trials thousands of subjects have been recruited, the clinical 
utility of PG-based dosing of warfarin has been mostly tested in small clinical 
trial or observational study populations. 
To deal with such a challenge, overcome the study populations’ limitations, 
and fill the translational research gaps using in silico trial and comparative 
effectiveness studies, in the first step, there is a need to generate realistic 
virtual subject populations and subpopulations representing the patient types 
that are likely to be studied in the actual studies. Among various methods, we 
have used the following methods to create virtual patient populations 
52 
 
 
 
(hereafter “Clinical Avatars”) in our in silico PC-CER translational framework, 
introduced in section 2.2. 
3.1.1.) Clinical Avatar Model 
Background in Bayesian Theory 
Simulating patient data (i.e., creating “Clinical Avatars”) poses several 
challenges common to big data research including missing values, high 
dimensionality and low sample size. We found that a Bayesian machine 
learning approach can address these issues in an efficient, effective and 
generalizable method. More specifically, our method to generate clinical 
avatars relies on constructing a Bayesian belief networks, hereafter called 
Bayesian network model (BNM). Using Bayes theorem and extensions of 
Bayesian theory, BNMs can accomplish two critical elements necessary for 
modeling patient data, pattern learning and parameter learning. Pattern 
learning describes a method for discovering graphical representation that 
correctly approximates relationships between variables within some set of 
data.  Parameter learning applies a graphical pattern with the names and 
number of categories within the pattern to create a Bayes net. The Bayes net 
is composed of distinct states each with unique conditional probabilities as 
defined by some graphic pattern and estimates provided by either training 
data or evidence.  
As recently summarized by Conca Bielza (2014) Bayesian Classification, (i.e., 
pattern learning) offers distinct advantages in modeling healthcare data over 
other statistical classification techniques (e.g., ad hoc, regression). Types of 
Bayesian classifiers, such as binary, categorical and continuous are used to 
capture the structure of data sets found in patient databases. Such classifiers 
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also efficiently accommodate missing data as well as feature selection in the 
learning and inference stages. Bayesian networks also provide “an explicit, 
graphical and interpretable representation of uncertain knowledge…based on 
the sound concept of conditional independence (as) an example of a 
probabilistic graphical model” (Bielza, 2014). Once the pattern is discovered, 
the parameters can be learned efficiently. In the following section, the basis 
and method to create Clinical Avatars are summarized: the fundamental 
principles of classification, Bayes theorem, Markov Blanket Based DAG 
Discovery and Bayesian belief networks.  
A.) Data Classification 
Classification is a broad term used to describe the process of assigning or 
predicting categorical classes and defining their respective relationships. 
Classification is a two-step process; the first step is termed the learning step 
and the second step is termed the classifier step. During the learning step, or 
training phase, a classification algorithm creates a model by learning from a 
set of training data (i.e., database tuples) and a set of corresponding classes 
C. A tuple, X, is represented by an n-dimensional attribute vector, X = (x1, x2, 
…, xn). X is composed of a random set of predictive n-measurements from the 
tuple of n-database attributes, such that, ai ∈ Ω ai = {A1, A2, …, An}.  Each 
tuple, X, is assumed to belong to a predefined class as determined by another 
database attribute called the class label attribute called C where  ∈ Ω c =
, 
, … , . The class label attribute is categorical in that each value of cn 
serves as a category or class. Classification denotes instances where the 
class label of each training tuple is provided, are known as supervised 
learning (i.e., the learning of the classifier is “supervised” in that it is told to 
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which class each training tuple belongs). In contrast Clustering denotes 
instances where the class label of each training tuple is unknown, known as 
unsupervised learning and the tuples as organized by a specified measure of 
similarity. The classification problem consists of inducing a model M from a 
random sample of individual tuples called a training set or training tuples D, 
where D = {(x(1), c(1)),…, {(x(N), c(N))} of size N from a joint probability 
distribution p(X, C).   
In the second step, the predictive accuracy of the induced model M is 
estimated. To do so, there are multiple measures such as classification 
accuracy and sensitivity and ROC curve all of which must validated by 
bootstrapping, k-fold cross validation, and/or holding-out a validation set of 
data tuples Xj and their associated class labels Cj from the original training 
data. Validation tuples are selected from the general data set at random. They 
are independent of the training tuples and were not used to construct the 
classifier. Then the accuracy of the classifier on the validation dataset is 
evaluated by the percentage of test set tuples that are correctly classified by 
the classifier. If the accuracy of the classifier is considered acceptable, the 
classifier can be used to classify future data tuples for which the class label is 
not known or can be used to simulate data tuples.  
B.)  Bayes' Theorem 
Bayes' theorem (also known as Bayes' rule) is a means for calculating the 
conditional probability of a random event given some additional information. In 
this section, it is described how Bayes theorem could be used for 
classification of random events (i.e., tuple X) of a given database. In this 
example, X is a tuple of the given database that is identified by measurements 
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of its attributes. For such case, we assume there exists a hypothesis 
indicating that the data tuple X belongs to a specified class C. Then, our goal 
is to determine P(C|X), or the probability that tuple X belongs to class C, given 
our knowledge and evidence on the attribute description of X. P(C), P(X|C), 
and P(X) are called the prior probability and are estimated from the a set of 
statistical evidence. The posterior probability, P(C|X) is calculated using the 
following equation based on Bayes' theorem: 
| = |  
As an example, having applied Bayes theorem to issue of correctly 
diagnosing prostate cancer, if we select men at random from a male 
population and remove their prostates for definitive diagnosis of cancer we 
would find the prior probability of prostate cancer, P(has cancer), in the given 
male population. If we want to know the probability that any randomly selected 
man has cancer without removing his prostate, we would want to know all 
relevant information such as age and Prostate Specific Antigen (PSA) level.  
We generate a dataset drawn from a random sample of men that includes 
data on the patients’ age and PSA level. A given patient with the age of 70 
years old and a PSA level of 4.0 ng/mL is represented by tuple X. Suppose a 
physician hypothesizes that her patient has prostate cancer. Then the 
posterior probability or P((has cancer)|X), indicates the probability that this 
random patient will be diagnosed with a prostate tumor given that we know 
the patient's age and PSA level. In this case we can use Bayes theorem to 
find P((has cancer)|X) when we are given P(has cancer), and P(X|(has cancer)) 
or the probability that a prior patient is 70 years old and has a PSA level of 4.0 
ng/mL, given that we know the patient will be diagnose with a prostate tumor.  
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C.)  Pattern Learning: Bayes Classifiers, Bayesian Network Classifiers  
A Bayes classifier applies Bayes theorem to the classification problem.  
Returning to our prostate cancer example, given a random set of variables, 
such as sex, income, car model, and age, we seek a model that can predict 
the probability of cancer in a randomly selected individual. More generally, the 
Bayes classifier defines a model M to a random set of training tuples D, where 
D = {(x(1), c(1)),…, {(x(N), c(N))} of size N from a joint probability distribution p(x, 
c). The Bayesian approach can be described as a non-deterministic 
polynomial-time hard optimization problem under a binary loss function that 
minimizes conditional risk based on prior probability (Bielza, 2014). The 
optimal model is one that seeks to derive the most probable posteriori class 
for any given example xr = (xr1, …, xrn) drawn from the same data source as 
the training tuples, or 
In contrast to the heuristic Bayes classifiers, constraint based Bayesian 
network classifiers approximate ,  according to a Bayesian network. A 
Bayesian network is a graphical depiction of a data called a directed acyclic 
graph (DAG) where the nodes of the DAG are the c classes of any given 
variable X1,…, Xn, and the edges (or vertices) define the (in)dependence 
relationships between those variables. In Figure 3.1, the nodes X, Y, Z, W 
X 
Z 
Y 
W 
Figure 3.1. Example DAG 
c                       c 
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correspond to the class C within a given data set. The arrows that define the 
asymmetrical relationships between the nodes X, Y, Z and W describe the 
probabilistic conditional dependences between the nodes. In other words, the 
prior probability of a given parental node such as X or Y can predict 
probability that any given tuple belongs to a particular class of child nodes 
such as Z and W. Once a Bayesian network (i.e., DAG) is constructed, it 
provides a logical and interpretable framework for learning the probability of 
any given set of data. The fact that each variable is conditionally independent 
of its non-descendants in the DAG, given its parents, allows the network to 
provide a complete representation of the existing joint probability distribution 
with the following equation: 
, … ,  =  | 

!
 
where P(x1, : : : , xn) is the probability of a particular combination of values of 
X, and the values for P(xi | Parents(Yi)) correspond to the probability for Yi 
based on a set of training data. 
There are multiple methods for Bayesian networks to approximate joint 
conditional probability distributions or , . Naïve Bayes modeling takes 
the simplifying assumptions that some class C is the parent of all predictor 
variables and there are no independence relationships between the predictor 
variables. In Figure 3.2 we see that X is the causal parent to Y, W and Z but it 
is assumed that there is no relationship between Y, W, and Z and it is 
X 
Z W Y 
Figure 3.2. Naïve Bayes 
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assumed that x has no parents. Although naïve Bayes requires very strong 
assumptions, it has proven effective in several machine-learning tasks 
(Garcia-Laencina, 2013).  However, in many models the simplifications prove 
too great to effectively model the data. A more complex variant of naïve 
Bayes is an ‘unrestricted’ Bayes pattern seen in Figure 3.3. This graphical 
approximation increases the number of conditional relationships between the 
nodes and thereby dramatically increases the number of states within the 
Bayes net. Models constructed from unrestricted patterns face the problem of 
overfitting and subsequent poor parameter learning.  
A more sophisticated approach allows that X could have some parent ‘a’ and 
there are potential relationships between the variables Y, W and Z. In order to 
find the causal parents of X we must search the Markov blanket of X.  Once 
we find DAG describing the conditional dependencies between classes within 
the Markov blanket, we assume this blanket represents the probabilistic 
dependences existing within a set of data. That is, the behavior of the true 
DAG equates to the DAG discovered within the Markov blanket. This 
assumption is known as the faithfulness assumption (Pearl, 1988; Sprites 
2000). The problem of classification thus becomes one of relationship 
discovery within a projection of some tuple X onto its respective Markov 
blanket.  
Figure 3.3. Unrestricted DAG 
X 
Z W Y 
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A key concept in the graphical representation of conditional independence is 
the concept of d-separation (Figure 3.4). This concept first described by 
(Pearl, 1988) provides the justification for simplified conditional independence 
relationships within a given Markov blanket. For example, we say that X and Y 
are d-separated if on any directed path between X and Y there is some 
variable Z that such that Z is known and is either a diverging parents 
connection or is known and is in serial connection between X and Y.  X and Y 
are also d-separated if there is some common unknown child that X and Y 
converge on, and Z has an unknown descendent. Full descriptions can be 
found in (Pearl, 2000; Pearl, 2009), while truncated but general description is 
explained in (Dawid, 2010). 
There are multiple methods for discovering the relationships within the Markov 
blanket and subsequently Bayesian network (i.e., DAG) discovery. Many of 
these published methods of DAG structure learning have been executed on 
real world datasets (Kalisch, 2010). Below we give a brief introduction into 
several different methods for conducting DAG structure learning as well as the 
assumptions, strengths and weakness. DAG structure learning procedures 
are usually highly variable, i.e., the learnt graph tends to change drastically 
with even small perturbation of the data.  We then elaborate our method 
which accommodates the instability of Bayesian search algorithms through a 
Figure 3.4. D-Separation. 
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combination of ensemble learning techniques each proven to individually 
increase the truthfulness of Bayesian search output.  
There are three branches to which we classify DAG learning methods 
employed on real world data sets, score-based, constraint-based and hybrid 
methods. Score based methods have essentially two parts, a scoring and an 
aggregating method that seeks to optimize the decided upon scoring 
technique. There are several ways of scoring such as negative log-likelihood 
score, Akaike information criterion (AIC) score, Bayesian information criterion 
(BIC) score, Bayesian Gaussian equivalent (BGe) score (Geiger, 1994). At 
each step the search method determines if including, orienting or deleting an 
edge between two notes will increase or decrease the score and optimizes for 
the lowest score. Because the potential relationships within a highly 
dimensional data wrapper are prohibitively large, greedy search algorithms, 
particularly hill climbing algorithms are employed. Greedy Hill climbing 
algorithms optimize local relationships in a forward step adding edges until a 
maximum score is achieved and then a backward step deleting edges until 
the scoring criteria can no longer be improved (Chickering, 2002). 
D.) Markov Blanket Based Pattern Discovery 
Constraint based DAG structure learning views a DAG as the result of a set of 
conditional independence tests applied across the Markov blanket of nodes.  
As such in contrast to scoring algorithms that approach classifier search as a 
simplification of the general classifier optimization problem, constraint based 
DAG searches approach classifier search as a feature selection problem. To 
select a feature, the data is tested against multiple different hypotheses.  
There are many published Constraint based algorithms with variety of 
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different assumptions and potential applications. Several of the mostly widely 
used algorithms are variants of the PC algorithm (e.g. Conservative PC, 
JCPC, PCD etc.), named after its creators Peter Sprites and Clark Glymour.   
Additional algorithms that all reside in this branch include Increment 
Association Markov Blanket (IAMB) and two IAMB variants (Margaritis and 
Thrun, 2000). There is also a large family of constraint-based methods 
designed to deal with latent variables (i.e., variables not found within the 
dataset). These methods, FCI, FCI variants, IDA and several others methods 
all output Partial Ancestral Graphs (PAGs) that can determine if measure 
variables could be the result of some unmeasured (latent) variable.   
Lastly, a third type of popular Bayesian search algorithms can be considered 
combinations of the score and constraint based DAG searches, also called 
hybrid methods. In hybrid methods, conditional independence tests are used 
to determine edges, but each local test between nodes are used to inform the 
proceeding tests. Primarily, the knowledge from each search is used to 
impose restrictions on the search space via a scoring system. Hybrid methods 
include Max-Min Hill Climbing (MMHC) (Tsamardinos, 2006) and L1MB 
(Schmidt, 2007). 
Constraint and Hybrid search algorithms can commonly be broken down into 
two phases, the search phase and the orientation phase. During the search 
phase, the algorithm asks a conditional independence oracle to perform a 
routine statistical test, usually either χ2 contingency test or G-test to determine 
if a pair Markov equivalent nodes are independent or not. Within the pattern 
discovery catalogue of algorithms, there are additional statistical methods for 
hypothesis testing that may be better suited for a dataset. Just as with any χ2 
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or G-hypothesis test, the user has the ability to set an α-value or significance 
value, above which the null hypothesis is rejected. These conditional 
independence tests, and therefore the Constraint based and hybrid searches 
demands that the data be either entirely continuous or entirely discrete. 
The PC family of algorithms performs a backward stepped algorithm that 
begins with a maximally connected Markov blanket. Relationships between 
the classes within the Markov blanket are then tested. If the statistical test 
rejects the null hypothesis the edge between two nodes in the Markov blanket 
is maintained. If the test determines the null hypothesis true, the edge is 
deleted stepwise until a graph depicting all true relationships. The conditional 
independence oracle describes a strategy for passing the tuples through the 
series of conditional independence tests that are performed across the 
Markov blanket.  
If two Markov nodes reject a null hypothesis via the conditional independence 
test, the algorithm outputs an undirected edge between two variables. Once 
all necessary independence tests have been applied across the Markov 
blanket, the algorithm enters the orientation stage. Here the algorithms 
determine directionality of the edges via application of the d-separation 
principle across triplets of tuples as well as the orientation rules described by 
Meek (1995). Orientation of the arrows is particularly susceptible to small 
perturbations of the data and can result in a partial failure of the algorithm.  
Partial failure would include multiple undirected edges and edges that are bi-
directional.  When search results demonstrate such a partial failure, a Pattern 
Graph can include several symmetrical relationships. Since DAG represents a 
collection of asymmetrical relationships, a single search result can suggest 
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multiple potential DAG’s.  
E.) Parameter Learning: Bayesian Belief Network 
A Bayesian belief network (G, Θ) is composed of two elements. ‘G’, a directed 
acyclic graph (DAG) and ‘Θ’ a subsequent collection of conditional probability 
tables (CPT) defined by the Bayes net parameters draw from the DAG. Figure 
3.5 depicts a modified Bayesian belief network example from (Jiawei Han et al 
2006). The DAG defines certain states within a bayes net, the parameters of 
which can then be learned. The DAG and subsequent parameters may 
correspond to actual attributes given in the data or to "hidden variables" 
believed to form a relationship (e.g., in the case of medical data, a hidden 
variable may indicate a syndrome, representing a number of symptoms that, 
together, characterize a specific disease).  
FamilyHistory Smoker 
LungCancer Bronchitis 
PositiveXRay Dyspnea 
CPT 
P(LC | FH, S) FH, S FH, ~S ~FH, S ~FH, ~S 
LC 0.8 0.5 0.7 0.1 
~LC 0.2 0.5 0.3 0.9 
 
 (a) 
(b) 
Figure 3.5. A simple Bayesian belief network: (a) A proposed causal model, 
represented by a DAG. (b) The conditional probability table (CPT) for the 
values of the variable LungCancer (LC) showing each possible combination 
of the values of its parent nodes, FamilyHistory (FH) and Smoker (S). Figure 
is adapted and modified from (Jiawei Han, 2006). 
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The belief network in Figure 3.5 includes six binary variables with the ability to 
infer the probability of either a ‘PositiveXRay’ or ‘Dyspnea’. For example, 
having lung cancer is influenced by a person's family history of lung cancer, 
as well as whether or not the person is a smoker, but is d-separated from 
bronchitis. Note that the variable ‘PositiveXRay’ is independent of whether the 
patient has a family history of lung cancer or is a smoker, given that we know 
the patient has lung cancer. In other words, once we know the outcome of the 
variable ‘LungCancer’, then the variables ‘FamilyHistory’ and ‘Bronchitis do 
not provide any additional information regarding ‘PositiveXRay’. That is, given 
the rules of d-separation, p(PositiveXRay | Smoker, Lung Cancer) and 
p(Dyspnea | Lung Cancer, Bronchitis). The edges also show that the variable 
‘LungCancer’ is conditionally independent of ‘Bronchitis’, given its parents, 
‘FamilyHistory’ and Smoker. 
Thus, a DAG provides a probabilistic Bayes net that approximate the optimal 
inferred probability. A belief network includes one conditional probability table 
(CPT) for each variable. Any node within the network can be selected as an 
“output” node, representing a class label attribute. There may be more than 
one output node.  Figure 3.6 includes an example CPT for the variable 
‘LungCancer’.  
FamilyHistory Smoker 
LungCancer 
P(FH) P(S) 
P(LC |FH, S) 
Figure 3.6. An Example of CPT for the variable “LungCancer”. 
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The CPT, labeled (b) within the Figure 3.5, provides the conditional probability 
for each known value of ‘LungCancer’ is given for each possible combination 
of values of its parents.  
P(LungCancer = yes | FamilyHistory = yes, Smoker = yes) = 0.8  
P(LungCancer = no | FamilyHistory = no, Smoker = no) = 0.9 
The probabilities that satisfy the specified states within the Bayes net are 
called ‘parameter learning’. There are several algorithms for learning, or 
estimating, the parameters, Θ, of a network. When the data is complete (e.g., 
without missing values), the Maximum Likelihood Estimator, MLE can be used 
to calculate the conditional probability of a given parameter, where D is any 
given node within the network 
max& log *|Θ  
This limit of which is calculated via the following, where Nx is the number of 
counts within the training data set as defined by pax or the parents of the 
desired node. 
 
 
ML-θ/,0123 =  
4/,012
∑ 4/,012/
 
 
A similar version of the MLE is called the MAP-estimator that relies on a 
dirchlet distribution of variables. This allows the user to specify with prior 
evidence or knowledge the specific distributions or priors of the model. 
max& log*|Θ Θ 
 
W Y 
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MAP-θ/,0123 =  
4/,012 +  9/,012 
∑ 4/,012/ + ∑ 9/,012 /
 
Both the MLE and the MAP-estimator demonstrate similar behavior; they both 
are asymptotically equivalent and consistent as the counts are varied within 
the training model.  More importantly both algorithms rely on sufficient 
statistics. The concept of sufficient statistics is two fold, both of which are 
critical for properly training the parameters of a model. First, if there is no 
training data provided to estimate the likelihood of a given parameter the 
algorithm has no sensible way for calculating the conditional probability.  
These cases are most common in data with significant outliers or subclasses 
within the data.  
Second, sufficient statistics also implies a subtle rule that assumes there is no 
bias within the original training data set. For instance, if we return to our 
example Bayesian belief network at the beginning of this section we can 
imagine that if we are to sample only individuals that were already in the 
hospital instead of the general population, our maximum likelihood estimation 
would primarily consist of individuals that did not represent the general 
representation of the belief network.  Unintended bias is a significant 
contributor to weak and ineffective Bayesian modeling.  
If the data has missing values the ML and MAP algorithms are unable to 
produce estimates. In these cases, parameter learning must be accomplished 
via the Estimator Maximizer (EM)-algorithm or some similar variant that has a 
sensible means of dealing with the missing data. The EM-algorithm is a two-
step algorithm. In the first part, it computes an expected count missing value 
based on inference from the Bayesian network. 
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Once it computes the value it estimates the probability for the given parameter 
using the ML or MAP algorithms. This continues iteratively until the 
probabilities converge within some predetermined threshold, usually 0.0001.  
When large amounts of data are missing or when multiple latent variables 
exist, learning parameters becomes increasingly variable. Additionally, it has 
been repeatedly demonstrated that since the EM and similar algorithms have 
weaker guarantees than the ML or MAP algorithms, they become trapped in 
local maxima (Liao, 2009). Although there are several modified versions of the 
EM algorithm that have improved on the original presentation, as of yet, none 
provide robust results when missing values for any given parameter rise 
above 30% (Kohavi, 1999). Therefore, domain knowledge, and data 
preprocessing retain critical importance when constructing the training data to 
provide the model.  
Method 
A.) Bayesian Network Modeling for Clinical Avatars 
Stoll and Schubert (Keeler, 2006) suggest a four step semantic chain from 
raw data to wisdom. Similarly, our method follows a four-step logic chain to 
progress from a set of data to clinical avatars (Figure 3.7). The method can be 
Section 1 
Section 4 
Figure 3.7. Semantic chain from raw data to understanding. 
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partitioned into four broad sections: (1) Data and knowledge aggregation and 
preprocessing. During this step, the data must be acquired from a source and 
characterized alongside any additional information regarding the nature of the 
collection method and data dictionary that could unintentionally bias the 
resultant clinical avatars. Additionally, and expert knowledge from published 
or unpublished sources should be developed and employed to enrich the 
patient data. (2) In the second section, an ensemble of Bayes search 
algorithms are employed along with the domain knowledge acquired in 
section 1 to discover any significant relationships between variables present 
in the patient data. The relationships are then mapped graphically in one or 
several Directed Acyclic Graphs (DAGs). (3) In section three the DAGs are 
used to construct an ensemble of parametric models that allows the 
estimation of joint conditional probabilities and subsequent deriving an 
instantiated model. Once the ensemble DAGs and conditional probabilities 
have been aggregated into data generating models we consider it a Bayesian 
network model (BNM). (4) In section four, the BNM is cross validated against 
a subset of the original data held out from sections 2 and 3. Each section 
therein consists of several steps summarized in Appendix Figure 3.21. 
Section 1: Data Preprocessing and Gathering of Domain Knowledge 
Before modeling can begin, the appropriate data must be aggregated into a 
data wrapper. The method described here is flexible. Almost any type of 
healthcare data can be used to train the BNM. However, in accordance with 
the “No-Free-Lunch theorem”, (Wolpert, 2008) minor modifications in the 
pipeline to accommodate specific data sets will invariably benefit the model. 
The quality of the data used to train and validate the BNM will reflect almost 
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identically the quality of the BNM produced. It is quite possible to produce a 
perfect model from imperfect data, a model with little relevance. Therefore, 
despite the empirical principles this method employs, domain and expert 
knowledge remain critical. Further, it is paramount that care and thought be 
applied during the querying and accumulation of the data before embarking 
on the modeling process. Once this is accomplished, the data can be brought 
into the pipeline for generating clinical avatars.  
This section has two branches performed in parallel. In Part I we accumulated 
domain knowledge (i.e., expert knowledge or literature-defined knowledge) to 
better understand both the specifics of our data such as the way the data was 
gathered, the semantics of the data dictionary and any measurement error as 
well as the general relationship between the variables as found in literature 
review. In Part II the patient data is characterized and prepared (i.e., data 
preprocessing). Data preparation is a multistep process as described in 
Appendix Figure 3.21. Once the data has gone through the data 
preprocessing procedure it is aggregated into a data wrapper.   
Part I:  
It has been said, “there can be nothing fully automatic about causal discovery” 
(Dawid, 2009). Domain Knowledge, both regarding the nature of the sample, 
the techniques involved in imputing or deriving the data and the general 
relationships between the variables is all critical for the development of clinical 
avatars. Domain knowledge is critical in accurately preparing the data for 
modeling. Deciding how to aggregate the data, how to accommodate outliers 
and appropriate handle missing values are all depending on the researcher 
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making explicit choices about the nature of the data and the intent of the final 
model. 
Beyond the data preparation, domain knowledge performs three definite 
functions within the clinical avatar pipeline. First, domain knowledge can 
constrain the search space of the Bayesian search algorithms by imposing 
known relationships across the data. The search space can be constrained 
via, required causal relationships and forbidden relationships. Required 
relationships are defined by a corollary link between variables previously 
established in peer-reviewed literature. Forbidden causal relationships restrict 
the search from finding false positive causal relationships in the data. The 
variables can also have a series of relationships defined by hierarchically 
categorizing the variables according to the principles of causation. By 
classifying the variables in this manner, the user forbids directed relationships 
from higher to lower tiers. Constraints typically make the structure learning 
more efficient and can improve the validity of the resultant DAG.   
The second function of domain knowledge is to provide directionality to the 
arrows across the Bayesian search results. Arrow directionality within a DAG 
is a subtle and nuanced subject, the significance of which is discussed in an 
upcoming section. Often times Bayesian classifier algorithms produce 
ambiguous directional results. There are three sources for this ambiguity 
because of the weak guarantees within the proofs necessary for theorems to 
be true, uncertainty within the training data and the inherent weak 
philosophical underpinnings of causality in the first place. In fact, some 
statisticians view causality as nothing more than a convenient concept. As an 
additional confounder, there are certain times when the directional causal 
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relationship may change over time. To give a short example borrowed from 
Sprites (2000), if the variable under consideration is the rotation of a car tire, I 
could determine that the function of the car engine is causal parent of the tire 
rotation. However, if I were to try and kick-start the engine via pushing the car 
down a hill and use the motion of the car to start the engine, then the direction 
of the rotation of the tire would be the causal parent to the engine starting. 
The result is often a direct cyclic graph and the directionality of certain causal 
relationships must be determined via domain knowledge. It is important to 
note these ambiguous or time dependent relationships as best as possible 
within a given dataset. 
Domain knowledge also comes into play while aggregating the Bayes pattern 
learning results. Once the results are aggregated, we use domain knowledge 
in parallel with empirical methods to determine the edges that should most 
likely be pruned. In general, domain knowledge can help support the 
simplifying assumption of developing DAG while also preparing the data to 
reduce the violations of those assumptions. In all three points of applying 
domain knowledge ad hoc to the modeling method there is a varying amount 
of uncertainty. However, to account for such inherent uncertainty in the model 
we combine several plausible causal structures into the final pipeline.  
Part II: 
Data Reduction and Characterization: 
Here the variables that are desired to be included in the model are segregated 
from the dataset. This includes the establishment of a data dictionary to 
document the significance of each variable. The goal here is to statistically 
describe the nature of each variable following data parsing.  It is important to 
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pay attention to the outliers and any missing values within the data.   
Data Cleaning: 
Of particular important in this process is the role of missing values. If there are 
no missing values, then we proceed to “Data Discretization and Aggregation”. 
Missing data can compromise the robustness of any statistical model and 
additional steps must be used to handle missing values. First the nature of the 
missing values must be determined. There are three forms of missing values, 
‘missing at random’, ‘missing completely at random’ and ‘not missing at 
random’. Missing at random denotes cases where missing values are 
scattered around the data at random and there are no hidden variables that 
contain missing values. ‘Missing complete at random’ denotes datasets where 
there is a hidden variables that is not represented in the training data and not 
missing at random where all variables are present, but missing values are 
concentrated in local classes.  
1.) If the missing values are randomly distributed and deleting all patient 
cases with missing values does not significantly alter the 
representativeness of the data, then delete the all rows of missing data 
and proceed to “Data Discretization and Aggregation”. We define 
significance as a change in proportion of 30% or greater in any single 
variable (Friedman, 97; Ramoni, 2000).  
2.) If the missing values are randomly distributed, but deleting the patient 
cases significantly alters one or more variables, then proceed to the 
following step. 
3.) If the missing data is non-randomly distributed or if the missing values 
are randomly distributed, but deleting the patient cases significantly 
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alters one or more variables, then imputation should be considered.  
The specifics of imputation are outside the scope of this document. If 
an evidence based method exists for imputing missing values that the 
research is confident in, the researcher should apply those methods 
wherever possible.  
4.) If the imputation method was capable of increasing data coverage to 
>70% in any given variable then proceed to “Data Discretization and 
Aggregation”.  
5.) If following execution of the imputation method, if any variable has 
more than 30% of values missing, then randomly assign values until 
data coverage increases to >70%. 
Every effort should be made to ensure that missing values are treated in the 
appropriate method. Additionally, not all missing values are of equal 
importance within the DAG it will train. Variables that are discovered to be the 
parent nodes to other child nodes are more sensitive to missing values than 
variables in the child nodes. Deleting data with missing values can both 
introduce bias into the results and prevent accurate estimation of conditional 
probabilities with the training the data. Each data set must be prepared 
according to the specific characteristics of the data. Preparation of the data 
should be approached as part of the experimental process in developing 
clinical avatars.  
Data Discretization and Aggregation: 
Often healthcare data includes a mix of categorical and discrete data, such as 
race and gender, and continuous data such as age and height. The Bayesian 
search algorithms we employ require training data that is either entirely 
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continuous and normally distributed or entirely discrete. The Aurora Health 
Care dataset included a combination of both continuous and discrete 
variables, therefore the continuous variables were discretized. The process of 
discretizing continuous data is a ubiquitous data preprocessing technique that 
must balance information loss inherent in the process with the benefits of 
greater processing efficiency. There are numerous discretization methods and 
the choice can impact both the posterior probability estimation as well as the 
discovery of inherent causal structure in the underlying graph. We employed a 
common unsupervised method, EqualWidth that has demonstrated its ability 
to produce accurate data mining results for Bayesian search algorithms when 
compared to other techniques (García-Laencina, 2013).  
Generally, there is a balance between information loss inherent in the 
discretization process and the need for sufficient population sizes to estimate 
conditional probabilities. For example when EqualFrequency is applied to 
normally distributed continuous variables, datums that approach the minimum 
and maximum are grouped into bins with more frequent ages. This has the 
advantage of providing additional data to determine the conditional probability 
of any particular state. In contrast, Equalwidth provides age bins that are 
consistent in size but have some bins with low frequency. In regard to learning 
the network structure, Sprits noted that a distinct challenge in discretization of 
continuous features is that conditionally independent continuous variables 
may be transposed into non-conditionally independent discretized foils.  
Therefore it is important to evaluate discretization methods that maintain the 
underlying causal relationships (Sprites, 2000). In practical application with 
the Aurora data, we found consistency and improved performance in 
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Bayesian classifier search results using EqualWidth when compared to other 
methods.   
Section 2: Directed Acyclic Graphs and Ensemble Learning 
Weakness within Bayesian Classifier searches:  
As outlined above, there are many Bayesian techniques for learning the 
causal structure of the variables. However, each of these methods is built 
upon several assumptions. For example, the PC algorithm and associated PC 
variants (e.g. CPC and JCPC) have the following assumptions: No hidden or 
selection variables that would suggest the number of variables grows with the 
sample size, if the underlying DAG is sparse, the data is multivariate normal 
and satisfies some regularity conditions on the partial correlations (Kalish, 
2007) and (Kalich, 2014). In contrast the FCI family of algorithms presumes 
that there may be hidden and selection variables; consistent in high-
dimensional settings if the so-called Possible-D-SEP are sparse (Sprites, 
2000), the data is multivariate normal and satisfies some regularity conditions 
on the partial correlations. These assumptions are necessary for the 
truthfulness of these search algorithms, yet they can often be violated and 
produce accurate results (Sprits; 2000; Domingos, 2012). How or to what 
degree the search assumptions may be violated and remain truthful is not 
consistent between data sets. Additionally, there is no known algorithm for 
determining the bounds that any given algorithm can be violated.  
Sprites (2000) does however offer a general guide of nine factors that 
determine the precision and accuracy of a DAG: 1. The correctness of the 
background knowledge, 2. How closely the Causal Markov Condition holds 
(e.g., no inter-unit causation, no mixtures of subpopulations in which causal 
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connections are in opposite directions), 3. How closely the Faithfulness 
Condition holds (e.g., no deterministic relations, no attempt to detect very 
small causal effects), 4. Whether the distributional assumptions made by the 
statistical tests hold (e.g., joint normality.), 5. The power of the statistical tests 
against alternatives, 6. The significance level used in the statistical tests, 7. 
The sample size, 8. The sampling method, 9. The sparseness of the true 
graphical model. Our goal then is creating a method that can be applied to 
any healthcare data set is to produce an evidence based method that can 
address the weaknesses in each Bayesian learning algorithm while 
simultaneously optimize the nine above conditions to determine the precision 
and accuracy of the DAG. In the following section, we describe several 
ensemble-learning techniques used in concert for increasing the robustness 
of DAG learning when employed on real world data sets. 
Bayesian Ensemble Learning  
Although there may be one particular algorithm that performs better for one 
data set over another, instead of experimenting to find one particular superior 
variation, the researcher can include many different algorithms at once with 
little additional effort. In many branches of applied machine learning 
ensembles have become the standard. As computational power increases 
alongside new combinations statistical techniques already developed (as well 
as those underdevelopment) the trend is towards ever-larger ensemble 
techniques. There are many techniques that have demonstrated improved 
results by linearly combining several Bayesian classifiers into an ensemble 
technique. The question then becomes what combination of ensemble 
techniques can best be applied to develop clinical avatars.  
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There are three widely tested and proven techniques within Bayesian 
ensemble learning, bootstrap aggregation (Bagging), Bayesian boosting and 
stacking.  Bagging is often considered the simplest technique. From one set 
of training data, the data is resampled at random and from each resample 
passes through a Bayesian search algorithm. Bagging has been shown to 
limit increase bias while dramatically increasing variance. There are both 
multiple methods for generating the random bootstraps and for combining 
results of the Bayesian searches. Boosting builds upon a similar principle as 
bagging, however, the results of each classifier result has a weight. The 
weights for each training set are varied so the proceeding classifier, training 
examples have weights, and these are varied so that each new classifier 
focuses on the previously weak results. In essence, boosting using several 
weak Bayesian classifiers and combines them into a single strong Bayesian 
classifier. In stacking, the outputs of individual classifiers are feed as input into 
a second Bayesian classifier. The second Bayesian algorithm then decides 
the best way to aggregate the results (Domingos, 2012). Our method includes 
the following ensemble techniques, bagging, two distinct methods of 
constraining both score and constraint based search algorithms with of 
domain knowledge, and lastly Bayesian Model Combination.  
The use of multiple bootstraps has been shown to address bias and variance 
reduction within the data and therefore reduce the number of false positives 
and false negatives (Friedman et al 1999). The demonstration of why bagging 
works and its implications has been discussed at length in previous 
publications (Domingos, 1997). As noted above, bagging generates an 
ensemble of DAGs from the bootstrap resamples of the training data and then 
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minimizing the overall distance to the entire ensemble derives an aggregated 
DAG. The size, the number of variables and character of those variables has 
an important role to play in the method used to bootstrap and segment the 
data into validation and training subset. There are several methods for 
bootstrapping that have demonstrated optimal results for particular sets of 
data. Four of the most common bootstrap methods were compared in a 
review by Broom (2012); the classic with replacement bootstrap, the Bayesian 
(or parametric) bootstrap, the bias corrected bootstrap and the double 
bootstrap aggregation (i.e., bootstrapping a bootstrap). Generally speaking 
the Bayesian bootstrap and the classic with replacement bootstrap perform 
comparably. There are several conditions that inform the researcher as to 
which technique should be applied to which data set (Broom, 2012). Bagging 
averages out General Noise features that cannot be cleaned from the data 
over progressively larger ensembles. Because we employ a pruning 
technique that removes edges with less that 50% commonality, this bagging 
also reduces false negatives. 
In experimentation with EMR data we employ a “repeated leave one out 
bootstrap aggregation” method (Clyde, 2004; Jiang 2007). Holding out data 
for cross validation is considered a data mining ‘best practice’ (Belazzi, 2004). 
However, when the sample size is small and outliers are important 
considerations in the data, holding out any amount of data reduces variance 
in the model. Therefore, it is recommended to perform the bootstrap sampling 
of the original data prior to the dividing the data between training and 
validation subsets. The choice of bootstrap sampling technique can ultimately 
impact the quality of the model. 
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The bootstraps should be drawn randomly with replacement to subsample of 
equal size to the original data. Regardless of what technique is used for 
bootstrapping, once the data is bootstrapped, then each bootstrap should be 
divided into training and 20% validation subset. The validation data should be 
pooled for validation of the BNM, while the training subsets should remain 
distinct for DAG training.  
The question of how many bootstrap resamples are needed is not easily 
answered because it depends on the specific sample size, dimensionality and 
characteristics of the data. Previous studies (Friedman, 1999) have used 
anywhere from one to two hundred bootstrap resamples to 2500 bootstrap 
resamples (Broom, 2012). No experiments to date have determined how 
many bootstraps are necessary when using conditional independence 
Bayesian search algorithms (such as the PC algorithm) with multidimensional 
data. However, our results demonstrate some consistency with the asymptotic 
improvement of search results with minimal increase in bias. Generally, the 
number of bootstraps should increase as the sample size gets smaller and the 
dimensionality gets larger. Across several types of Bayesian search 
classifiers, the ability for bagging of any variety to correctly infer causality 
breaks down between n=125 and n=250. We found that in healthcare data 
with 20 variables can be resampled with as few as 5 bootstraps and 
significantly increase variance and improve search results.  
As an additional method for increasing variance and correcting for bias in the 
generation of clinical avatars we recommend performing an ensemble of 
Bayesian classifier search algorithms on each bootstrap of data. Although it is 
likely that one search algorithm will produce the most accurate DAG, by 
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performing multiple types of Bayesian classifier searches on each bootstrap 
we found iterative convergence on particular edges. There are multiple ways 
to increases variance and adjust for bias in the selection of Bayes search 
algorithms. Since each particular Bayes search algorithm has specific 
assumptions (e.g., PC algorithm vs. IAMB) and it may be unknown as to 
which assumptions best suit the data, we suggest performing several types of 
algorithms on the same dataset. For example, given a set of training data the 
CFCI may produce superior results to the CPC algorithm if the data contains 
latent variables that affect the conditional probabilistic dependences since the 
CFCI does not make the same assumptions of no latent or hidden variables 
perturbing the data. If however there are known latent variables but it 
unknown definitive whether they affect the probabilistic dependences in the 
data, than the CPC algorithm may produce superior results.  
If the data has significant non-random missing values, or other forms of 
sampling bias, we recommend a second method for broadening the ensemble 
of Bayes searches. This method involves constraining some search 
algorithms with domain knowledge and allowing other the search algorithms 
to perform the search unconstrained the adjusting the orientation of the edges 
according to some predetermined tiers (see Section 1 Part II). The PC 
algorithm as well as variants of the PC algorithm (e.g., CPC, JCPC) is 
receptive to constraining the search space via domain knowledge. If you 
impose particular forbidden or required edges on the search space, the 
conditional independence oracle will adjust the series of independence tests it 
performs across the data. In highly dimensional data sets with limited sample 
size, this can increase the variability between search results. An additional 
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method involving ambiguity or time sensitive uncertainty within the domain 
knowledge is to modify the domain knowledge between certain bootstraps or 
groups of bootstrapped data sets. This enriches the hypothesis space that 
allows for certain DAGs to be true at certain moments in time and allowing 
others to be right at other times. As similarly recommended by Spirites (2000), 
we do not recommend the Bonferonni adjustment for multiple hypothesis 
tests.  However, if perform a large number of searches on the same data 
vector, it is possible to increase α to a more stringent parameter such as α = 
0.01 or 0.001. In respect to the PC family of algorithms, the graphical output 
because increasingly sparse as α value increases.  
Once all the necessary searches have been performed on the data, the 
resultant DAGs must be aggregated. There are several methods described for 
combining Bayesian search results. In accordance with other applications of 
Bayesian ensemble learning, we recommend combining all edges for each 
bootstrap and then pruning the edges according to some cut off. Depending 
on the dataset, some have pruned edges that were returned in greater than 
20% of search results, while others have selected edges that received 50% or 
more commonality. As of yet, there is not demonstrated empirical technique to 
determine how to aggregate edges within an ensemble of Bayesian search 
results. Therefore, we recommend applying both the 50% common edges 
and/or those edges that are supported by the domain knowledge aggregated 
prior to performing the search.  
With any data or domain knowledge that has the potential for significant bias, 
we recommend performing Bayesian model combination. Bayesian model 
combination has been demonstrated to improve search results when 
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compared to and combined with other ensemble learning techniques, 
(Monteith, 2011). Bayesian model combination is unique from aggregating 
multiple search results into one DAG because it allows for multiple potentially 
true DAGs to exist given ambiguous training data and or domain knowledge.  
Bias can be significant if the original training data contained missing values 
approaching 30% in any given variable and/or there was imputation 
performed. The essential element of Bayesian model combination is that 
instead of converging all Bayesian searches performed in this section into a 
single DAG, several resultant DAGs are then used in parallel for section three.  
Each DAG is used to derive a parametric model that is input into conditional 
probability estimators. Each DAG plus conditional probability will ultimately 
generate data via Monte Carlo simulation. The data is then aggregated via 
either a Dirichlet weighted distribution or an unweighted distribution. Lastly, to 
further demonstrate the robustness of particular classifiers, this aggregation of 
data can be searched and the results compared to the DAGs used to model 
the input data.  
A strength and a weakness of DAG’s are their openness to interpretation. No 
fewer than half a dozen different interpretations are used in the application of 
DAG’s to various fields and in their theoretical discourse. Standard practice in 
Epidemiology dictates that the directed arrows within the DAG have direct 
causal meaning, (e.g., “X  Y“ would read as X is the causal parent to Y, or 
even stronger, X is the cause of Y) (Evens, 2012). There are three explicit 
assumptions that must be undertaken to assume that DAG’s represent a 
causal map: 1.) There exists some true DAG that is a causal DAG 
representation of the system being studied, 2.) This causal DAG is identical to 
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the DAG representative of the probabilistic conditional independence 
properties of the system, 3) The third is the faithfulness assumption, that the 
causal DAG is a probabilistically faithful representation of the system. A 
weaker interpretation has been described as probabilistic conditional 
independence of two particular variables and the causal independence of 
those same two variables given a third (Sprites, 2008).   
In the development of clinical avatars we apply the most robust and 
theoretically truthful interpretation of the DAGs. According to a strict 
theoretical presentation, A DAG mirrors the symmetric conditional 
independence relationships within the data and imposes asymmetric 
probabilistic relationships between the variables via geometric interpretation. 
The directionality of the arrows, in a purely theoretic plane, has been 
described as “artifact…although it plays an important role in the formal syntax 
of the model it has no direct counterpart in the world and contributes only 
indirectly to the semantic interpretation of the model” (Dawid, 2010). Because 
of the ambiguity inherent in any given DAG, the bootstrap aggregation 
(“Bagging”) procedure provides more robust clinical avatars. By widening the 
hypothesis space to include a greater collection of possibly true results (e.g., 
DAGs), we allow for the final clinical avatar population to be maximally 
consistent with conditionally independent relationships within both the data 
and the real world representing the data. Any additional reference to specific 
strong causal relationships found within the DAG search results are strictly 
outside the scope of developing clinical avatars. We do recognize that this 
method could be used to guide a more causally complete interpretation of a 
given set of data. Applying the clinical avatar pipeline would be useful in 
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inferring causal patterns in a number of fields and datasets. Nevertheless for 
the development of clinical avatars this strong assumption is not necessary.  
Rather it is more important to find the significant probabilistic relationships that 
need to be replicated in order to capture the essence of the data. The 
resultant DAG from the executed searches is used to derive a parametric 
model that is input into conditional probability estimators. The DAG plus 
conditional posterior probabilities will ultimately generate clinical avatars.  
Section 3:  Estimating Conditional Probabilities via Ensemble learning 
Once the DAG is developed in section two there are a variety of 
computational efficient Bayesian algorithms that estimate the conditional 
probability of each particular state within the DAG. However, as noted in the 
introduction section, there are several important assumptions that should be 
examined before applying these algorithms to the training data. Again these 
assumptions revolved around statistical sufficiency. We found that bagging in 
the same manner as completed in section 2 for structure learning, can 
dramatically improve the resultant clinical avatars. The original training data 
can be bootstrapped via a parametric bootstrap or a classic bootstrap. 
However, of critical importance, we recommend again holding out a portion of 
the data within the bootstrap to be used for validation of the model.  
Even with bagging there are challenges of statistical sufficiency. There are 
times when the available training data is not sufficiently large to calculate the 
probability of a parameter within the Bayes net. When such an event occurs 
there are several ways to refine the model to appropriately accommodate the 
available training data. We suggest that the DAG be simplified via removing 
edges from the DAG results one at a time in order of confidence until 
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sufficient cases exist within training data to calculate conditional probabilities.  
There are several methods to determine robustness of an edge within a DAG.  
We recommend the following logic flow for pruning edges from the DAG until 
there are sufficient cases in the training data to calculate the conditional 
probability for all relevant states from the parent nodes.  
1.) If ensemble Bayesian searches were performed on the data, delete the 
edge that returned the fewest search results  
2.) If there were not multiple searches performed, iteratively complete the 
search at a more stringent α value until an edge is deleted.  
3.) If all search results produce the same causal parents to the point of α = 
0.0000001 then use evidence and or domain knowledge to delete the 
least robust edge 
4.) Lastly, if there is no relevant domain knowledge or unambiguous 
evidence then use regression to delete the least robust edge. 
Once the DAG has been simplified, the conditional probabilities derived from 
the simplified model were then used as input for the original parametric 
model.   
The second element of statistical sufficiency is the issue of missing values.  
Although as noted in the background section, MLE and MAP-estimators 
produce stronger results because they are not subject to becoming trapped in 
local maxima within high-dimensional datasets, they are unable to 
accommodate missing values. Therefore if data has non-random missing 
values, and certain parameters have a high concentration of missing values 
while others do not have missing values, we recommend that the parameters 
without missing values be estimated use MLE or MAP-estimators while the 
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parameters with missing values use the EM or EM-variant algorithm to 
estimate the parameters. If any sub-parameter within a categorical data set is 
also subject to a concentration of missing values greater than 30%, we 
recommend using the Median probability for the variable on as a whole if 
binary or the average if it is categorical.   
Once the parameters of one or more Bayes net are estimated via the training 
data, the estimations should be aggregated into a single instantiated model. 
Here the conditional probability estimates from several algorithms can be 
combined into an ensemble for each bootstrap of data. Each parameter 
should be estimated using the most robust technique given the limitations of 
the available data. Once each parameter is associated with a conditional 
probability, a set of data can be generated using Monte Carlo simulation 
techniques. Each bootstrap and instantiated model should have an equal 
amount of data generated. We have called these sets of data "preliminary 
avatars" since they satisfy the conditions of being simulated patients. But 
since the model has not yet been validated they cannot yet be considered 
“functional” clones of the original patient training dataset. Each set of 
preliminary avatars should be pooled into a signal set of data.   
At this point the pooled preliminary avatars may enter final section for 
validation. If the preliminary avatars lack a variable, either a latent parent or 
hidden descendent, the pooled preliminary avatars should enter a final series 
of parameter learning. Here the DAG(s) already developed from section 2 are 
again put to use to derive the necessary parametric models that establish the 
Bayes net. The pooled preliminary avatars can then been used to again 
estimate the conditional probabilities across the Bayes net.  At this stage, only 
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the MLE or MAP-estimators should be used since there are no missing values 
within the dataset. If however there is a similar problem with insufficient 
statistics to estimate the conditional probabilities, a similar 4-step strategy 
should be used to simplify the conditional dependences within the DAG. This 
single Instantiated model can then be used to generate the avatars for section 
four. 
Section 4: Validation of the BNM 
Following the pattern learning as well as the parameter learning, the model is 
nearly complete. In section four, the process enters the validation stage of the 
method. There are many potential ways to validate the BNM. We suggest that 
following data mining best practices, a portion of the data should be held out 
for validation. As noted in sections 2 and 3, each bootstrap should have a 
portion held out for validation. Validation can proceed via aggregating the 
bootstrap portions of the data, or the validation sections can be maintained 
distinct and to allow for k-fold validation testing. If the validation data is 
pooled, there are several methods for validating the model against the pooled 
validation data. Two of the most basic styles of comparisons used to ensure 
that the simulated population is representative of the original data. The first is 
univariate distribution, or the comparative frequency of a single attribute 
between the training data and clinical avatars. The second comparison is the 
bivariate frequency distribution between the training and clinical avatar data 
sets. Variables in which the Bayesian algorithm determined a causal 
connection and are "d-connected" are plotted in frequency histograms. 
Different statistical tests should be used to determine variance between the 
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variables. Z-tests can be used for continuous variables and χ2 contingency 
test or G-test can be used for discrete variables.  
The development of clinical avatars is an iterative process that often requires 
perfecting. If significant variance is found in either the univariate or bivariate 
distribution, the process is refined until there is no significant difference. At 
each section there are several options that may be refined depending on the 
type, size and quality of data used to train the Bayesian model. Of critical 
importance is the use time and care spent in section one, preprocessing the 
data and aggregating domain knowledge. Different styles of data aggregation 
and reduction as well as imputation can dramatically change the structure and 
output of a Bayesian Network Model. If any significant variation is found in the 
first model, the entire structure should be dissolved and the method should be 
restarted from section one.   
If the clinical avatars have demonstrated no significant variance, then at this 
step, the latent or hidden variables should be added to the final instantiated 
model in section 3. The variables that are imposed on the Bayesian network 
model should be associated with some additional evidence that demonstrates 
a probabilistic conditional dependency to a variable(s) existing within the 
model. Thus, when the parameters for the additional variable(s) are imposed 
on the model the estimated conditional probabilities can be imposed on the 
Instantiated model. Once all the desired variables exist within the DAG, and 
the relationships within the Bayes net are associated with conditional 
probabilities, the BNM is complete and ready to produce an unlimited number 
of clinical avatars via Monte Carlo methods.  
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3.2.) Clinical Pharmacology 
Anticoagulation agents do not directly affect established thrombi. In the case 
of occurrence of a thrombus, anticoagulants are usually administered to (a) 
prevent the growth of the existing clots and (b) prevent the movement of the 
clots which might result in serious and possibly fatal thromboembolic 
complications.  
Warfarin or coumadin is an anticoagulation agent which inhibits the synthesis 
of vitamin K-dependent coagulation factors (i.e., Factors II, VII, IX and X). 
Crystalline warfarin sodium (3-(a-acetonylbenzyl)-4-hydroxycoumarin) is a 
racemic mixture of the R- and S-enantiomers. Its empirical formula is C19H15 
NaO4 (Figure 3.8). 
Warfarin is the most commonly prescribed anticoagulant in the world 
(Pirmohamed, 2006). The number of dispensed warfarin prescription has 
reached to 30 millions and over 2 million patients are on warfarin in the United 
States to prevent and for the complications that may occur from 
thromboembolism (e.g., stroke, heart attack) (Wysowski, 2007; Guyatt, 2012). 
Warfarin is an effective medication but also has some clinical shortcomings. 
For instance, a large number of medications and foods interact with it. Many 
Figure 3.8. The structural formula of crystalline warfarin sodium. 
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commonly used medications interact with warfarin. Consequently, it is 
monitored by international normalized ratio (INR) blood tests to ensure safe 
adequate doses are taken (Ansell, 2008). An INR beyond the targeted range 
predisposes to a high risk of bleeding, while an INR below the therapeutic 
target range indicates that the dose of warfarin is insufficient to protect against 
thromboembolic events. 
3.2.1.) Mechanism of Action 
Anticoagulant warfarin inhibits the synthesis of vitamin K dependent 
coagulation factors (e.g., Factors II, VII, IX and X) and also the anticoagulant 
proteins C and S.  
Table 3.1. Half-life of blood factors and proteins involved in coagulation. 
Coagulation Factors and Proteins Half-Life (hour) 
Factor II 60 
Factor VII 4-6 
Factor IX 24 
Factor X 48-72 
Protein C 8 
Protein S 30 
 
Warfarin suppresses the process of coagulation by decreasing the production 
and activities of the coagulation factors by inhibition of the regeneration of 
vitamin K1 epoxide. Vitamin K is an essential cofactor for the gamma-
carboxylation of the coagulation factors.  
3.2.2.) Pharmacokinetics and Pharmacodynamics 
Pharmacodynamics (PD) 
Based on the current evidence, warfarin inhibits C1 subunit of the vitamin K 
epoxide reductase (VKORC1) enzyme resulting in reduction in synthesis of 
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clotting factors as well as vitamin K1 epoxide. This effect is proportional to the 
VKORC1 genotypic profile of patients and also the dosage of the medication. 
“Therapeutic doses of warfarin decrease the total amount of the active form of 
each vitamin K dependent clotting factor made by the liver by approximately 
30% to 50%. An anticoagulation effect generally occurs within 24 hours after 
warfarin administration. However, peak anticoagulant effect may be delayed 
72 to 96 hours. The duration of action of a single dose of racemic warfarin is 2 
to 5 days. The effects of warfarin may become more pronounced as effects of 
daily maintenance doses overlap. This is consistent with the half-lives of the 
affected vitamin K-dependent clotting factors and anticoagulation proteins: 
Factor II - 60 hours, VII - 4 to 6 hours, IX - 24 hours, X - 48 to 72 hours, and 
proteins C and S are approximately 8 hours and 30 hours, respectively” 
(Coumadin, 2011). 
Pharmacokinetics (PK) 
Warfarin is a racemic mixture of the R- and S-enantiomers. The clearance of 
S-enantiomer in the body is much quicker than R-enantiomer. It is also a more 
active anticoagulant component compared to R- enantiomer (i.e., 2 to 5 times 
more active). 
Absorption 
Warfarin’s maximum blood concentration is usually attained within 4 hours 
after oral administration. Warfarin is completely absorbed after oral 
administration. 
Distribution 
Almost all warfarin binds to plasma proteins. According to the warfarin’s label 
(Coumadin, 2011), “using a one compartment model, and assuming complete 
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bioavailability, estimates of the volumes of distribution of R- and S-warfarin 
are similar to each other and to that of the racemate.” 
Metabolism 
According to the warfarin’s label (Coumadin, 2011), “the elimination of 
warfarin is almost entirely by metabolism. Warfarin is stereoselectively 
metabolized by hepatic microsomal enzymes (cytochrome P-450) to inactive 
hydroxylated metabolites (predominant route) and by reductases to reduced 
metabolites (warfarin alcohols). The warfarin alcohols have minimal 
anticoagulant activity. The metabolites are principally excreted into the urine; 
and to a lesser extent into the bile. The metabolites of warfarin that have been 
identified include dehydrowarfarin, two diastereoisomer alcohols, 4'-, 6-, 7-, 8- 
and 10-hydroxywarfarin. The cytochrome P-450 isozymes involved in the 
metabolism of warfarin include 2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. 2C9 is 
likely to be the principal form of human liver P-450 which modulates the in 
vivo anticoagulant activity of warfarin. The S-enantiomer of warfarin is mainly 
metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme.” 
CYP2C9 variant alleles have significant effects on the metabolism of warfarin. 
The single or multiple variant alleles of this gene (e.g., *1/*2, *1/*3, *2/*2, 
*2/*3, *3/*3) decrease metabolism of warfarin through lower CYP2C9 
enzymatic 7-hydroxylation of S-warfarin and results in decreased S-warfarin 
clearance (Table 3.2, Yasar, 1999). 
Excretion 
The half-life of R-warfarin ranges from 37 to 89 hours, while that of S-warfarin 
ranges from 21 to 43 hours. More than 90% of the received warfarin is 
detectable in urine and is excreted through urine in the form of metabolites.   
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Table 3.2. Relationship between S-Warfarin Clearance and CYP2C9 
Genotype in Caucasians Patients (Yasar, 1999). 
CYP2C9 Genotype 
Number of 
Study Subjects 
S-Warfarin Clearance/Lean Body Weight  
(mL/min/kg) Mean(SD) 
*1/*1 118 0.065(0.025) 
*1/*2 or *1/*3 59 0.041(0.021) 
*2/*2, *2/*2, or *3/*3 11 0.020(0.011) 
Total 188  
 
Elderly 
According to different dosing guidelines (e.g., AGSCP Guidelines, 2000), the 
use of warfarin in older people requires special consideration as their PT/INR 
response to the anticoagulant effects of warfarin is greater than expected. It is 
unknown why they are more sensitive to warfarin. Therefore, as patient age 
increases, a lower dose of warfarin is usually required to reach the therapeutic 
INR level. 
Asians 
Asian patients may require lower initiation and maintenance doses of warfarin. 
In a number of studies, it has been observed that Chinese patients require 
lower warfarin dosages to achieve an INR of 2-2.5 (Veenstra, 2005). Some 
studies also have shown that the most important determinant of warfarin 
dosage in Chinese patients is age (e.g., Veenstra, 2005). 
Renal Dysfunction 
Given that renal clearance has minor effect body’s response to warfarin, there 
is no need to make dose adjustment if a patient had renal failure. 
Hepatic Dysfunction 
Liver has an important role in the metabolism of warfarin. Accordingly, any 
hepatic dysfunction, which usually results in impairment in the synthesis of 
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clotting factors as well as decreased warfarin metabolism, can enhance body 
response to warfarin. 
3.2.3.) Pharmacogenomics 
In 2005, Sanderson team reported the results of a meta-analysis of 9 studies 
(2775 patients: 99% Caucasian) performed to investigate the CYP2C9 gene 
variants-associated clinical outcomes in warfarin-treated patients (Sanderson, 
2005). In this meta-analysis, some of the qualified included studies assessed 
bleeding risks and the rest of the studies assessed daily dose requirements. 
The analysis suggested a higher risk of bleeding risk and lower mean daily 
dose of warfarin for patients with either the CYP2C9*2 or CYP2C9*3 alleles.  
Patients with CYP2C9*2 and CYP2C9*3 alleles have lower mean daily 
warfarin doses and a greater risk of bleeding, 17% and 37% less than the 
mean daily dose for patients homozygous for the CYP2C9*1, respectively.  
In a prospective study of 219 Swedish patients under warfarin treatment who 
were stratified by CYP2C9 genotype, Lindh et al. discovered that the risk of 
overanticoagulation (i.e., achieving INR >3) during the first 2 weeks of 
warfarin therapy was two times higher for the patients with the polymorphic 
variant alleles (CYP2C9*2 and CYP2C9*3) compared to patients with wild-
type CYP2C9 (Lindh, 2005). 
Many studies have found that patients with some of the VKORC1 gene’s 
single nucleotide polymorphisms (e.g., -1639G>A, rs9923231) require lower 
initial doses of warfarin. Gene VKORC1 regulates the synthesis of the vitamin 
K–epoxide reductase (VKOR) protein which is the target enzyme of warfarin 
(Rost, 2004; Li, 2004). The -1639G>A polymorphism alters the biding sites of 
the VKOR which results in a reduction in protein expression (Rieder, 2005; 
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Yuan 2005). A large number studies have discovered that the variants of 
VKORC1 and CYP2C9 genes are individually responsible for 35% to 50% of 
the variable dose response to warfarin. For example, Wadelius team reported 
an association between VKORC1 gene variations and lower required dose of 
warfarin. In this study with a study cohort of 201 white patients under warfarin, 
they attributed about 30% and 40% of the variance in warfarin dose to 
variations in the VKORC1 gene and variations in VKORC1 and CYP2C9 
genes combined, respectively (Wadelius, 2005). Several multivariate analyses 
have shown that the addition of patient characteristics, such as age, gender, 
height, weight and other medications, to CYP2C9 and VKORC1 accounts for 
approximately 50-60% of warfarin dose variability. 
3.2.4.) Accounting for Adverse Reactions 
Oral anticoagulants, most commonly warfarin, reduce risk to thrombosis and 
treat conditions that might lead to stroke, pulmonary embolism, deep vein 
thrombosis or other blood clotting related disease. The impact and value of 
anticoagulation medication in the U.S. is dramatic. For example, stroke is the 
third leading cause of death in the U.S. with over 140,000 deaths annually.  
The majority of stroke incidences are due to ischemia (87%) or transient 
ischemic attack (TIA, ~5-10%) and are typically managed by the use of 
anticoagulation agents such as warfarin, dabigatran, and clopidogrel.  
Whatever the patient’s disease or condition leading to a prescription of an 
anticoagulation agent, selecting the best combination of drug and treatment 
protocol is complicated by the individual differences in anticoagulation 
medication response (e.g. >20-fold difference for warfarin) due to genetics, 
physiology, and compliance. Consequently, given this characteristic, any 
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small increase or decrease in medication dosage might increase the risks of 
bleeding or thromboembolic events, respectively (Ansell 2008). In practice, 
providers use a combination of experience, scientific evidence and clinical trial 
results to develop anticoagulation “best practice” treatment plans designed to 
roughly minimize the patient-to-patient response variability and risks across 
the provider’s patient population. However, the high degree of patient 
heterogeneity causes variations in individual patient response to these “best 
practice” drug-protocol approaches. Another factor that makes the 
management of warfarin more complex is its interactions with many other 
medications and foods. Therefore, warfarin is among the medications with a 
high rate of associated adverse reactions (Ansell, 2008). 
According to the 2010 FDA-approved warfarin (Coumadin) product label 
(Coumadin, 2011), there are a wide range of adverse reactions associated 
with warfarin: 
- Fatal or nonfatal bleeding from any tissue or organ. Depending on the 
severity and location of the bleeding, the complications may present as 
paralysis; paresthesia; headache, chest, abdomen, joint, muscle or other pain; 
dizziness; shortness of breath, difficult breathing or swallowing; unexplained 
swelling; weakness; hypotension; or unexplained shock. One important point 
with regard to bleeding during anticoagulation therapy is that it does not 
always correlate with PT/INR. In this case, the bleeding might have been 
resulted from other disorders such as tumors and ulcers. 
- Necrosis of skin and other tissues. 
- Infrequent or rare adverse reactions: hypersensitivity/allergic reactions, 
including anaphylactic reactions, systemic cholesterol microembolization, 
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purple toes syndrome, hepatitis, cholestatic hepatic injury, jaundice, elevated 
liver enzymes, hypotension, vasculitis, edema, anemia, pallor, fever, rash, 
dermatitis, including bullous eruptions, urticaria, angina syndrome, chest pain, 
abdominal pain including cramping, flatulence/bloating, fatigue, lethargy, 
malaise, asthenia, nausea, vomiting, diarrhea, pain, headache, dizziness, loss 
of consciousness, syncope, coma, taste perversion, pruritus, alopecia, cold 
intolerance, paresthesia including feeling cold and chills, tracheal or 
tracheobronchial calcification, and priapism. 
3.2.5.) Clinical Protocols 
The narrow therapeutic range and wide interindividual variability in warfarin 
therapeutic dose (such as 4.5–77 mg/week (Wadelius, 2004)) make 
anticoagulation management challenging and anticoagulation response 
unpredictable. Current clinical best practice relies primarily on empirical 
dosing. Accordingly, most patients usually start taking a fixed dose each day 
(such as 5 mg/day) during the “initiation phase” of warfarin on the basis of 
population averages, regardless of clinical and genetic factors (Garcia, 2005). 
Then, based on the INR results, the dose is titrated. This empirical clinical 
practice approach requires frequent changes in the dose of warfarin in 
response to out-of-therapeutic range INRs and to avoid adverse effects and 
maintain therapeutic efficacy. To address this challenge, mainly before the 
completion of the Human Genome Project, a number of dosing algorithms that 
included clinical variables were developed. Since the successful completion of 
the project and in the light of discoveries of polymorphisms in cytochrome 
P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1) 
which jointly account for about 40-50% of the inter-individual variability in dose 
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requirements, a large number of pharmacogenetic-based dosing algorithms 
have been also developed. However, the potential benefit of these dosing 
algorithms in terms of their safety and clinical utility has not been adequately 
investigated in randomized settings. 
3.2.6.) Dosage and Administration 
The dosage and administration of warfarin must be individualized for each 
patient. The warfarin dose management is an iterative process which starts 
with administering an initial dose and then is followed with dose adjustments 
based on the patient’s INR response to the medication (Figure 3.9).  
 
As discussed earlier, many factors cause warfarin dose variability such as 
clinical factors including age, race, body weight, sex, concomitant 
medications, comorbidities and diet and genetic factors including CYP2C9 
and VKORC1 genotypes. To initiate a warfarin dose, there are different 
options such as: 
- According to FDA, if the patient’s genotypes are known, we can use the 
following table (Table 3.3) to select the initial dose. If the genotypes are not 
available, the initial dose of warfarin is usually 2 to 5 mg/day. This dose 
should be modified based on consideration of patient-specific clinical factors. 
 
Figure 3.9. The iterative process of dosing and adjusting warfarin 
dose until achieving maintenance dose and INR in therapeutic range. 
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Table 3.3. Recommended daily warfarin doses (mg/day) to achieve a 
therapeutic INR based on CYP2C9 and VKORC1 genotype using the warfarin 
label approved by the US Food and Drug Administration (Johnson, 2011). 
VKORC1 Genotype  
(-1639G>A, rs9923231) 
CYP2C9 Genotype 
*1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3 
GG 5-7 5-7 3-4 3-4 3-4 0.5-2 
GA 5-7 3-4 3-4 3-4 0.5-2 0.5-2 
AA 3-4 3-4 0.5-2 0.5-2 0.5-2 0.5-2 
 
- Use any available clinical or PG-based dosing algorithms to calculate 
appropriate initial dose or 
- Use the standard fixed-dose practice (5mg/day, Loading Dose: 10 mg/day). 
After initiating warfarin, the subsequent dosage adjustments must be made 
based on INR results until achieving a maintenance dose and an INR in 
therapeutic range.  
3.2.7.) PK/PD Modeling and Simulation (INR Prediction) 
In order to model the pharmacodynamics (PD) and pharmacokinetics (PK) of 
a medication, the relationship between drug dose, plasma concentration, 
biophase concentration (pharmacokinetics), and drug effect or side-effects 
(pharmacodynamics) is characterized, and relevant patient covariates are 
included in the model (Figure 3.10). Modeling of pharmacokinetic and 
pharmacodynamic can be used to make predictions about the “temporal 
profile of the drug concentration” and “its effect” which ultimately helps select 
PK 
Model 
Concentration Effect Drug 
PD 
Model 
Figure 3.10. A schema depicting the general relationship of pharmacokinetic 
(PK) and pharmacodynamic (PD) models used in clinical pharmacology. 
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appropriate dosing protocol and “optimal delivery profile” (Yan, 2013). 
A number of studies have been undertaken to model PK and PD of warfarin. 
The aim of most of these studies have been to develop population models to 
describe the PKs of both S- and R-warfarin and the PK-PD relationship 
between warfarin exposure/concentrations and anticoagulant response (i.e., 
INR), including identification of important predictors for a priori dose 
individualization of warfarin. 
In the next following section before reviewing one of the warfarin’s PK/PD 
models, We are going to briefly go over some fundamental concepts of PK 
and PD.  
Pharmacokinetic Models 
Pharmacokinetics (PK) studies the relationship between drug concentration 
and its effect on the body. PK principles are often used to reduce toxicity and 
improve efficacy during patient care. The suite of tools used in PK studies are 
mathematical models, used to quantify the processes of drug Absorption, 
Distribution, Metabolism, and Excretion (ADME) in the body. Rates of 
reactions and compartmental architecture are two important properties of PK 
models that control how these ADME processes are modeled. 
Rates of Reaction 
The ADME processes can be modeled as either zero-order or first-order 
reactions. The order of the reaction is the rate of change of a variable over 
time. Consider an example where drug A is modeled. In a zero-order reaction, 
the rate of change of drug A would be constant (see equation A), where k* is a 
zero-order rate constant. Here the rate of change of A is independent of the 
concentration of A. In a first-order reaction, the rate of change of drug A is 
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proportional to A (see equation B), where k is a first-order rate constant 
(Dhillon, 2006). 
DE
DF =  −H
∗     (A) 
DE
DF =  −HJ     (B) 
The drug’s rate of reaction has important clinical implications. Drugs that have 
first-order rate of elimination do not accumulate within the body because as 
concentration increases so does the elimination rate. In contrast, drugs with 
zero-order rates of elimination will accumulate with continued administration. 
However, a first-order reaction can be altered to appear as a zero-order 
reaction in such situations as overdosing. At clinical dosages though, most 
drugs are first-order reactions, with a few zero-order examples such as 
phenytoin and high-dose salicylates. 
Compartmental Models 
The compartmental architecture of a PK model determines the fate of a drug 
after it enters the body. Although the compartments are hypothetical 
structures to model the body, they do have underlying biological reasoning to 
describe how a drug is processed. In reality, drug concentration and kinetics 
will vary with the type of tissue (e.g. brain versus muscle). Therefore, to 
accommodate different modeling scenarios there are several types of 
compartmental architectures. 
One-compartment Model 
The one-compartment model represents the body with one compartment and 
makes the simple assumption that once the drug is introduced it is 
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instantaneously and homogeneously distributed throughout the body (Figure 
3.11, Dhillon, 2006). The drug concentration is monophasic and decreases 
exponentially with time, or linearly if the log of drug concentration is taken 
(Figure 3.12, Dhillon, 2006). 
 
Two-compartment Model 
The two-compartment models decompose the body into two tissues types: the 
central component represents highly perfuse tissue (e.g. heart, kidneys and 
lung) and the peripheral component represents tissues that are less perfuse 
(e.g. skin, muscle and fat). The two-compartment model allows more complex 
drug concentration dynamics than the one-compartment model. Upon 
administration, the drug’s concentration has a two phases: it is initially highly 
concentrated in the central component but rapidly declines as it distributes to 
the peripheral component. After reaching equilibrium between the two 
Figure 3.11. One-compartment model. ka = absorption rate constant, k = 
elimination rate constant. Adopted from (Dhillon, 2006). 
Figure 3.12. (a) Plasma concentration (Cp) versus time. (b) 
Time profile of a one-compartment model showing log Cp 
versus time. Adopted from (Dhillon, 2006). 
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compartments, the drug then declines more slowly as it is eliminated from the 
central compartment. Hence, the drug concentration over time shows a 
biphasic response (Figure 3.13, Dhillon, 2006). 
Multi-compartment Model 
The multi-compartment models allow even more complex drug concentration 
dynamics. With higher number of compartments there will be more phases in 
the drug concentration over time (Figure 3.14). 
Pharmacodynamics 
Pharmacodynamics studies the drug’s effect on the body by describing how 
the drug affects local physiological and biochemical processes in the body. At 
the core of the pharmacodynamics approach is the reaction equation (see 
Figure 3.13. (a) Plasma concentration versus time profile of a drug 
showing a two compartment model. (b) Time profile of a two-
compartment model showing log Cp versus time. Adopted from 
(Dhillon, 2006). 
Figure 3.14. (a) Plasma concentration versus time profile of a drug 
showing multi-compartment model. (b) Time profile of a multi-
compartment model showing log Cp versus time. Adopted from 
(Dhillon, 2006). 
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equation 1) describing the relationship between the drug (D), receptor (R), 
drug-receptor complex (DR), and the effect (E), where kon and koff are the rate 
of drug and receptor association and the rate the complex dissociation, 
respectively. Of course more complex kinetics is possible, but even with such 
a simple expression some very useful clinical information can be gleaned. The 
responsibility of researchers and clinicians is then to tailor the mathematical 
model describing the reaction equation to their pharmacodynamics scenario 
(Dhillon, 2006).  
The expression in equation C has several clinically relevant properties.  
* + K 
LMNN
OPPPQRRRRRRRRRS
AMT  *K AU→  W                       
The receptor dissociation rate constant (kD) describes the equilibrium rate 
between the rate of kon and koff (equation D). This principal demonstrates, for 
example, that if [D] is very high then the receptors are saturated, and no 
significant increase in [E] can take place. The idea that there can be a limit to 
the amount of effect is quantified with Emax, the maximal effect for all drugs. 
There is another, related value denoted EC50, which quantifies the 
concentration at which E is 50% of Emax. These constants are important for 
determining the relationship between drug concentration and effect, and how 
pharmacodynamics models are put into use (Dhillon, 2006). 
XYZZ
XY = XD =
=*>=K>
=*K>                       * 
Different pharmacodynamics scenarios dictate the mathematical form 
describing equation C. Effect can be sigmoidal or linearly related to drug 
concentration depending on modeling assumptions. The most general 
equation is shown in equation E, a sigmoidal relationship (Dhillon, 2006).  
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W =  W[\/ .  

W^_ +                        W 
C represents the drug concentration, and n is the “Hill” coefficient, determining 
the “steepness” of the concentration-effect relationship. Very high values of n 
(n>5) can make the relationship so steep as to effectively make the drug have 
a binary effect (i.e. the effect is present or not). Equation F represents the 
case of n=1 (Dhillon, 2006).  
W =  W[\/ . W^_ +                       ` 
Equation G simplifies equation 3 to a linear relationship. This may be useful in 
situations where C is much less than EC50 and the range of clinical dosage is 
very narrow (Dhillon, 2006).  
W ≈  W[\/W^_ .  = bcd.                       B 
The log of equation G can be taken to yield equation H (Dhillon, 2006).  
W = bcd. log                       e 
A model describing a log-linear relationship can be useful in situations where 
there is high intrinsic variability, but the drawbacks of such models include the 
inability to represent the case where C is zero such as in placebo studies. The 
fundamental concentration-effect relationships are outlined in Figure 3.15. 
Continuous PD models 
PD models can be either continuous or categorical, although the focus here is 
on continuous models. The type of model used depends on the nature of the 
data, such as whether the data is continuous (e.g., blood pressure and 
weight), categorical (e.g., grade of adverse event), and the frequency of 
measurement. The different concentration-effect relationships discussed 
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 above provide crucial flexibility for different pharmacodynamics scenarios, but 
more building blocks are needed to accommodate the diverse physiological 
context the concentration-effect dynamics take place. Figure 3.16 outlines five 
common types of continuous PD models in use. 
 
 
 
 
 
Figure 3.15. Fundamental concentration-effect relationships. (a) The Emax 
concentration-effect relationship that arises from receptor theory for the binding 
of a single drug to a single receptor. Fifty percent of the maximum effect is 
achieved at the EC50 concentration. (b) The same relationship over a much 
wider log-concentration scale. (c) The sigmoid Emax concentration-effect 
relationship that arises from receptor theory when there is allosteric inhibition or 
simulation of binding. The “Hill factor” n controls the steepness of the middle 
part of the curve. (d) A linear concentration-effect relationship that is a 
semiempirical but sometimes useful substitute for an Emax relationship when the 
range of concentration is relatively small and the drug effect is well below Emax. 
Adopted from (Upton, 2014). 
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Hamberg’s PK/PD Model  
The aim of the Hamberg’s study (Hamberg, 2007) was to characterize the 
Figure 3.16. Representative continuous pharmacodynamic models. (a) A 
direct response model where effect is driven by the plasma drug 
concentration. (b) An effect compartment model where effect is driven by 
the effect compartment drug concentration, which is delayed relative to 
the plasma concentration by a first-order rate constant ke0. (c) A turnover 
model where drug effect is a balance between an apparent production 
rate (kin) and an apparent removal rate (kout). Drug affects the net effect 
by altering kin or (kout). (d) A transit compartment model, where the drug 
effect is at the end of chain of processes and drug action is on the first 
process. (e) A tolerance compartment model, where the drug effect is 
described by an effect compartment and the development of tolerance is 
described by a slower inhibitory compartment that reduces the net drug 
effect with time. Adopted from (Upton, 2014). 
a 
b 
d 
c 
e 
108 
 
 
 
relationship between warfarin concentrations and international normalized 
ratio (INR) response and to identify predictors important for dose 
individualization. S- and R-warfarin concentrations, INR, and CYP2C9 and 
VKORC1 genotypes from 150 patients were used to develop a population 
pharmacokinetic/pharmacodynamic model in NONMEM (Beal, 1994). The 
anticoagulant response was best described by an inhibitory EMAX model, 
with S-warfarin concentration as the only exposure predictor for response. 
Delay between exposure and response was accounted for by a transit 
compartment model with two parallel transit compartment chains (Figure 
3.17).  
 
They also found a two-compartment PK model with first-order input and first 
order elimination to appropriately characterize the disposition of S-warfarin 
(Figure 3.18). 
Figure 3.17. A two-chain transit compartment PD model used by Hamberg et 
al. to describe the INR response to warfarin therapy. Mean Transit Times 
(MTTs), Apparent clearance of S-warfarin [CLs], EC50 (concentration 
resulting in 50% of Emax), λ is the sigmoidisity factor, describing the 
steepness of the concentration–effect relationship, A1–7 indicate 
compartment amounts, A1–6 are the compartment amounts in the "long" 
transit chain, whereas A7 is the compartment amount in the "short" transit 
chain (Hamberg, 2007).  
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In their study, CYP2C9 genotype and age were identified as predictors for S-
warfarin clearance, and VKORC1 genotype as a predictor for warfarin 
sensitivity. Accordingly they have modeled the ith individual’s jth observed 
INR value (INRij) according to:  
INRij=BASEi+INRMAX(1-A6*A7)λ 
BASEi is the ith individuals observed baseline INR value whose predictive 
covariates are Age, CYP2C9 and VKORC1, INRMAX is the maximum INR 
increase from baseline, λ is the sigmoidisity factor, describing the steepness 
of the concentration - effect relationship, A1–7 indicate compartment 
amounts, A1–6 are the compartment amounts in the "long" transit chain, 
whereas A7 is the compartment amount in the "short" transit chain (Hamberg, 
2007). According to Hamberg, predicted INR curves show significant steady-
state differences across patients with different covariates. They indicated that 
Figure 3.18. Observed time profiles of S-warfarin 
concentrations following administration of a single 10 mg 
warfarin dose and at steady state (Hamberg, 2007).  
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it was not possible to anticipate these differences based on just early INR 
assessments. 
 The following table (Table 3.4) depicts warfarin doses predicted using 
Hamberg’s model for 54 individuals with different set of predictive covariates 
of CYP2C9 and VKORC1 genotypes for three age groups of 50, 70, and 90 
years old. The desired target INR in this effort was 2.5. As an example, the 
predictions show the significant difference (20 fold) between a priori doses 
(9.08 mg/day vs. 0.47 mg/day) for two individual with different combination of 
predictive covariates (“A 50-year-old patient with CYP2C9 *1/*1 and VKORC1 
GG genotypes” vs. “A 90-year-old patient with CYP2C9 *3/*3 and VKORC1 
AA genotypes”). 
Table 3.4. Predicted daily warfarin dose with target INR of 2.5 in three groups 
of patients with different set of predictive covariates (i.e., Age, CYP2C9 and 
VKORC1 genotypes) (Hamberg, 2007) 
 
The authors indicated that the influence of warfarin therapy on INR response 
of the R warfarin was not statistically significant. Therefore, the model only 
considered the PK/PD effects of S-warfarin. They concluded that it is 
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important to account for CYP2C9 and VKORC1 genotypes and age to 
improve a priori and a posteriori individualization of warfarin therapy. 
PK-PD modeling for INR response in our in silico framework 
We have adapted the PK-PD model from Hamberg (Hamberg, 2007) to 
predict the INR response for each clinical avatar at a given warfarin dose. In 
order the make the INR model work within our framework, we ported the code 
from NONMEM to R. According to the model, we only considered the PK-PD 
effects of S-warfarin. We modeled the PK effects using a two-compartment 
model with first order input and first order elimination and the PD effects using 
a two-chain transit compartment model. Due to limitations on the original 
model it has been necessary to make assumptions about the covariance of 
the variables because the complete covariance matrix was not provided. We 
have used a random log normal distribution to estimate the variability of the 
clearance rate, the volume in the central compartment, and the volume in the 
peripheral compartment and restricted the range to be within physiological 
ranges. 
To model the accumulation of warfarin concentration over time (assuming 
daily doses), we have used the principle of superposition. Superpositioning 
does not require assumptions regarding a PK model or absorption kinetics, 
but instead assumes each dose of the drug acts independently and that the 
rate and extent of absorption and average systemic clearance are the same 
for each dosing interval and that linear PK apply (Gibaldi, 1982). We create a 
table of warfarin concentrations over time and summed across the rows at 24-
hour time intervals to predict the amount of warfarin remaining in the system. 
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3.3.) Design of Comparative Effectiveness and Clinical 
Trial Studies 
A large number of the definitions have been offered for Comparative 
Effectiveness Research (CER). According to the Center for Clinical and 
Translational Science of Ohio State University, CER is “a field of study that 
utilizes data generation (new studies) and synthesis (comparisons of existing 
studies) to provide evidence identifying best practices and policies related to 
improving health care.” CER studies are generally conducted after 
randomized controlled trials (RCTs) (CER Resources, 2014). The focus of 
most of RCTs has been to study the efficacy of treatments under ideal 
conditions. On the other side, CER studies mostly focus on effectiveness by 
comparing one or more treatments, tools, procedures or medications to 
determine what works best for which individuals or patient populations under 
real world situations. CER studies have gained significant attention in clinical 
medicine in last few years since the Patient Protection and Affordable Care 
Act (PPACA, 2010) established Patient-Centered Comparative Effectiveness 
Research (PC-CER) as a US national medical research priority. Although this 
law has provided tremendous resources for CER studies to improve the 
evidence base that supports the use of genomic information to improve 
healthcare, however, efforts to translate critical genomic discoveries require 
prohibitively expensive clinical trial and clinical study validation which are 
severely hindered by regulatory, technical and validation barriers not easily 
conducted using current clinical-research or clinical enterprise environments. 
According to Khoury (2007), the reality is that “a small proportion of human 
genomics research has progressed from gene discovery to an evidence-
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based health application that has been effectively integrated into practice and 
has demonstrated health impact.” Based on Tunis (2003), to address this 
situation and make the clinical trials’ results more efficient and generalizable, 
there is a need for CER studies in which we (1) select clinically relevant 
alternative interventions to compare, (2) include a diverse population of study 
participants, (3) recruit participants from heterogeneous practice settings, (4) 
collect data on a broad range of health outcomes, and (5) pay special 
attention to the study time frame. 
One "poster" example of this translational complexity and need for a new 
approach to predicting a population wide treatment plan is the case of 
"optimal" warfarin dosing (~30 million US prescriptions/year) which 
demonstrates highly variable individual risks to serious under and over dosing 
adverse responses (thrombotic or bleeding event) and rapidly increasing 
health care costs associated with warfarin complications estimated at over $1 
billion/year (McWilliam, 2006). The clinical potential of genetics has driven 
significant scientific and clinical efforts to study the warfarin dosing question. 
Key scientific findings have demonstrated significant relationship between 
genotypes of VKORC1 and CYP2C9 and the metabolism of warfarin (e.g. 
Rieder, 2005). Consequently, the genotype-dosing relationship of warfarin as 
one of the emerging collection of pharmacogenomic results has led to a large 
number of clinical trials. As a result, various warfarin PG-based dosing 
algorithms and protocols have been offered and many outcome metrics (e.g, 
INR and TTR) have been tested in different related studies. However, given 
that anticoagulation therapy is usually a long term treatment and the fact that 
clinical utility of the PG-based warfarin algorithms has been tested only in 
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small study populations and highly constrained conditions (Anderson, 2007; 
Caraco, 2008; Burmester, 2011; Wang 2012), conducting longitudinal CER 
studies including multiple dosing protocols are still necessary to evaluate the 
ultimate impact of the available warfarin dosing algorithms on practice and 
different populations (i.e., external validity). These studies could address 
questions such as how and under which conditions PG-based dosing 
algorithms could perform well in certain populations for whom PG-based 
algorithms have shown less effective performance compared to other 
populations (Schelleman, 2008; Gage, 2008; Cavallari, 2012). 
3.3.1.) Longitudinal Studies 
Long-term warfarin anticoagulation is commonly used to prevent 
thromboembolism in patients with medical conditions such as atrial fibrillation 
and venous thromboembolism (e.g., deep vein thrombosis (DVT) or 
pulmonary embolism), or when treating patients with mechanical heart valves 
(MHVs) (Daniels, 2005). Long-term use of warfarin along with its narrow 
therapeutic index and a high risk/benefit ratio necessitate close and long-term 
monitoring. Through monitoring, different temporal quality measures are 
examined: the patterns of warfarin use in terms of discontinuations and 
interruptions, quality of anticoagulation therapy using primary anticoagulation 
outcome metrics (e.g., INR and TTR) as well as the relationship of these 
patterns with subsequent stroke and bleeding events as secondary and 
clinical outcomes. To study these patterns, in addition to prospective clinical 
trials, the secondary use of EMR data provides a great opportunity to design 
and conduct observational longitudinal studies or retrospective longitudinal 
cohort studies. Using treatment data from longitudinal studies, we can 
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estimate quantitative and temporal parameters associated with the quality of 
anticoagulation therapy. It helps to individualize doses and consistent and 
efficient dose adjustment practices using PG-based or non PG-based dosing 
protocols. This kind of studies could be conducted not only to study the 
effectiveness of different PG-based dosing algorithms for initiating warfarin 
doses but also they could be done to address questions such as how long 
genotype remains a significant predictor of warfarin dose.  
Our in silico translational research framework could take advantage of 
longitudinal EMR data of warfarin patients to conduct the CER studies that 
could address the effectiveness of different dosing algorithms/protocols over 
the period or treatment. It is discussed in more detail in chapters 5 and 6. 
3.3.2.) INR and TTR Estimation 
Percent Time in Therapeutic Range of INR (TTR) for each cohort of patients 
can be determined using any of the following three methodologies (Table 3.5):  
1- The fraction of INR's in range (Loeliger, 1985). The fraction of INR's in 
range is calculated by taking the number of INR's within target range for all 
patients divided by the total number of INR's during selected time interval. 
2- The Rosendaal linear interpolation method (Rosendaal, 1993). The 
Rosendaal linear interpolation methodology assumes a linear relationship 
exists between two INR values and allows one to allocate a specific INR value 
to each day for each patient. An average time in range for all patients was 
determined. The Rosendaal method has demonstrated to be valid and 
reproducible when the level of missing INR values is not high (e.g., ~20%) 
(Hutten, 1999). 
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3- The cross-section-of-the-files methodology (Ansell, 2004). The method 
takes each patient whose INR value is in range at one point in time (the INR 
value that was closet the midpoint of the selected interval ± 7 days) divided by 
the total number of INR's done on all patients at that point in time. In other 
words, it assesses all patients being managed at one point in time by taking 
the total of those whose INR is in range and dividing it by the total number of 
patients who had an INR at that point in time. 
Table 3.5. Advantages and Disadvantages of Methods to Calculate Time-in-
Therapeutic Range (TTR) (Schmitt, 2003). 
Methodology Advantage Disadvantage 
Fraction on INRs 
Simple to calculate 
Requires only one INR 
value per patient in clinic 
population 
Not influenced by extent of 
INR out-of-range 
More frequent testing in 
unstable patients may 
bias overall results (will 
under-estimate TTR of 
group) 
Does not take into 
account days within 
target range 
Does not consider 
individual patients 
Cross-section-of-
the-files 
Simple to calculate 
Considers individual 
patients 
Not influenced by extent of 
INR out-of-range 
Does not take into 
account actual days 
within target range 
Only considers one 
point in time 
Rosendaal linear 
interpolation 
Takes into account actual 
days in target range 
Allows one to calculate 
INR specific incidence 
rates of adverse events 
Calculation more 
difficult 
Makes assumptions 
about INR between 
actual tests 
Does not consider 
individual patients 
Extreme out-of-range 
INR values may bias 
overall results 
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3.3.3.) Multiple Protocol Studies 
Clinical trials have produced a host of treatment protocols for anticlotting 
medications such as warfarin, where over 40 protocols were published in the 
past 30 years. In practice, providers use a combination of experience, 
scientific evidence and clinical trial results to develop anticoagulation “best 
practice” treatment plans designed to roughly minimize the patient-to-patient 
response variability and risks across the practice’s patient population. 
However, the high degree of patient heterogeneity (based on factors such as 
race, age, individual medical data, family history and genetics) causes 
variations in individual patient response to these “best practice” drug-protocol 
approaches. The sheer number of treatment options and risk factors preclude 
the full array of clinical trials required to test all combinations of patients and 
drug-treatment protocol options. In short, no practical approach to identify the 
optimal anticoagulation treatment plan exists for large heterogeneous patient 
populations that accounts for individual risk factors; drug and protocol options; 
and achieves minimal risk to adverse events such as stroke. Current access 
to large comprehensive electronic medical records (EMR) covering diverse 
patient populations, coupled with novel modeling and computational 
simulations provides an unprecedented opportunity to conduct in silico 
identification and validation of optimal treatment strategies. 
To address such a challenge, our in Silico WiAD PCOR CER Framework is 
used to produce large, representative synthetic patient populations that can 
be used to conduct replicated clinical simulations testing and comparing 
multiple anticoagulation medication-protocol options. 
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3.4.) Model and Simulation Requirements 
In our adjustable modular anticoagulation therapy simulation framework 
(Figure 3.19), we use a highly adaptable modeling and software application 
development paradigm to create models of actual patient populations and 
then use those models to produce simulated patient populations (“clinical 
avatar” populations) and conduct simulations to predict the clinical validity and 
efficacy of genetic tests and algorithms applied to each clinical avatar. The 
mathematical representation of statistically accurate clinical avatar 
populations are used to simulate clinical data, warfarin dose (initial and 
adjusted doses) and INR response over desired period of time for 
anticoagulation treatment courses using different patient populations and a 
collection of pharmacogenetic and non-pharmacogenetic dosing algorithms. 
Different outcome metrics are calculated and examined to determine which 
Figure 3.19. Adjustable Modular Anticoagulation Therapy Simulation 
Framework. 
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algorithm provides the evidence supporting the best clinical outcome for each 
patient population.  
Next, we will use Aurora Health Care’s patient-based electronic medical 
record to assemble hospital, city, county-wide and regional patient 
populations. We will use the modeling framework to conduct 90 day 
simulations on these hospital patient populations and test the predictions of 
over and under dosed patients against data provided by Aurora Health Care. 
In addition to the clinical trial simulations, we will also simulate Milwaukee 
City, County and South East Wisconsin populations and apply standard health 
disparity and geographical analysis to predict the likelihood of higher 
incidences of adverse events in geographically and racially diverse sub 
populations. We will test these predictions against Aurora’s stratified patient 
population to determine accuracy of the population-wide simulations. 
Our approach to generate clinical avatars follows the standard applied 
mathematical modeling approach (explained in detail in section 3.1.2.): 
Analyze and characterize the data; Formulate a phenomenological model that 
‘fits’ the data; Test the performance of the model against a sub-collection of 
data; Evaluate the accuracy of the model; and Adjust the model based on the 
accuracy (or lack thereof) (Blue box in Figure 3.20).  
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3.4.1.) Patient Populations 
Enormous number of clinical trials have been conducted to test the value of 
genotyping on warfarin dosing and treatment. In fact, 364 clinical trials have 
been or are being conducted to test the accuracy of previous dosing 
algorithms, construct new dosing algorithms, or test the value of genetic 
variants in warfarin dosing (clinicaltrials.gov). In those costly clinical trials, 
tens of thousands of patients have been or are being recruited. The variety of 
trials, objectives, subject populations and results demonstrate a complex 
problem that has no obvious solution so far (~100 warfarin trials are still open 
as of June 1, 2014).  
As mentioned, more than 40 warfarin prediction algorithms that use patient 
specific data to predict therapeutic warfarin dosing have been published in the 
last three decades. This collection of algorithms contain a number of 
Figure 3.20. The Applied mathematical modeling schemata to 
generate clinical avatars consists of an iterative process of 
model development, testing, validation, refinement and repeat. 
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physiological, genetic, clinical lab, and clinical care variables used in one or 
more algorithms. We have recorded each variable’s nomenclature, data 
constraints, range of values, and data type (Table 3.6). It is a source of 
defining which variable (clinical, genetic, personal or family) should be 
included in the algorithms.  
Table 3.6. General characteristics of the variables used in most of the warfarin 
dosing algorithms. 
Field Units Description Format Constraint Example 
Race n/a race Controlled 
Dictionary 
{White, African-
American, Native-
American, Asian, 
Pacific-Islander, 
Other, Unknown} 
Other 
Age years age in years Integer 13 <= x <= 94 25 
Gender n/a gender Controlled 
Dictionary 
{M, F} M 
Height in Height in 
inches 
Integer 56 <= x < = 82 65 
Weight lbs Weight in 
pounds 
Integer 100 <= x < = 308 165 
BSA m^2 Body Surface 
Area 
Real 
Number 
1.3 <= x <= 2.8 1.6 
CYP2C9 n/a CYP2C9 
genotype 
Controlled 
Dictionary 
{*1/*1,*1/*2,*1/*3,
*2/*2,*2/*3,*3/*3} 
*1/*1 
VKORC1 n/a VKORC1 
genotype 
Controlled 
Dictionary 
{A/A, A/B, B/B} A/A 
CYP2C9*2 n/a CYP2C9*2 
genotype 
Controlled 
Dictionary 
{C/C, C/T, T/T} C/T 
CYP2C9*3 n/a CYP2C9*3 
genotype 
Controlled 
Dictionary 
{A/A, A/C, C/C} A/C 
VKORC1 
(1173) 
n/a VKORC1(1173
) genotype 
Controlled 
Dictionary 
{C/C, C/T, T/T} C/T 
VKORC1 n/a VKORC1(- Controlled {G/G, G/A, A/A} G/A 
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(-1639) 1639) 
genotype 
Dictionary 
DVT n/a Warfarin usage 
indicated for 
DVT/PE or not 
Controlled 
Dictionary 
{Y, N} Y 
Smoker n/a Smokes or not Controlled 
Dictionary 
{Y, N} Y 
Target INR n/a Desired INR Real 
Number 
x = 2.5 2.5 
Amiodarone n/a Amiodarone 
use or not 
Controlled 
Dictionary 
{Y, N} Y 
 
Based on our simulation study design, available population dataset that will be used 
for training and validation of Clinical Avatar BNM and the required variables in the 
simulation model, demographic, clinical, and genetic characteristics of the dataset 
are extracted and calculated. Prior to this step, the datasets are carefully vetted to 
determine the quality and quantitative properties. 
3.4.2.) Parameters 
For each study population, we extract and record the clinically and 
physiological valid ranges for each variable and create a representative 
statistical correlation of the variables important to the study. As explained in 
section 3.4.1, these characteristics are crucial to create clinical avatars model 
and simulation and PK/PD models. This information along with published 
statistics, correlations, and clinical associations will be used to define a clinical 
avatar statistical data model representative of a hypothetical population of 
warfarin patients. Then the clinical avatar simulation framework is used to 
generate clinical avatar populations. Each clinical avatar will reflect a 
hypothetical patient’s medical record and the collection of avatars (the clinical 
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avatar population) will adhere to the prescribed statistics and inter-variable 
correlation structure prescribed by the clinical avatar model. 
As an example, Table 3.7 presents the initial statistical distribution of the 5700 
warfarin patient medical record datasets in PharmGKB (Whirl-Carrillo, 2012). 
The statistical results displayed in the table show the first order analysis 
(mean and standard deviation) of the variables assuming independence. The 
far right column provides a p-value for tests between the actual PharmGKB 
data and representative simulated clinical avatars. 
Table 3.7. Statistical characteristics of the PharmGKB warfarin dataset versus 
its clinical avatar population. 
Parameter 
Actual PharmGKB Patients 
(n=5700) 
Clinical Avatars 
(n = 20,000) 
P-
Value 
Age 
<18 
18 – 24 
25 – 44 
45 – 64 
65 – 94 
 
0.18% (10) 
1.3% (75) 
9.9% (559) 
36% (2,040) 
52.5% (2,974) 
 
0.13% (26) 
1.2% (235) 
9.8% (1,957) 
36.4% (7,282) 
52.5% (10,500) 
0.75 
Gender by age 
<18 
 
18 – 24 
 
25 – 44 
 
45 – 64 
 
65 – 94 
 
M: 30% (3) 
F: 70% (7) 
M: 42.7% (32) 
F: 57.3% (43) 
M: 49.9% (279) 
F: 50.1% (280) 
M: 60% (1225) 
F: 40% (815) 
M: 59.3% (1,855) 
F: 40.7% (1,272) 
 
M: 34.6% (9) 
F: 65.4% (17) 
M: 47.2% (111) 
F: 52.7% (124) 
M: 50.6% (990) 
F: 49.4% (967) 
M: 59.4% (4,324) 
F: 40.6% (2,958) 
M: 59.4% (6,353) 
F: 40.6% (4,344) 
0.89 
Race 
  White 
  African American 
  Native American 
  Asian 
  Pacific Islander 
  Other  
  Unknown 
 
54.8% (3,122) 
8.1% (462) 
0% (0) 
28.7% (1,634) 
0% (0) 
0% (0) 
8.4% (482) 
 
54.2% (10,835) 
7.9% (1,583) 
0% 
29.7% (5,936) 
0% 
0% 
8.2% (1,646) 
0.51 
Height (in) 
Mean 
Min 
Max 
 
66.11 ± 4.3 
49 
80 
 
66.50 ± 4 
49 
80 
1.2e-8 
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As mentioned in the previous sections, we use PK/PD models to simulate 
anticoagulation medication response (e.g., INR). The PK/PD model predicts 
treatment outcomes depending on the medication, its metabolism, clearance 
and physical properties. As an example, 2 different clinical avatars (that 
represent 2 patients) may have different outcomes on the same medication-
dosing algorithm and -protocol plan. In addition, the clinical avatars may have 
very different outcomes for 2 different medication-protocol plans or even for 
the same medication but different dosing protocols. As explained in section 
3.2.7, we have implemented a PK/PD model for daily warfarin dosing whose 
PK model uses a 2-compartment model with first order input and first order 
elimination and its PD model affects using a 2-chain transit compartment 
Weight (lbs) 
Mean 
Min 
Max 
 
171.58 ± 48.2 
66 
524 
 
173.51 ± 27.87 
92 
290 
7.7e-
31 
Smoker 
  White 
  African American 
  Native American 
  Asian/Pac Islander 
  Other/Unknown 
 
14.4% (324) 
20.8% (91) 
0% (0) 
6.4% (18) 
6.5% (16) 
 
14.3% (1,552) 
20.9% (332) 
0% (0) 
5.7% (340) 
5.7% (94) 
2.4e-
11 
Amiodarone 
Yes 
No 
 
4.5% (258) 
95.5% (5,442) 
 
4.6% (921) 
95.4% (19,079) 
 
DVT 
Yes 
No 
 
16.4% (817) 
83.6% (4,191) 
 
16% (3,203) 
84% (16,797) 
 
VKORC1 
A/A 
A/B 
B/B 
 
52.2% (1,245) 
25.8% (614) 
22.0% (525) 
 
52% (10,404) 
26.3% (5,261) 
21.7% (4,335) 
0.83 
CYP2C9 
*1/*1 
*1/*2  
*1/*3 
*2/*2 
*2/*3 
*3/*3 
 
74.9% (4,155) 
13.4% (742) 
9% (501) 
1% (58) 
1.3% (72) 
0.4% (22) 
 
75.4% (15, 079) 
13.4% (2,676) 
8.8% (1,756) 
1% (194) 
1.1% (227) 
0.3% (68) 
0.81 
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model. The predictive variables for this PK/PD model are: age, CYP2C9 and 
VKORC1 genotypes. So, these three characteristics of the clinical avatars are 
used to run the PK/PD model and predict INRs.    
3.5.) Outcome Metrics 
In anticoagulation therapy studies, a number of outcome metrics are used to 
measure the quality of therapy. They generally are categorized into two group; 
primary and secondary.  
3.5.1.) Primary Outcome Metrics 
The main primary outcome is the percentage of time in therapeutic range 
(TTR) of international normalized ratio (INR). TTR could be calculated using 
different methods explained in section 3.3.2. TTR is the most popular and 
widely used quality measure to monitor warfarin management. During the 
process of anticoagulation which is usually a long term one, most risk factors 
for bleeding or thromboembolic events such as age and underpinning 
comorbid conditions cannot be changed and the only modifiable factor that 
can be improved to avoid such complications is TTR (Levine, 1998).    
3.5.2.) Secondary Outcome Metrics 
This group of outcomes are categorized in the two following groups; principal 
secondary outcomes and non-principal secondary outcomes. The secondary 
outcomes are as follows: 
- Occurrence of INR >4 or major clinical events in the first 4 weeks. This 
composite outcome measure is a principal secondary outcome measure and 
is defined as any INR of 4 or more, major bleeding, or thromboembolism in 
the first 4 weeks. The major clinical outcomes to be included in this measure 
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are major bleeding and thromboembolism events. The reason this measure is 
an important outcome measure is that many studies have shown that there is 
a significant correlation between INR >4 and increase risk of bleeding (van 
der Meer, 1993). 
- Time to first therapeutic INR. This is measure defined as the first INR that is 
between the therapeutic ranges of INR depending on the indication of 
anticoagulation therapy. Even though it looks that this measure is an 
important one but there is no evidence showing a correlation between this 
measure and improved clinical outcomes of anticoagulation. 
- Time to the determination of a maintenance dose. This is an outcome 
measure which is defined as the time to two consecutive INR measurements 
in therapeutic range without any change in dose, measured at least 1 week 
apart (Kimmel, 2013).  
- Time to an adverse event. This measure is defined as the time to occurrence 
of adverse events ranging from minor bleedings and thromboembolism (TIA) 
to major bleedings and thromboembolism as well as death in specific time 
frames (e.g., 4 weeks and 3 months). Bleeding is the most serious 
complication of the use of oral anticoagulation in the prevention and treatment 
of thromboembolic complications. The definition of this event as used in major 
clinical trials is the following one adopted from the Italian Study on 
Complications of Oral Anticoagulant Therapy (Palareti, 1996):  Major bleeding 
is classified as: “fatal (death due to hemorrhage); intracranial (documented by 
imaging), ocular (with blindness), articular, or retroperitoneal; if surgery or 
angiographic intervention was required to stop bleeding; and if bleeding led to 
hemoglobin reduction of 2 g/dL or more and/or need for transfusion of two or 
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more blood units. Minor bleeding is all cases of bleeding not classified as 
major. Non-relevant (small) bleeding is bruising, small ecchymosis or 
epistaxis, occasional hemorrhagic bleeding, or microscopic hematuria.”  
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4.1.) Introduction 
The Patient-Centered Outcomes Research Institute (PCORI) has proposed 
and approved five national priorities for research (Shelby, 2012). The goal of 
the fifth priority “Accelerating patient-centered outcomes research and 
methodology” is “Improving the nation’s capacity to conduct patient-centered 
outcomes research, by building data infrastructure, improving analytic 
methods, and training researchers, patients and other stakeholders to 
participate in this research.” The PCORI’s “National Priorities for Research 
and Research Agenda” encompasses a number of prioritized research areas. 
Secondary use of large diverse healthcare EMR data for patient-centered 
comparative effectiveness research (PC-CER) is highlighted under the fifth 
priority as “The Research that determines the validity and efficiency of data 
sources commonly used in PCOR.” The offered examples are: research that 
seeks to improve the volume, completeness, comprehensiveness, accuracy, 
and efficiency of use of clinical data collected across healthcare systems, 
clinical data networks, registries, or payer databases, and the utility of this 
data for conducting longitudinal studies of patient outcomes; research that 
explores the potential of large clinical data networks to support PCOR; or 
research that develops and promotes the utility, performance, and efficiency 
of large clinical data networks or registries for supporting patient-centered 
outcomes research for patients with rare diseases. This agenda encourages 
conducting a spectrum of PC-CER studies including health care disparity in 
part by seeking evidence of treatments’ effectiveness across various 
populations.  
139 
 
 
 
American Medical Informatics Association (AMIA) has defined secondary use 
of data (Safran, 2007) as “non-direct care use of personal health information 
(PHI) including but not limited to analysis, research, quality/safety 
measurement, public health, payment, provider certification or accreditation, 
and marketing and other business including strictly commercial activities.” 
Basically, secondary use of data implies use of health data for any purpose or 
activity other than direct healthcare delivery such as quality and safety 
measurement, clinical and translational research and improvement public 
health. Quality EMR data is central to any secondary use of the data and is 
essential to the process of decision-making and providing good quality patient 
care (Cruz-Correia, 2010). Secondary use of EMR as a means of 
retrospective analysis of health data has potentials to accelerate knowledge 
translation in healthcare and constitutes a significant part of clinical research. 
Currently, secondary use of clinical data is still at its early stage (Prokosch, 
2009). National initiatives have been established to extend and facilitate 
secondary use of EMR to support clinical research (CDRNs, 2014). 
Aurora Health Care (AHC) is the largest health care system in Wisconsin 
operating 15 hospitals throughout the state with more than 3600 licensed 
beds, 172 physician clinic facilities, and several other health care related 
entities. It serves about 1.2 million unique patients each year through 7.8 
million patient encounters per year. AHC’s EMR is the most comprehensive 
(by size, type of health care and period of time) digitized health care resource 
of Southeast Wisconsin’s population capturing urban, suburban, and rural 
constituents of all racial, ethnic, and socioeconomic backgrounds. This 
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resource provides a unique opportunity to capture data and information vital to 
conducting retrospective and predictive PC-CER studies.  
UWM and AHC have established a collaboration to conduct a series of 
research studies whose goal is to, using AHC electronic medical records 
(EMR), demonstrate that in silico pharmacogenetic PC-CERs based on actual 
EMR patient data provide predictive evidence useful in detecting “optimal” 
anticoagulation dosing protocols that reduce adverse drug responses, 
improve overall patient outcomes and reduce health disparities in the Aurora 
Milwaukee County patient population. One of the main steps in this 
collaboration is to build a longitudinal EMR-based anticoagulation research 
database. Such a database is an essential tool in conducting 
pharmacogenetic PC-CERs. 
However, there are challenges in the re-use of the data captured and stored 
in EMR systems for comparative-effectiveness studies as they have not been 
originally been developed for research purposes. Some of the most popular 
barriers and challenges to the secondary use of EMR data are as follows: 
missing data, erroneous data, uninterpretable data, inconsistencies among 
providers and over time, and data stored in noncoded text notes (free text) 
(Bayley, 2013; Elkin, 2010). Considering the fact that the designed 
pharmacogenetic PC-CER studies by UWM and AHC required quality data, a 
rigorous multilayer and iterative process of extraction, transformation and 
loading (ETL) was designed and performed to ensure the resulted research 
database fits the use. In the following sections the ETL process and the 
research database are explained. 
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4.2.) Methods 
The process of developing the anticoagulation research database consisted of 
an iterative process of extraction, transformation and loading by the two 
teams of Aurora Health Care (AHC) and University of Wisconsin-Milwaukee 
(UWM). The first step was to determine the scope of the desired data. 
4.2.1.) Determination of Inclusion Criteria and Scope of 
Data 
After a rigorous literature review, the UWM team developed a data model of 
the required patient’s attributes and value sets for extracting the required data 
from AHC EMR data repository. Based on some practical facts, the data 
model was refined collaboratively by the UWM and AHC teams to be 
compatible with the data models and dictionaries of the heterogeneous AHC’s 
databases (Table 4.1.). For example, even though the initial data model 
included the full lists of National Drug Code (NDC) codes for each of the 
included medications or associated ICD-10 codes were considered for clinical 
characteristics (e.g., medical indication and comorbidities), the final model 
were refined to include medication names and ICD-9 codes given that AHC 
data warehouse were not using NDC and ICD-10 codes. 
Table 4.1. Patient’s characteristics used to identify patients with evidence of 
anticoagulation/anticlotting treatment from AHC’s EMR data warehouse. 
Patient Characteristics ICD-9 or CPT Codes 
Demographics  
Gender Male, Female, Unknown 
Age Year (Age >=18) 
Patient’s Zipcode 5-digit zipcode 
Patient’s County  
Patient’s City  
Provider’s Zipcode 5-digit zipcode 
Smoking Status  
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Race  
Height Inch 
Weight Pound 
Date of Visit  
Date of Death  
Medications  
Date Received/Date Prescribed   
Medication Type: 
- Coumadin (Warfarin) 
- Heparin 
- Ticlopidine (Ticlid) 
- Clopidogrel (Plavix) 
- Dipyridamole (Persantine) 
- Abciximab (ReoPro) 
- Eptifibatide (Integrilin) 
- Tirofiban (Aggrastat) 
- Dabigatran (Pradaxa) 
Name of the medications 
Dosage  
Frequency  
Interacting Medications  
Date Received/Date Prescribed  
Medication Type: 
- Amiodarone (Cordarone, Pacerone) 
- Simvastatin (Zocor) 
- Fluvastatin (Lescol) 
- Lovastatin (Altocor, Altoprev, 
Mevacor) 
- Atrovastatin (Lipitor) 
- Rosuvastatin (Crestor) 
- Pravastatin (Pravachol) 
- Aspirin 
Name of the medications 
Dosage  
Frequency  
Medical Indications  
Date of Indication  
  Indication Type:  
- Orthopedic Procedures 
 
CPT codes: 77.65, 77.66, 77.67, 77.69, 
77.75, 77.76, 77.77, 77.79, 77.85, 77.86, 
77.87, 77.95, 77.96, 77.97, 78.05, 78.06, 
78.07, 78.09, 78.15, 78.16, 78.17, 78.19, 
78.25, 78.27, 78.29, 78.35, 78.37, 78.39, 
78.45, 78.46, 78.47, 78.49, 78.55, 78.56, 
78.57, 78.59, 79.05, 79.06, 79.09, 79.15, 
79.16, 79.19, 79.25, 79.26, 79.29, 79.35, 
79.36, 79.39, 79.45, 79.46, 79.49, 79.55, 
79.56, 79.59, 79.65, 79.66, 79.69, 79.75, 
79.76, 79.79, 79.85, 79.86, 79.89, 80.25, 
80.26, 80.27, 80.6, 80.75, 80.76, 81.00, 
81.09, 81.30, 81.39, 81.40, 81.42, 81.43, 
81.44, 81.45, 81.46, 81.47, 81.49, 81.51, 
81.52, 81.53, 81.54, 81.55, 81.56, 81.57, 
143 
 
 
 
81.59, 81.61, 81.62, 81.63, 81.64, 81.65, 
81.66, 84.10, 84.11, 84.12, 84.13, 84.14, 
84.15, 84.16, 84.17, 84.18, 84.19, 84.26, 
84.27, 84.28, 84.45, 84.46, 84.47, 84.48, 
84.51, 84.58, 84.59, 84.60, 84.61, 84.62, 
84.63, 84.64, 84.65, 84.66, 84.67, 84.68, 
84.69, 84.80, 84.81, 84.82, 84.83, 84.84, 
84.85, 84.91 
- Deep vein thrombosis (DVT) ICD-9 codes: 451.x, 453.x 
- Pulmonary embolism (PE)  ICD-9 codes: 415.1x 
- Atrial fibrillation  ICD-9 codes: 427.31 
- Atrial flutter  ICD-9 codes: 427.32 
- Atrial fibrillation and flutter  ICD-9 codes: 427.3 
- Stroke  ICD-9 codes: 433.x, 434.x, 435.x, 436, 
437.1x, 437.9x, 438.x 
- Heart valve replacement  ICD-9 codes: V43.3 
Lab Test Results  
INR Test Result Numeric 
Date of INR Test  
Adverse Events/Comorbidities  
Date of Event/Comorbidity  
Event Type:  
- Deep vein thrombosis (DVT)  ICD-9 codes: 451.x, 453.x 
- Pulmonary embolism (PE)  ICD-9 codes: 415.1x 
- Stroke  ICD-9 codes: 433.x, 434.x, 435.x, 436, 
437.1x, 437.9x, 438.x 
- Myocardial infarction  ICD-9 codes: 410.x 
- Bleeding  ICD-9 codes: 431.x, 432.x, 459.0, 578, 
578.9, 784.7, 784.8, 786.30 
- Diabetes Mellitus ICD-9 codes: 250.x 
- Heart Failure ICD-9 codes: 428.x 
- Hypertension ICD-9 codes: 401.x 
- Peripheral artery diseases ICD-9 codes: 250.6, 443.x, 785.4 
- Atherosclerosis of aorta ICD-9 codes: 440-0 
- Coronary artery disease ICD-9 codes: 414.0x 
 
4.2.1.1.) Extract, Transform, and Load (ETL) Process 
The process of extraction, transformation and loading (ETL) of data is usually 
a multilayer, iterative one addressing both data and data models. In this 
project, the ETL process was done by both AHC and UWM LPHIG teams. 
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4.2.1.1.1.) AHC ETL Process 
Once the Internal Review Board (IRB) approval was granted by both AHC and 
UWM and a Data Use Agreement was signed by two institutes, the AHC 
team, before delivering the data to UWM team, performed an internally 
developed ETL process to identify, extract, transform and load patient’s 
records into a database. Using the data model depicted in Table 4.1, the AHC 
team constructed the extraction algorithms and search strategies to mine 
AHC’s hospitals’ and clinics’ EMR data warehouses and retrieved the AHC 
EMR for patients treated with anticoagulation/anticlotting agents for the period 
of 2002 to 2012 and subsequently all post-treatment events from each patient. 
In the process of the transformation, the patient data was de-identified per 
IRB approval (allowing zipcode) by an AHC honest broker. This process 
resulted in the longitudinal data records of 157,450 patients including: gender, 
race, height, weight, age, day of visit, patient's zipcode, patient's city, 
provider's zipcode, smoking status, INR, medications received (day, dose, 
frequency), interacting medications (Amiodarone, Simvastatin, Fluvastatin, 
Lovastatin, Atrovastatin, Rosuvastatin, Pravastatin, Aspirin), medication 
indications (by ICD-9 codes for Deep Vein Thrombosis (DVT), Pulmonary 
embolism, Atrial fibrillation, Atrial flutter, Atrial fibrillation and flutter, Stroke, 
Heart valve replacement and CPT codes for Orthopedic surgery-hip or knee) 
and comorbidities (by ICD-9 codes for DVT, Pulmonary embolism, Stroke, 
Myocardial infarction, Bleeding). The AHC team loaded the data into an MS 
Access database (“Original Access Database”). The data model of the Access 
database is depicted in Figure 4.1. 
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4.2.1.1.2.) LPHIG ETL Process 
Once receiving the Original Access Database, the UWM LPHIG (Laboratory 
for Public Health Informatics and Genomics) team performed another iterative 
round of ETL process aiming to create the anticoagulation/anticlotting 
research database namely Wisconsin Anticoagulation Database (WiAD). The 
first round of the ETL process at this stage was to remove complete duplicate 
records from the Original Access Database’s tables, identify primary and 
foreign keys across the tables and create a relational database in a MySQL 
Server which would be a “Base Database” for further processes. The Entity 
Relationship (ER) data model of the MySQL Base Database is depicted in 
Figure 4.2. This process was followed by another round of transformation 
including multiple steps of cleaning up the data and data validation and quality 
Figure 4.1. The Data Model of the Original Access Database Provided by 
AHC Team. 
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control. In this process, few data dictionaries were developed for some of the 
attributes’ value sets. 
Data cleaning and quality control is an important task in the process of 
developing research databases especially when the extracted data come from 
heterogeneous data sources. Data cleaning is basically a process in which 
errors and inconsistencies in data are detected and removed.  
 
Subsequent data cleaning, quality control and quality assurance included an 
iterative process of data parsing to detect irregularities; statistical analysis 
designed to test population-wide distributions and possible biases; refinement 
of inclusion and extraction data mining codes to address irregularities, 
possible missing data and detected biases; and ultimately, data 
transformation to produce a cohesive set of records capturing all available 
Figure 4.2. Entity Relationship (ER) Data Model of the Base MySQL Database.  
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medical records in a consistent format following Weiskopf (2013). According 
to Weiskopf different dimensions of data quality are as follows: 
- Completeness: “Is a truth about a patient present in the EMR?” 
- Correctness: “Is an element that is present in the EMR true?” 
- Concordance: “Is there agreement between elements in the EMR, or 
between the EMR and another data source?” 
Table 4.2. AHC dataset’s data quality issues. 
 
 - Plausibility: “Does an element in the EMR makes sense in light of other 
knowledge about what that element is measuring?” 
Scope/Problem Original Data 
Attribute 
Missing values Race = “UNKNOWN” 
Misspellings Medication Name= “warfin” 
Awkward Abbreviations Medication Frequency= “zUBC” 
Free Text Embedded values 
Medication Name= “warfarin 2.5 
mg 5 days a week  
and 2 mg two days a week” 
Miscoded values Patient zip code= “WI” 
Incorrect values Weight= -165 
Record 
Violated attribute dependency 
City= “Milwaukee”, zip 
code=99999 
Duplicated records 
(partial and complete) 
ID=165, Day= 199; Medication= 
Warfarin 4 mg, Frequency= QOD; 
ID=165, Day= 199; Medication= 
Warfarin 4 mg, Frequency= daily 
Contradicting records 
ID= 78, Day= 1101, Medication= 
Coumadin, Dose= 3 mg; 
ID= 78, Day= 1101, Medication= 
Coumadin, Dose= 4 mg 
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- Currency: “Is an element in the EMR a relevant representation of the patient 
state at a given point in time?” 
We identified a number of data quality issues across the AHC dataset stored 
in the Base Database. Table 4.2 demonstrates the data quality issues of the 
AHC data at attribute and cross-attribute (record) levels. 
To address these data quality issues across the AHC’s structured and 
unstructured data, the team performed a number of data quality and cleaning 
tasks as detailed below. 
- Age: Although the AHC data is longitudinal, there was only one Gender and 
one Age record for each unique subject stored in table “patients”. The rate of 
missing data for age was very low (i.e., 1 subject). However, about 1% of the 
whole population (i.e., 2662 subjects) have age value of 0. Subjects with age 
of zero or missing age were excluded. Since our age inclusion criteria was 
subjects with the age of 18 years old or above, any subject with an age lower 
than 18 years old (i.e., 357 subjects) was excluded. The following table (Table 
4.3.) shows the age distribution of subjects in the AHC Base Database. As 
depicted, the most populated age groups are 65-74 and 75-84 years old  
Table 4.3. Age distribution of the subjects in the AHC Base Database. 
Age Group (Years) Percentage 
18-24 1.09 
25-34 2.46 
35-44 5.81 
45-54 14.11 
55-59 9.92 
60-64 10.62 
65-74 22.22 
75-84 22.70 
>85 11.08 
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which is consistent with the fact that the prevalence of anticoagulation therapy 
increases as people get older and experience more chronic diseases. 
- Gender: The gender values were either female or male. Less than 0.01% of 
the subjects had no gender information. The subjects with missing gender 
were excluded from the study population. Table 4.4 depicts the gender 
distribution of the subjects in the AHC Base Database compared to that of in 
Milwaukee county (MKE) and Wisconsin (WI). As a quality control measure, 
the age distribution of the AHC Base Database was compared with that of 
MKE and WI which did not show significant difference (p >0.05). 
Table 4.4. Gender Distributions across the three populations of AHC Base 
Database, Milwaukee County (MKE) and Wisconsin (WI). 
Gender AHC Base Database (%) MKE (%) WI (%) 
Male 50.34 48.30 49.60 
Female 49.65 51.70 50.40 
Missing 0.01 NA NA 
 
- Race: In the AHC Base Database, each subject had one race record. Race 
is a key piece of information for our PC-CER studies. Only 52.85% of AHC 
Base Database’s subjects had race information. About 0.01% of the subjects 
in table “race” (i.e., 1662 subjects) had no race information. The race values 
of the subjects were: White, Black or African American, Asian, American 
Indian or Alaskan Native, Native Hawaiian/Other Pacific Islander and 
Unknown. The following table (Table 4.5) depicts the racial distribution of the 
AHC Base Database’s subjects who had identified race information versus the 
racial distributions across Milwaukee County (MKE) and Wisconsin (WI). As a 
quality control measure, the racial distribution of the AHC Base Database was 
compared with that of MKE and WI. The racial distributions of the Base 
Database was not significantly different from that of WI (p >0.05). 
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Table 4.5. Race distribution across the AHC Base Database’s subjects and 
Milwaukee County’s and Wisconsin’s populations. 
Race AHC Base Database (%) MKE (%) WI (%) 
White 90.41 65.9 88.4 
Black or African 
American 
8.52 27.0 6.5 
American Indian and 
Alaska Native 
0.27 0.9 1.1 
Asian 0.79 3.6 2.4 
Native Hawaiian or Other 
Pacific Islander 
0.02 0.1 0.05 
Subjects reporting two or 
more races 
NA 2.5 1.6 
 
- Height: In the AHC Base Database, each subject has longitudinal height 
records with multiple height records for each measurement day which were 
not on a regular basis. Each height record contained the attributes 
{SURROGATE_ID, DAY, HEIGHT, SOURCE_SYSTEM}. Since height 
measurement can vary within a specific time frame due to factors such as lack 
of standard protocols, inaccurate measuring, and imprecise equipment set-up, 
we created a cleaning algorithm. Before applying the algorithm, first, each 
height record was examined to identify and exclude any height record whose 
Figure 4.3. Height records cleaning algorithm. 
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HEIGHT attribute’s value was missing. Then the height cleaning algorithm 
was applied (Figure 4.3).   
According to the algorithm, we first removed all height values we considered 
biologically implausible (Census Bureau, 2012; Muthalagu, 2014). 
Accordingly, we set the plausible thresholds greater than 39.5 inches and less 
than 98.5 inches. Then we took the next steps of the algorithm. If all height 
records for a single subject in a single day differed (i.e., difference between 
minimum height and maximum height for the same day) by less than 
measurement error of 1.5 inches (Muthalagu, 2014), then all height records 
for that subject for that day were marked correct by the algorithm and the 
mean of the height records was calculated representing height value for the 
day. For all other days, median height for each day was calculated. The 
median height for each day was compared with that of the prior and next 
median; when the difference in medians was greater than 1.5 inches for both, 
the median height for that day was considered as potentially erroneous 
(Muthalagu, 2014). For the days that had an erroneous median height, the 
algorithm assigned the nearest correct median height. 
The rate of height record completeness for the AHC Base Database was 
43.17%. The subjects with height records had 3.07 height records on 
average. The average height of the population was 66.09 inches (±7.23).  
- Weight: In the AHC Base Database, each subject has longitudinal weight 
records with multiple weight records for each measurement day which were 
not on a regular basis. Each weight record contained the attributes 
{SURROGATE_ID, DAY, WEIGHT, SOURCE_SYSTEM}. Since weight 
measurement can vary within a specific time frame due to factors such as 
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lack of standard protocols, inaccurate measuring, and imprecise equipment 
set-up, we created a cleaning algorithm. Before applying the algorithm, first, 
each weight record was examined to identify and exclude any weight record 
whose WEIGHT attribute’s value was missing. Then the weight cleaning 
algorithm was applied (Figure 4.4).   
According to the algorithm, we first removed all weight values we considered 
biologically implausible (Census Bureau, 2012). We set the plausible 
thresholds greater than 70 pounds and less than 500 pounds. Then we took 
the next steps of the algorithm. If all weight records for a single subject in a 
single day differ (i.e., difference between minimum weight and maximum 
weight for the same day) by less than measurement error of 10% (Maskin, 
2010), then all weight records for that subject for that day are marked correct 
by the algorithm and the mean of the weight records is calculated 
representing weight value for the day. For all other days, median weight for 
each day is calculated. The median weight for each day is compared with that 
of the prior and next median; when the difference in medians is greater than 
Figure 4.4. Weight records cleaning algorithm. 
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measurement error for both, the median weight for that day is considered as 
potentially erroneous. For the days that have an erroneous median weight, 
the algorithm assigns the nearest correct median weight. 
The rate of weight record completeness for the AHC Base Database is 
49.58%. The subjects with weight records had 7.39 weight records on 
average. The average weight of the population was 195.12 pounds (±50.1).  
- Medications: In the AHC Base Database’s table “medication”, each subject 
has multiple medication records. Each medication record contained the 
attributes {SURROGATE ID, DAY, MEDICATION_NAME, FREQ, 
DOSE_QTY, DOSE_QTY_UNIT, SOURCE_SYSTEM}. In the table, the entire 
columns of {DOSE_QTY, DOSE_QTY_UNIT} were completely blank. The 
column {FREQ} was partially complete. The cells under column 
{MEDICATION_NAME} were populated with free-text. Before conducting any 
cleaning or quality control measures, we had to extract information from the 
free-text in cells under column {MEDICATION_NAME} and translate them into 
a structured format. Through a text analysis step, the required data from the 
free text were extracted and presented in normalized and consistent 
structured formats. We used a multistep process which involved parsing the 
free texts into their components, normalizing the identified components, and 
extraction of the required data elements (i.e., name of medication, dosage, 
unit, and route of administration). The rate of incompleteness of the resulted 
records was high. Table 4.6 depicts the distribution of medication records by 
each medication in the cleaned and controlled medication table and also 
presents an example of the rate of completeness (i.e., percentage of each 
medication’s records with dosage information). 99.02% of the medications 
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records included one of the three medications of warfarin (37.85%), heparin 
(36.24%) and clopidogrel (24.93%). Warfarin records which have dosage 
information have the highest percentage of whole the records (11%). Although 
the number of heparin records was higher than the number of clopidogrel 
records, the percentage of clopidogrel records with dosage information out of 
whole the records was higher than that of heparin.   
Table 4.6. Distribution of number of subjects under each medication and the 
rate of medication records’ dosage information completeness. 
Medication 
Number of 
Subjects under 
Medication 
Rate of the Records’ 
Dosage Information 
Completeness  
Warfarin 74,102 70.03% 
Heparin 71,537 33.4% 
Clopidogrel 61,517 68.03% 
Dabigatran 1,793 89.18% 
Dipyridamole 2,292 22.9% 
Eptifibatide 2886 71.58% 
Ticlopidine 434 73.5% 
Abciximab 1,310 90.15% 
Tirofiban 48 0% 
The above table indicates that a big number of subjects have received more 
than one medication. The following table (Table 4.7) shows the number of 
subjects who have been under treatment with 1 to 6 medications. 
Table 4.7. Distribution of subjects by number of medications. 
No. of 
Medications 
1 2 3 4 5 6 
No. of Subjects 75282 16441 3049 358 20 1 
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- Patient Residence: In the AHC Base Database’s table “patient_residence”, 
each subject has multiple residence records. Each residence record 
contained the attributes {SURROGATE_ID, DAY, PATIENT_ZIP, 
PATIENT_CITY, SOURCE_SYSTEM}. As a quality control measure, the 
recorded 5-digit zipcodes were examined against a standard zipcode 
dictionary to find any inconsistency between the recorded zipcodes and their 
recorded associated cities. It also helped find and exclude invalid numeric or 
non-numeric values which were reported as 5-digit zipcodes (e.g., 0, 99999, 
WI, MI, *R2Y1, *CV11, *). 83.73% of the whole AHC Base Database’s 
population have at least one residence record. The partially (i.e., the same 
zipcode on the same day at two different “SOURCE_SYSTEM”s) and 
complete duplicated records were also excluded (46.36% of the records). 
After the above QC and cleaning process, the average number of residence 
records for each subject with residence records was 1.76 (range 1-4). Out of 
the subjects with residence record, 3.33% had more than one reported 
zipcode. The reported zipcodes were distributed across 44 states with the 
highest frequency in Wisconsin, Illinois, Michigan, and Florida. The subjects in 
Wisconsin were also distributed across the 72 counties of the state with the 
highest frequency in counties Milwaukee, Sheboygan, Racine, Waukesha, 
Walworth, and Kenosha. The distribution of the subjects across the states and 
the counties have been visualized on two separate interactive Google Maps at 
the following URLs: 
https://www.google.com/fusiontables/DataSource?docid=1MPew8EhUQvoES
HZJP9RaykxHDm8ir0W7LUhYC4U#map:id=3 
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https://www.google.com/fusiontables/DataSource?docid=1OP6Wrdt56g6ZAt0j
Yuyt3i4nc6RbUBFElqVtvnU  
The following figure demonstrates a snapshot of the map displaying the 
subject distribution across the counties of Wisconsin. 
- Provider Location: In the AHC base database’s table “provider_location”, 
each subject has multiple provider location’s records. Each provider location’s 
record contained the attributes {SURROGATE ID, DAY, PROVIDER_ZIP, 
SOURCE_SYSTEM}. As a quality measure, the recorded 5-digit zipcodes 
were examined against a standard zipcode dictionary to find and exclude any 
invalid recorded zipcodes. 54.10% of the whole AHC Base Database’s 
population have at least one provider location record. The partially (i.e., the 
same zipcode on the same day at two different “SOURCE_SYSTEM”s) and 
complete duplicated records were also excluded (3.93% of the records). The 
average number of provider location records for subjects with provider 
location records was 1.06 (range 1-4). Out of the subjects with provider 
> 10,000 
5,000-9,999 
1,000-4,999 
< 1,000 
Figure 4.5. Distribution of AHC Base Database’s subjects across 
Wisconsin counties. 
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location record, 6.65% had more than one reported zipcode. The reported 
provider locations’ zipcodes were distributed across 20 states with the highest 
frequency in Wisconsin and Illinois (97.75% and 1.15%, respectively). The 
provider locations in Wisconsin were also distributed across the 29 counties of 
the state with the highest frequency in counties Milwaukee and Brown 
(59.56% and 8.65%, respectively). 
- Smoking: In the AHC Base Database’s table “smoking”, each subject has 
longitudinal smoking records with multiple smoking records for each record 
day which were not on a regular basis. Each smoking record contained the 
attributes {SURROGATE_ID, DAY, TOBACCO_USE, SOURCE_SYSTEM}. 
The TOBACCO_USE value fields were populated with a large number of 
different unstructured data values. To address this issue, a dictionary was 
created to refine and translate the recorded values to a set of well-defined 
ones (Table 4.8). Almost 68% of the Base Database’s subjects had smoking 
status records.  
Table 4.8. Smoking Status value dictionary. 
Tobacco Use 
Smoking 
Status 
Definition 
Current Smoker YES Currently Smoker 
Former Smoker < or = to 12 months ago NO Not currently smoker 
Former Smoker >12 months ago NO Not currently smoker 
Never Smoker NO Never smoker 
Unknown if Ever Smoked NO Unknown 
 
- Indication: In the AHC Base Database’s table “indication”, each subject has 
multiple indication records. Each indication record contained the attributes 
{SURROGATE ID, DAY, CODE, SOURCE_SYSTEM}. As a quality measure, 
first, the reported codes were examined against the published ICD-9 CM 2011 
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codes (ICD-9-CM, 2014) to test their validity (i.e., in acceptable range). All of 
the reported codes were in acceptable range (Table 4.9). 
Table 4.9. ICD-9 Codes for indications of the AHC Base Database's subjects. 
ICD-9-CM 2011 Diagnostic and Procedure 
Code Class 
Indication codes reported 
at the AHC Base Database 
Myocardial Infarction 
410 Acute myocardial infarction 
410.0 Of anterolateral wall 
410.1 Of other anterior wall 
410.2 Of inferolateral wall 
410.3 Of inferoposterior wall 
410.4 Of other inferior wall 
410.5 Of other lateral wall 
410.6 True posterior wall infarction 
410.7 Subendocardial infarction 
410.8 Of other specified sites 
410.9 Unspecified site  
410.01 410.02 410.11 410.12 
410.21 410.22 410.32 410.41 
410.51 410.72 410.81 410.82 
410.91 410.92 
Pulmonary Embolism 
415 Acute pulmonary heart disease 
415.1 Pulmonary embolism and infarction 
415.11 415.12 415.13 415.19 
Cardiac Dysrhythmias 
427 Cardiac dysrhythmias  
427.3 Atrial fibrillation and flutter 
427.31 427.32 
Cerebrovascular Disease 
432 Other and unspecified intracranial 
hemorrhage 
432.1 Subdural hemorrhage  
433 Occlusion and stenosis of precerebral 
arteries 
433.1 Occlusion and stenosis of carotid 
artery 
433.2 Occlusion and stenosis of vertebral 
artery 
433.8 Occlusion and stenosis of other 
specified precerebral artery 
433.9 Occlusion and stenosis of unspecified 
precerebral artery 
434 Occlusion of cerebral arteries 
434.1 Cerebral embolism 
434.9 Cerebral artery occlusion unspecified 
435 Transient cerebral ischemia 
435.1 Vertebral artery syndrome convert 
435.2 Subclavian steal syndrome convert 
435.3 Vertebrobasilar artery syndrome 
convert 
435.8 Other specified transient cerebral 
432.1 433.01 433.11 433.21 
433.31 433.81 433.91 434.01 
434.11 434.91 435.1 435.2 
435.3 435.8 435.9 436 437.1 
437.9 438.11 438.12 438.13 
438.14 438.19 438.21 438.22 
438.31 438.32 438.41 438.42 
438.51 438.52 438.53 438.6 
438.7 438.81 438.82 438.83 
438.84 438.85 438.89 438.9 
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ischemias convert 
435.9 Unspecified transient cerebral 
ischemia convert 
436 Acute, but ill-defined, cerebrovascular 
disease 
437 Other and ill-defined cerebrovascular 
disease 
437.1 Other generalized ischemic 
cerebrovascular disease convert 
437.9 Unspecified cerebrovascular disease 
convert  
438 Late effects of cerebrovascular disease 
438.0 Late effects of cerebrovascular 
disease, cognitive deficits 
438.1 Speech and language deficits 
438.2 Hemiplegia/hemiparesis 
438.3 Monoplegia of upper limb 
438.4 Monoplegia of lower limb 
438.5 Other paralytic syndrome 
438.6 Late effects of cerebrovascular 
disease, alterations of sensations 
438.7 Late effects of cerebrovascular 
disease, disturbances of vision 
438.8 Other late effects of cerebrovascular 
disease 
438.9 Unspecified late effects of 
cerebrovascular disease 
Gastrointestinal Hemorrhage 
578 Gastrointestinal hemorrhage 
578.1 Blood in stool 
578.9 Hemorrhage of gastrointestinal tract, 
unspecified 
578.1 578.9 
Hemorrhage in Head and Neck 
784 Symptoms involving head and neck 
784.7 Epistaxis  
784.8 Hemorrhage from throat 
784.7 784.8 
Hemorrhage in Respiratory System 
786 Symptoms involving respiratory system 
and other chest symptoms 
786.3 Hemoptysis 
786.3 
Phlebitis and Thrombophlebitis 
451 Phlebitis and thrombophlebitis 
451.1 Phlebitis and thrombophlebitis of deep 
veins of lower extremities 
451.2 Phlebitis and thrombophlebitis of 
lower extremities, unspecified 
451.8 Phlebitis and thrombophlebitis of other 
sites 
451.9 Phlebitis and thrombophlebitis of 
451.11 451.19 451.2 451.81 
451.82 451.83 451.84 451.89 
451.9 453.1 453.2 453.3 
453.41 453.42 453.51 453.52 
453.6 453.71 453.72 453.73 
453.74 453.75 453.76 453.77 
453.79 453.8 453.81 453.82 
453.83 453.84 453.85 453.86 
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unspecified site 
452 Portal vein thrombosis 
453 Other venous embolism and thrombosis 
453.1 Thrombophlebitis migrans 
453.2 Other venous embolism and 
thrombosis of inferior vena cava 
453.3 Other venous embolism and 
thrombosis of renal vein 
453.4 Acute venous embolism and 
thrombosis of deep vessels of lower 
extremity 
453.5 Chronic venous embolism and 
thrombosis of deep vessels of lower 
extremity 
453.6 Venous embolism and thrombosis of 
superficial vessels of lower extremity 
453.7 Chronic venous embolism and 
thrombosis of other specified vessels 
453.8 Acute venous embolism and 
thrombosis of other specified veins 
453.9 Other venous embolism and 
thrombosis of unspecified site 
454 Varicose veins of lower extremities 
455 Hemorrhoids 
456 Varicose veins of other sites 
457 Noninfectious disorders of lymphatic 
channels 
458 Hypotension 
459 Other disorders of circulatory system 
459.1 Postphlebitic syndrome 
459.3 Chronic venous hypertension 
(idiopathic) 
459.8 Other specified disorders of 
circulatory system 
459.9 Unspecified circulatory system 
disorder 
453.87 453.89 453.9 459.11 
459.12 459.19 459.31 459.32 
459.81 459.89 459.9 
Heart Valve Replacement 
V43.3 Heart valve 
V43.3 
 
The reported CPT Codes in the table “indication” were also examined against 
the Current Procedural Terminology (CPT) to test their validity (i.e., in 
acceptable range). The following table (Table 4.10) shows the reported the 
CPT codes. 
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Table 4.10. CPT Codes for indications of the AHC Base Database's Subjects. 
CPT Code Class CPT Codes 
Orthopedic Procedures 77.65 77.66 77.67 77.69 
77.75 77.76 77.77 77.79 
77.85 77.86 77.87 77.96 
78.05 78.06 78.07 78.09 
78.15 78.16 78.17 78.19 
78.29 78.45 78.46 78.47 
78.49 78.55 78.56 78.57 
78.59 79.05 79.06 79.09 
79.15 79.16 79.19 79.25 
79.26 79.29 79.35 79.36 
79.39 79.56 79.65 79.66 
79.75 79.76 79.85 79.86 
79.89 80.25 80.26 80.27 
80.6 80.75 80.76 81.44 
81.45 81.46 81.47 81.49 
81.51 81.52 81.53 81.54 
81.55 81.56 81.57 81.59 
81.62 81.63 81.64 81.65 
81.66 84.11 84.12 84.13 
84.14 84.15 84.16 84.17 
84.18 84.19 84.51 84.58 
84.59 84.61 84.62 84.65 
84.81 84.84 
 
On average, each subject had 1.83 indication record (range 1-14). The 
following table (Table 4.11) depicts the distribution of number of indication 
records per subject. 
Table 4.11. Distribution of number of indication records among the subjects 
with indication records. 
Number of Indication 
Records/Subject 
Number of Subjects (%) 
1 50196 (50.14) 
2 29253(29.22) 
3 12701(12.68) 
4 4990(4.98) 
5 1885(1.88) 
6 688(0.68) 
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7 251(0.25) 
8 97(<0.001) 
9 23(<0.001) 
10 9(<0.001) 
11 4(<0.001) 
12 1(<0.001) 
13 4(<0.001) 
14 1(<0.001) 
Total 100103 (100%) 
 
18.46% of the indication records were reported before patients’ first 
prescription start date of an anticoagulation medication at AHC. The 
distribution of the reported days of indications are depicted in Table 4.12. 
Table 4.12. Distribution of day numbers in which the indications were 
recorded before or after patients’ start date of anticoagulation therapy. 
Recorded Day of Indication 
Number of Indication Records 
(%) 
Within 12 weeks before the start date 13768(7.51) 
Within 4 weeks before the start date 11875(6.47) 
Within 1 week before the start date 9426(5.14) 
On the start date 26429(14.42) 
Within 1 week after the start date 35628(19.44) 
Within 4 weeks after the start date 44986(24.54) 
Within 12 weeks after the start date 54856(29.93) 
 
The complete duplicated records and partially duplicated ones (i.e., records 
with the same indication on different days) were identified and excluded 
(17.58% of the records). The following table (Table 4.13) depicts the 
distribution of number of unique indications among the subjects with indication 
records. 
Table 4.13. Distribution of number of unique indications among the subjects 
with indication records. 
Number of Unique 
Indications/Subject 
Number of Subjects (%) 
1 64360 (64.29) 
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2 25330(25.30) 
3 7056(7.04) 
4 2227(2.22) 
5 730(0.72) 
6 267(0.26) 
7 94(<0.001) 
8 23(<0.001) 
9 5(<0.001) 
10 4(<0.001) 
11 5(<0.001) 
12 1(<0.001) 
13 1(<0.001) 
Total 100103 (100%) 
 
- Comorbidity: In the AHC Base Database’s table “comorbidity”, each subject 
has multiple comorbidity records. Each comorbidity record contained the 
attributes {SURROGATE ID, DAY, CODE, SOURCE_SYSTEM}. As a quality 
measure, first, the reported codes were examined against the published ICD-
9-CM 2011 codes (ICD-9-CM, 2014) to make sure that they were in the 
acceptable range of the codes. All of the reported codes were in acceptable 
range (Table 4.14). 
Table 4.14. ICD-9 Codes for comorbidities of the AHC Base Database's 
Subjects. 
ICD-9-CM 2011 Diagnostic and 
Procedure Code Class 
Comorbidity codes reported at 
the AHC Base Database 
Myocardial Infarction 
410 Acute myocardial infarction 
410.0 Of anterolateral wall 
410.1 Of other anterior wall 
410.2 Of inferolateral wall 
410.3 Of inferoposterior wall 
410.4 Of other inferior wall 
410.5 Of other lateral wall 
410.6 True posterior wall 
infarction 
410.7 Subendocardial infarction 
410.8 Of other specified sites 
   410.9 Unspecified site 
410.01 410.02 410.11 410.12 
410.21 410.22 410.31 410.32 
410.41 410.42 410.51 410.52 
410.61 410.62 410.71 410.72 
410.81 410.82 410.91 410.92 
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Pulmonary Embolism 
415 Acute pulmonary heart 
disease 
415.1 Pulmonary embolism and 
infarction 
415.11 415.12 415.13 415.19 
Cerebrovascular Disease 
431 Intracerebral hemorrhage 
432 Other and unspecified 
intracranial hemorrhage 
432.1 Subdural hemorrhage  
433 Occlusion and stenosis of 
precerebral arteries 
433.1 Occlusion and stenosis 
of carotid artery 
433.2 Occlusion and stenosis 
of vertebral artery 
433.8 Occlusion and stenosis 
of other specified precerebral 
artery 
433.9 Occlusion and stenosis 
of unspecified precerebral 
artery 
434 Occlusion of cerebral 
arteries 
434.1 Cerebral embolism 
434.9 Cerebral artery occlusion 
unspecified 
435 Transient cerebral ischemia 
435.1 Vertebral artery 
syndrome convert 
435.2 Subclavian steal 
syndrome convert 
435.3 Vertebrobasilar artery 
syndrome convert 
435.8 Other specified transient 
cerebral ischemias convert 
435.9 Unspecified transient 
cerebral ischemia convert 
436 Acute, but ill-defined, 
cerebrovascular disease 
437 Other and ill-defined 
cerebrovascular disease 
437.1 Other generalized 
ischemic cerebrovascular 
disease convert 
437.9 Unspecified 
cerebrovascular disease 
convert  
438 Late effects of 
cerebrovascular disease 
431 432.1 432.9 433.01 433.11 
433.21 433.31 433.81 433.91 
434.01 434.11 434.91 435.1 435.2 
435.3 435.8 435.9 436 437.1 437.9 
438.11 438.12 438.13 438.14 
438.19 438.21 438.22 438.31 
438.32 438.41 438.42 438.51 
438.52 438.53 438.6 438.7 438.81 
438.82 438.83 438.84 438.85 
438.89 438.9 
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438.0 Late effects of 
cerebrovascular disease, 
cognitive deficits 
438.1 Speech and language 
deficits 
438.2 Hemiplegia/hemiparesis 
438.3 Monoplegia of upper limb 
438.4 Monoplegia of lower limb 
438.5 Other paralytic syndrome 
438.6 Late effects of 
cerebrovascular disease, 
alterations of sensations 
438.7 Late effects of 
cerebrovascular disease, 
disturbances of vision 
438.8 Other late effects of 
cerebrovascular disease 
438.9 Unspecified late effects 
of cerebrovascular disease 
Gastrointestinal Hemorrhage 
578 Gastrointestinal hemorrhage 
578.9 Hemorrhage of 
gastrointestinal tract, 
unspecified 
578.9 
Hemorrhage in Head and Neck 
784 Symptoms involving head 
and neck 
784.7 Epistaxis  
784.8 Hemorrhage from throat 
784.7 784.8 
Hemorrhage in Respiratory 
System 
786 Symptoms involving 
respiratory system and other 
chest symptoms 
786.3 Hemoptysis 
786.3 
Phlebitis and Thrombophlebitis 
451 Phlebitis and 
thrombophlebitis 
451.1 Phlebitis and 
thrombophlebitis of deep veins 
of lower extremities 
451.2 Phlebitis and 
thrombophlebitis of lower 
extremities, unspecified 
451.8 Phlebitis and 
thrombophlebitis of other sites 
451.9 Phlebitis and 
thrombophlebitis of unspecified 
site 
452 Portal vein thrombosis 
451.11 451.19 451.2 451.81 451.82 
451.83 451.84 451.89 451.9 453.1 
453.2 453.3 453.41 453.42 453.51 
453.52 453.6 453.71 453.72 453.73 
453.74 453.75 453.76 453.77 
453.79 453.8 453.81 453.82 453.83 
453.84 453.85 453.86 453.87 
453.89 453.9 
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453 Other venous embolism and 
thrombosis 
453.1 Thrombophlebitis 
migrans 
453.2 Other venous embolism 
and thrombosis of inferior vena 
cava 
453.3 Other venous embolism 
and thrombosis of renal vein 
453.4 Acute venous embolism 
and thrombosis of deep vessels 
of lower extremity 
453.5 Chronic venous 
embolism and thrombosis of 
deep vessels of lower extremity 
453.6 Venous embolism and 
thrombosis of superficial 
vessels of lower extremity 
453.7 Chronic venous 
embolism and thrombosis of 
other specified vessels 
453.8 Acute venous embolism 
and thrombosis of other 
specified veins 
453.9 Other venous embolism 
and thrombosis of unspecified 
site 
454 Varicose veins of lower 
extremities 
455 Hemorrhoids 
456 Varicose veins of other sites 
457 Noninfectious disorders of 
lymphatic channels 
458 Hypotension 
459 Other disorders of circulatory 
system 
459.1 Postphlebitic syndrome 
459.3 Chronic venous 
hypertension (idiopathic) 
459.8 Other specified disorders 
of circulatory system 
459.9 Unspecified circulatory 
system disorder 
 
About 1/3 (37.46%) of the AHC Base Database’s subjects had comorbidity 
records. On average within the subjects with comorbidity records, each 
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subject had 1.61 comorbidity record (range 1-13). The following table (Table 
14.15) depicts the distribution of number of comorbidity records per subject. 
Table 4.15. Distribution of number of comorbidity records among the subjects 
with comorbidity records. 
Number of Comorbidity 
Records/Subject 
Number of Subjects (%) 
1 36118(61.22) 
2 14739(24.98) 
3 5188(8.79) 
4 1851(3.13) 
5 685(1.16) 
6 254(0.43) 
7 109(<0.001) 
8 29(<0.001) 
9 7(<0.001) 
10 2(<0.001) 
11 4(<0.001) 
12 1(<0.001) 
13 1(<0.001) 
Total 58988(100%) 
 
18.36% of the comorbidity records were reported before patients’ first 
prescription start date of an anticoagulation medication at AHC. The 
distribution of the reported days of comorbidities are depicted in table 4.16. 
Table 4.16. Distribution of day numbers in which the comorbidities were 
recorded before or after patients’ start date of anticoagulation therapy. 
Recorded Day of Comorbidity 
Number of Comorbidity Records 
(%) 
Within 12 weeks before the start date 7697(8.13) 
Within 4 weeks before the start date 6588(6.95) 
Within 1 week before the start date 5215(5.50) 
On the start date 13971(14.75) 
Within 1 week after the start date 20553(21.71) 
Within 4 weeks after the start date 26782(28.29) 
Within 12 weeks after the start date 32354(34.17) 
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Having compared the records of tables “indication” and “comorbidity”, it was 
revealed that 69.26% of the comorbidity records were shared with indication 
records. Given this fact, the two quality controlled and cleaned tables were 
merged to create a new table called “morbidity”. Each record of this new table 
has attributes {SURROGATE_ID, DAY, CODE, SOURCE_SYSTEM}. About 
2/3 (65.68%) of the AHC Base Database’s subjects had morbidity records. On 
average within the subjects with morbidity records, each subject had 1.71 
morbidity records (range 1-13). Table 4.17 depicts the distribution of number 
of morbidity records per subject. 
Table 4.17. Distribution of number of morbidity records among the subjects 
with morbidity records. 
Number of Morbidity 
Records/Subject 
Number of Subjects (%) 
1 57116(55.22) 
2 29131(28.16) 
3 11346(10.97) 
4 3756(3.63) 
5 1326(1.28) 
6 468(0.45) 
7 181(0.17) 
8 68(<0.001) 
9 10(<0.001) 
10 3(<0.001) 
11 8(<0.001) 
12 2(<0.001) 
13 1(<0.001) 
Total 103416(100%) 
 
38.55% of the morbidity records were reported before patients’ first 
prescription start date of an anticoagulation medication at AHC. The 
distribution of the reported days of morbidities are depicted in table 4.18. 
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Table 4.18. Distribution of day numbers in which the morbidities were 
recorded before or after patients’ start date of anticoagulation therapy. 
Recorded Day of Morbidity Number of Morbidity Records (%) 
Within 12 weeks before the start date 16430(15.88) 
Within 4 weeks before the start date 14191(13.72) 
Within 1 week before the start date 11340(10.96) 
On the start date 29200(28.23) 
Within 1 week after the start date 37351(36.11) 
Within 4 weeks after the start date 44180(42.72) 
Within 12 weeks after the start date 55412(53.58) 
 
- Interacting Medications: In the AHC Base Database’s table 
“interacting_medication”, each subject has multiple medication records. Each 
interacting medication record contained the attributes {SURROGATE ID, 
DAY, MEDICATION_NAME, FREQ, DOSE_QTY, DOSE_QTY_UNIT, 
SOURCE_SYSTEM}. In the table, the entire columns of {DOSE_QTY, 
DOSE_QTY_UNIT} were completely blank. The column {FREQ} was partially 
complete. The cells under column {MEDICATION_NAME} were populated 
with free-text. Before conducting any cleaning or quality control measures, we 
had to extract information from the free-text in cells under column 
{MEDICATION_NAME} and translate them into a structured format. Through 
a text analysis step, the required data from the free text were extracted and 
presented in normalized and consistent structured formats. We used a 
multistep process which involved parsing the free texts into their components, 
normalizing the identified components, and extraction of the required data 
elements (i.e., name of medication, dosage, unit, and route of administration). 
The rate of incompleteness of the resulted records was high. Table 4.19 
depicts the distribution of interacting medication records by each medication 
in the cleaned and controlled interacting_medication table and also presents 
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an example of the rate of completeness (i.e., percentage of each interacting 
medication’s records with dosage information).  
99.02% of the interacting medications records included one of the three 
medications of warfarin (37.85%), heparin (36.24%) and clopidogrel (24.93%). 
Warfarin records which have dosage information have the highest percentage 
of whole the records (11%). Although the number of heparin records was 
higher than the number of clopidogrel records, the percentage of clopidogrel 
records with dosage information out of whole the records was higher than that 
of heparin. 
Table 4.19. Distribution of number of subjects under each interacting 
medication and the rate of medication records’ dosage information 
completeness. 
Interacting 
Medication 
Number of Subjects 
under Interacting 
Medication 
Rate of the Records’ 
Dosage Information 
Completeness  
Amiodarone 74,102 70.03% 
Simvastatin 71,537 33.4% 
Fluvastatin 61,517 68.03% 
Lovastatin 1,793 89.18% 
Atrovastatin 2,292 22.9% 
Rosuvastatin 2886 71.58% 
Pravastatin 434 73.5% 
Aspirin 1,310 90.15% 
 
The above table indicates that a big number of subjects have received more 
than one medication. The following table (Table 4.20) shows the number of 
subjects who have been under treatment with 1 to 6 medications. 
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Table 4.20. Distribution of subjects by number of medications. 
 
- INR: In the AHC Base Database, each subject has longitudinal INR records 
with multiple INR records for each measurement day which were not on a 
regular basis. Each INR record contained the attributes {"SURROGATE_ID", 
"EFFECTIVE_DAY", "LAB_DESCRIPTION", "LAB_VALUE", 
"SOURCE_SYSTEM"}. Since INR measurement can vary within a specific 
time frame due to factors such as different measurement methods (e.g., 
medical laboratory testing, point-of-care testing, patient self-testing), we 
created a cleaning algorithm for INR records. Before applying the algorithm, 
first, each INR record was examined to identify and exclude any INR record 
whose INR lab value was missing. Then the INR cleaning algorithm was 
applied (Figure 4.6). 
According to the algorithm, we first removed all INR values we considered 
technically not acceptable according to the AHC’s laboratory guidelines (i.e., 
0.9 > INRs > 10). Then we took the next steps of the algorithm. If all INR 
No. of Medications 1 2 3 4 5 6 
No of Subjects 75282 16441 3049 358 20 1 
Figure 4.6. INR records cleaning algorithm. 
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records for a single subject in a single day differed (i.e., difference between 
minimum INR and maximum INR for the same day) by less than acceptable 
measurement variance of 0.5 INR-units (Rasmussen, 2012), then all INR 
records for that subject for that day were marked acceptable by the algorithm 
and the mean of the INR records was calculated representing INR value for 
the day. For all other days, median INR for each day was calculated. The rate 
of INR record completeness for the AHC Base Database is 77.03%. The 
subjects with INR records had 19.17 INR records on average.  
4.2.2.) WiAD Database and Data Load 
The next step in the process of developing a research anticoagulation 
database was to load the quality controlled and transformed data into a 
working database now called "WiAD" standing for "Wisconsin 
Anticoagulation/Anti-clotting Database". The database was implemented in a 
MySQL Server and i2b2. Two specifics tasks were undertaken in this process: 
designing data models consistent with the research needs and also making 
some vocabularies and ontologies across the data models to make sure that 
the queries run against the implemented databases would consistently return 
the data meeting the research oriented criteria. 
4.2.2.1.) MySQL Database 
WiAD was implemented in MySQL Server as one of its database 
management systems. The database could be queried directly through the 
MySQL server or it could be done using a tool called WiAD-Miner (explained 
in section 4.3.4). The data model of WiAD on the MySQL server is depicted in 
Figure 4.7. In this star schema, table “patients” is the core table which 
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basically stores non-longitudinal attributes of the subjects (e.g., Gender, Age, 
and Race). The other tables store the subjects’ longitudinal attributes. 
4.2.2.2.) i2b2 Database 
Our anticoagulation/anticlotting research database “WiAD” was also 
implemented in i2b2. The data model provided in the i2b2 database is called 
“star schema” where tables are connected as a star. Figure 4.8 shows the star 
schema consisting of Observation Fact surrounded by Patient Dimension, 
Visit Dimension, Concept Dimension, and Provider Dimension for the WiAD 
database. 
Figure 4.7. Entity Relationship (ER) Model of the WiAD’s MySQL Database. 
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In this schema, the Observation Fact table represents a patient object and 
other four dimensions represent its attributes such as who (patient 
information), when (dates), what (ontology for clinical patients' data) and 
where (hospital or treatment facility), respectively.  
Table 4.21. Definitions of the concepts of the WiAD’s i2b2 data model. 
Concept Definition 
surrogate_id Patient unique identification number 
encounter_num Patient visit number (surrogate_id + day) 
concept_cd 
Code for observation of interest (i.e., morbidity, 
medications, lab test) 
provider_id Provider unique identification number 
day Starting date-time of observation (i.e. “DAY”) 
concept_path Ontology path for concepts 
concept_id Unique identification number for concepts 
concept_name Actual name of the concept 
location Zipcode of the provider 
 
Figure 4.8. WiAD's i2b2 Data Model. 
175 
 
 
 
In i2b2, ontology represents a data model of a target domain. Ontology is 
stored in Concept Dimension table, which contains a symbolic name of an 
individual attribute (Concept ID) and a path from a root of ontology to an 
individual attribute (Concept Path). Every attribute is allowed to have only one 
conceptual path, so that ontology in the i2b2 includes no multiple inheritance. 
The following table provides definitions for some of the specific concepts of 
the WiAD’s i2b2 data model. 
The following table (Table 4.22) details the WiAD’s i2b2 ontology. 
Table 4.22. Hierarchical structure of the WiAD’s i2b2 ontology. 
Demographics 
Demographics\Age\ 
Demographics\Gender\ 
Demographics\Gender\Female\ 
Demographics\Gender\Male\ 
Demographics\Height\ 
Demographics\Patient Zipcode\ 
Demographics\Provider Zipcode\ 
Demographics\Race\ 
Demographics\Race\African American\ 
Demographics\Race\American Indian or Alaskan Native\ 
Demographics\Race\Asian\ 
Demographics\Race\Hispanic\ 
Demographics\Race\Not Asked\ 
Demographics\Race\Null\ 
Demographics\Race\Other\ 
Demographics\Race\Pacific Islander\ 
Demographics\Race\Unknown\ 
Demographics\Race\White\ 
Demographics\Tobacco Use\ 
Demographics\Weight\ 
Morbidity 
Morbidity\Diagnosis\ 
Morbidity\Diagnosis\Atherosclerosis of Aorta\ 
Morbidity\Diagnosis\Atrial Fibrillation\  
Morbidity\Diagnosis\Atrial Flutter\ 
Morbidity\Diagnosis\Bleeding\   
Morbidity\Diagnosis\Coronary Artery Disease\ 
Morbidity\Diagnosis\Deep Vein Thrombosis\ 
Morbidity\Diagnosis\Diabetes Mellitus\ 
Morbidity\Diagnosis\Heart Failure\ 
Morbidity\Diagnosis\Hypertension\ 
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Morbidity\Diagnosis\Myocardial Infarction\ 
Morbidity\Diagnosis\Peripheral Artery Diseases\ 
Morbidity\Diagnosis\Pulmonary Embolism\ 
Morbidity\Diagnosis\Stroke\ 
Morbidity\Procedure\ 
Morbidity\Procedure\Heart Valve Replacement\ 
Morbidity\Diagnosis\Orthopedic Procedures\ 
Medications 
Medications\Anticoagulation Agent\Abciximab 
Medications\Anticoagulation Agent\Clopidogrel\ 
Medications\Anticoagulation Agent\Dabigatran\ 
Medications\Anticoagulation Agent\Dipyridamole\ 
Medications\Anticoagulation Agent\Eptifibatide\ 
Medications\Anticoagulation Agent\Heparin\ 
Medications\Anticoagulation Agent\Ticlopidine\ 
Medications\Anticoagulation Agent\Tirofiban\ 
Medications\Anticoagulation Agent\Warfarin\ 
Medications\Interacting Medication\Amiodarone\ 
Medications\Interacting Medication\Aspirin\ 
Medications\Interacting Medication\Atrovastatin\ 
Medications\Interacting Medication\Fluvastatin\ 
Medications\Interacting Medication\Lovastatin\ 
Medications\Interacting Medication\Pravastatin\ 
Medications\Interacting Medication\Rosuvastatin\ 
Medications\Interacting Medication\Simvastatin\ 
Lab Test 
Labe Test\INR\ 
 
4.2.2.3.) Ontology issues 
Usually in clinical datasets, there exist different data types in data which can 
each be supported by a separate dictionary such as the ones we have 
developed for the AHC dataset. The advantage of using ontologies and 
dictionaries is that they help standardize raw data and also add logical 
hierarchical structure. In the case of i2b2, these are essential component of its 
ontology too. In the ideal situation and with the aim of interoperability, the data 
are mapped to reference standard dictionaries and ontologies. With the use of 
reference standard dictionaries and ontologies (e.g., Drug Bank), we could 
subgroup data types then support data elements across all data sources. 
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Even though there are different reference dictionaries and ontologies to use 
for normalizing and standardizing data (e.g., ICD-9, CPT, LOINC, NDC), the 
standard ontologies used are largely based on the data available. For the 
AHC dataset, our diagnosis data are coded in ICD-9, so that is the hierarchy 
we use in our ontology. The same holds true for procedures. With our 
medication and laboratory data, it is not coded in terminology with a standard 
hierarchy, so we had to organize the data using other locally developed 
dictionaries.       
4.2.3.) Data Analysis Methods and Tools 
As introduced, WiAD is a longitudinal database which includes subjects’ 
characteristics, treatment plans and outcomes that have been at multiple 
follow-up times. A longitudinal database generally provides multiple or 
repeated measurements and records on each subject. Accordingly and given 
that such repeated measurements and records are correlated within subjects, 
there are needs for special analysis and inference techniques for a 
longitudinal dataset. Although longitudinal data are very beneficial but there 
challenges in using such data which in some cases are not without cost. 
There are several challenges posed (Heagerty, 2014):  
- Participants follow-up. There is always the possibility of bias as the 
retrospective longitudinal EMR data might include the data of subjects who 
might have incomplete follow-up or drop-out during their treatment periods. 
Accordingly, the analysis of such data requires special attention to make sure 
that the extracted subset of the data meets the assumptions of the study that 
it is going to be used for. 
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- Analysis of correlated data. Given the nature of the longitudinal of EMR data, 
we need to use statistical methods that can account for the intra-attributes 
and /or intra-subjects correlations.  
- Time-varying covariates. Although longitudinal data provide the opportunity 
to study the association between the changes in one subject’s attribute by 
changes in other attributes or outcome of interest, the direction of causality 
can be complicated by feedback between the attributes.   
In the following section, some of the aspects of the longitudinal WiAD data is 
presented.  
4.2.3.1.) Landscape of the WiAD Data 
In the previous sections, it was explained the methods that we have applied to 
clean and quality control some of the longitudinal aspects of the WiAD data. 
However, there are some aspects of the data that should be managed and 
adjusted based on each study’s goals and design. For instance, one of the 
potential cross-attribute studies in the WiAD could be to study the correlation 
between the changes in warfarin doses and the subjects’ INR values. 
Figure 4.9.Warfarin dose changes versus INR values changes for two 
WiAD’s subjects. 
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However, the fact is that longitudinal data patterns for these attributes are 
very complex and affected by different factors so that it requires applying 
some specific methods to extract the data records which are appropriate for 
such a study. Figure 4.9 demonstrates the warfarin recorded doses versus 
INR recorded values for two different WiAD’s subjects.     
Taking into consideration that INR is used to monitor different anticoagulation 
agents and also the fact that a given patient under anticoagulaton therapy 
might receive different types of anticoagulation agents during his/her 
treatment period depending on his/her treatment condition (e.g., ambulatory, 
in-patient care or surgical procedure), it is important to find the desired 
warfarin exposure periods in the EMR data and extract the associated data. 
Given this complexity, we have developed some algorithms which help extract 
data from WiAD based on desired longitudinal patterns such as treatment 
periods (e.g. fixed time or medical procedure periods), treatment indications 
which require different target therapeutic INR ranges, and interval and 
frequency between successive observed dose records or INR values. These 
features have been implemented in WiAD-Miner explained in the next section. 
4.2.3.2.) WiAD-Miner 
An interactive data profiling and population "segmentation" tool for WiAD 
(WiAD-Miner) has been developed in R (R Core Team, 2014) using RStudio 
(RStudio, 2014). WiAD-Miner (Figure 4.10) which also has a web application 
version includes all the profiling, outcome metric, and related data analysis 
functions for anticoagulation agents. WiAD-Miner includes a cohort selection 
tool to profile and identify patient subpopulations by any or a combination of 
patients' characteristics including gender, age group, race, patient's residence 
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zipcode, provider's zipcode, medication, medication exposure, duration of 
treatment, number of dose records, frequency of INR values, medication 
indication, and comorbidities. WiAD-Miner presents a clear view of each 
extracted subset by producing statistical characteristics and visual profiling 
and allows adjustment of various parameters such as the medication 
exposure period definition, triggering a re-profiling and thereafter, re-
calculation of outcome metrics. 
4.2.4.) Estimating Parameters for PK/PD 
Our in silico simulation model takes advantage of Hamberg's PK/PD model 
(Hamberg, 2007) for individualization of warfarin therapy. As introduced in 
Chapter 3, Hamberg et al. have characterized the relationship between 
warfarin dose and international normalized ratio (INR) response and they 
have identified CYP2C9 genotype and age as predictors for S-warfarin 
clearance, and VKORC1 genotype as a predictor for warfarin sensitivity. Our 
in silico platform is able to take advantage of domain knowledge and integrate 
population characteristics such as genotype distributions if they are not 
provided for the study populations. Accordingly and given that WiAD originally 
Figure 4.10. A screenshot of the WiAD-Miner’s interface. 
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did not include genotype information, we have derived distribution of required 
genotypes for our study populations from some studies such as the one 
conducted by Scott (2010). A recent study by Scott (2010) has provided the 
allele frequencies of some of the principal genes known to influence 
interindividual warfarin dose variability (e.g., CYP2C9 and VKORC1) in 
African-American, Asian and White populations. We have used these 
information to impose population genotype distribution information into our in 
silico platform. Table 4.23 summarizes the CYP2C9 allele and genotype 
frequencies.  
Table 4.23. CYP2C9 Genotype Frequencies (Scott, 2010). 
CYP2C9 African-American Asian White 
Extensive Metabolizer 
*1/*1 75.5 86.3 66 
Intermediate Metabolizer 
*1/*2 4.3 3.9 15.1 
*1/*3 3.3 6.9 9.4 
*1/*5 2.7 0 0 
*1/*6 1.7 0 0 
*1/*8 8.7 1 0 
*1/*11 2 0 0.9 
Poor Metabolizer 
*2/*2 0.3 1 6.6 
*2/*3 0.3 0 1.9 
*2/*8 0 0 0 
*3/*3 0 0 0 
*3/*5 0 0 0 
*3/*8 0 1 0 
*3/*11 0.3 0 0 
*5/*6 0.3 0 0 
*8/*11 0.3 0 0 
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Table 4.24 demonstrates the VKORC1G 1639G>A allele frequencies.            
Table 4.24. VKORC1 Genotype Frequencies (Scott, 2010). 
VKORC1 
1639G>A 
African-American 
(%) 
Asian 
(%) 
White 
(%) 
G/G 80.3 22.5 36.8 
G/A 17.7 21.6 45.3 
A/A 2 55.9 17.9 
 
Table 4.25 summarizes the combined CYP2C9 and VKORC1 genotype 
frequencies for some of the study populations such as African-American, 
Asian and White. As depicted in the table, a majority of White and Asian 
individuals carry a variant of CYP2C9 and VKORC1 compared with African-
American.   
Table 4.25. Combined CYP2C9 and VKORC1 Genotype Frequencies (Scott, 
2010). 
CYP2C9 VKORC1 
1639G>A 
African-American 
(%) 
Asian 
(%) 
White 
(%) 
Extensive 
Metabolizer 
G/G 63.4 20.6 41.5 
G/A 0 0 0 
A/A 1.4 55 13.3 
Intermediate 
Metabolizer 
G/G 20.3 7.9 10.3 
G/A 2.9 3 10.4 
A/A 0.7 1 4.7 
Poor 
Metabolizer 
G/G 0 2 4.7 
G/A 0.4 0 3.7 
A/A 0 0 0 
 
4.3.) Results 
This effort has resulted in an EMR-based longitudinal 
anticoagulation/anticlotting database, WiAD, using Aurora Health Care’s 
electronic medical records. This database is a seminal translational 
anticoagulation research tool that support US-prioritized "Secondary Use" of 
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electronic medical records to improve health care and comparative 
effectiveness research studies. The database could be used to develop and 
derive conditional parametric models for WiAD-based studies such as studies 
that are presented in Chapters 5 and 6.  
4.4.) Conclusion and Future Work 
This effort has shown that EMR longitudinal data is a rich resource to develop 
research-grade databases. Our effort is aligned with current national 
developments such as PCORnet aiming to leverage the secondary use of 
EMR data for research purposes. As presented in the next chapters, WiAD 
database has significant potential for comparative effectiveness research and 
conducting patient-centered outcomes research. In future, we plan to improve 
the database by including more cardiovascular associated patient 
characteristics and also embedding more robust data transforming and 
extraction algorithms.   
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5.1.) Introduction 
We have developed an in silico pharmacogenetic PC-CER framework for 
anticoagulation therapy. The framework includes options to simulate patient 
populations ("Clinical Avatars"), multiple initial dosing protocols including PG-
based and non PG-based, multiple dose adjustment and maintenance 
protocols, PK/PD modeling and prediction of various types of outcome 
measures. We have validated the framework against two major warfarin 
clinical trials, CoumaGen-I and CoumaGen-II (Anderson, 2007a, 2012b). 
Then, we have used our highly adaptable in silico framework to conduct 90-
day anticoagulation therapy simulations for the Aurora Heath Care (AHC) 
state-wide warfarin patient population using a collection of warfarin dosing 
protocols to study comparative effectiveness and to identify different optimal 
protocols depending on subpopulations defined by patient characteristics. 
5.2.) CoumaGen-I Clinical Trial Simulation 
5.2.1.) Background and Objective 
The details of this study were published by Fusaro (2013) in the journal 
Circulation. In this study, the accuracy of the clinical trial simulator of our in 
silico PC-CER framework was demonstrated by reproducing the CoumaGen-I 
clinical trial outcomes (“CoumaGen-I Simulation 1”), and then the simulator 
was used to evaluate a new dosing protocol (“CoumaGen-I Simulation 2”), to 
determine whether this new study design was significantly more beneficial for 
the same population.  
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5.2.2.) Methods 
5.2.2.1) Study Design 
- The original study. The original CoumaGen-I clinical trial study (Anderson, 
2007) was designed as a prospective, randomized study comparing PG-
based and standard empirical dosing in patients being initiated on oral 
anticoagulation. The study objectives were prospectively to validate a PG-
based dosing algorithm (Anderson, 2007) and to assess its impact on INR-
based efficacy and safety end points. 
In the original study, the inclusion criteria to recruit subjects were as follows: 
Figure 5.1. Study design for the original CoumaGen-I clinical trial. PG: 
Pharmacogenetic arm, STD: Standard arm.  
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age ≥18 years and an indication for anticoagulation with a target INR of 2 to 3. 
And the subjects with the following characteristics were excluded: women who 
were pregnant, lactating, or of child-bearing potential, those taking rifampin 
within 3 weeks, or patients with comorbidities precluding standard dosing 
(e.g., advanced physiological age, renal insufficiency/creatinine >2.5 mg/dL, 
hepatic insufficiency, terminal disease). Then, the 200 qualified subjects 
underwent blind randomization to the pharmacogenetic (PG) or standard 
(STD) arm. The study recruited 101 patients into the PG arm and 99 patients 
into the standard clinical STD arm. Figure 5.1 illustrates the study design of 
the original clinical trial.  
- The simulation study. In this study, the two following simulations were 
designed and conducted: “CoumaGen-I Simulation 1” and “CoumaGen-I 
Simulation 2”. For each of these, with the use of a Bayesian Network Model 
(BNM), a sufficient number of clinical avatars (n=200000) was created to 
conduct 1000 simulations. For each of the 1000 simulations, 101 avatars for 
the PG arm and 99 for the STD arm were randomly recruited from this large 
clinical avatar population. Then, following the specific dosing protocol for each 
arm explained in the following sections, daily dose and INR for each avatar for 
that arm for 90 days were predicted. 
CoumaGen-I Simulation 1 followed the dosing protocol as specified in the 
original CoumaGen-I clinical trial (Anderson, 2007; Figure 5.1). The standard 
arm dosing followed the 10-mg warfarin nomogram from Kovacs (2003) for 
days 1 and 2 followed by dose adjustment based on INR according to the 
Kovacs (2003) protocol for days 3 to 7. For days 8 to 90, CoumaGen-I used 
the Intermountain Healthcare warfarin dosing algorithm. The CoumaGen-I 
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pharmacogenetic arm dosing followed a dosing algorithm which required both 
clinical and genotype (i.e., CYP2C9 and VKORC1) information to calculate 
doses for days 1 and 2. Like the original study, the initial doses were followed 
by a dose adjustment based on INR by multiplying standard arm changes by 
a pharmacogenetic algorithm coefficient for days 3 to 7. The pharmacogenetic 
algorithm coefficient was defined as the ratio of the estimated individual 
weekly dose determined by the pharmacogenetic algorithm to the standard 
weekly dose of 35 mg. For days 8 to 90, CoumaGen-I used the Intermountain 
Healthcare warfarin dosing protocol. 
Figure 5.2. The study design of the CoumaGen-I Simulation 1 and 2. 
Black text represents new features compared to the original 
CoumaGen-I study, whereas gray text represents those features in 
common with the original study as depicted in Figure 5.1. PG: 
Pharmacogenetic arm, STD: Standard arm.   
A. CoumaGen-I Simulation 1                            B. CoumaGen-I Simulation 2 
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The design of the CoumaGen-I Simulation 2 was different from the original 
clinical trial. It was conducted using a third dosing protocol (nomogram) 
offered by Wilson (2007). In this study, the same starting doses were used for 
days 1 to 2 as in the original CoumaGen-I trial, 10-mg/d for the standard arm 
and 2 times the pharmacogenetic dose for the pharmacogenetic arm. For 
days 3 to 90, the Wilson protocol was used to increase or decrease the dose 
proportionally based on low or high INR values, respectively. The following 
figure (Figure 5.2) illustrates the design of the two simulation studies. 
5.2.2.2) Clinical Avatar Populations 
With regard to the BNM used for creating clinical avatars in this study, some 
consideration were made as the original CoumaGen-I’s individual patients’ 
information were not available. Taking into consideration the subjects’ 
characteristics required for the dosing algorithms used in this study, the prior 
probabilities used for the study’s BNM were based on the statistical 
characterization of the patient population including age, sex, weight, height, 
race, body surface area (calculated from height and weight), smoking status, 
deep vein thrombosis status, amiodarone use status, and genotypes for 
CYP2C9*2, CYP2C*3, and VKORC1. The CoumaGen-I trial data used age, 
sex, weight, height, deep vein thrombosis, smoking status, and genotypes as 
their variables. In the simulation study, some other required prior probabilities 
(e.g., amiodarone status) for the BNM were estimated by using data from the 
Centers for Disease Control and Prevention and the 2000 US Census. The 
extracted prior probabilities were mostly for whites as about 95% of the 
original CoumaGen-I trial’s subjects were white.  
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Another challenge in developing a BNM for this study which helped produce 
physiologically realistic clinical avatars was the lack of joint conditional 
probability distributions for the characteristics. To deal with this case, some 
external data and information sources were used such as the US Census 
2007 to 2008 Table 209 (http://www. 
census.gov/compendia/statab/2012/tables/12s0210.pdf) which details height 
and weight distributions as functions of age and sex. The extracted normal 
distributions from the above sources were transformed to match the actual 
population in the CoumaGen-I trial. For instance, the distributions for subjects 
40 to 49, 50 to 59, and 60 to 69 years of age were z-transformed and scaled 
according to the mean and standard deviation for the CoumaGen-I trial 
pharmacogenetic and standard arms, respectively. For use in the BNM, then 
a dependency table by sampling from these distributions and calculating the 
percentages for each age/sex group was developed. The BNM was 
implemented in TETRAD IV (Scheines, 1998) to produce the clinical avatar 
populations for the both Simulations 1 and 2. 
5.2.2.3.) Measuring Outcome Metrics 
The primary outcome metric was Percent Time INR in Therapeutic Range 
(“TTR”). Consistent with the original CoumaGen-I study, TTR was defined as 
the percentage of time an individual avatar had an INR between 1.8 and 3.2 
during the 90-day simulation. Although our simulator could calculate daily INR 
values, only INRs on those days in which the INR would have been checked 
in the clinic according to the specific protocol were considered. 
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5.2.2.4.) Clinical Trial Simulations  
As stated in previous sections, in the original CoumaGen-I randomized 
controlled trial, the 200 subjects were randomly assigned to two PG (n=101) 
and STD (n=99) arms. Accordingly, in the Simulation 1 and 2 studies, the 
200,000 clinical avatars were also randomly sampled to recruit 101 and 99 
avatars for the PG and the STD simulation arms. The number of created 
avatars provided the opportunity to create 1000 parallel arms for simulations. 
Then daily dose and INR for each avatar were predicted following a specific 
protocol for that arm for 90 days. The predicted doses, INR, INR-monitoring 
frequency, and population statistics for each clinical trial simulation and 
across all 1000 simulations were recorded to calculate and produce the mean, 
standard deviation, and probability value (unpaired t test) for TTR for each 
study arm and for the aggregated populations from the 1000 clinical trial 
simulations. The simulations produced predictions were then compared with 
the CoumaGen-I results. The simulations were implemented in R (R Core 
Team, 2013) and run on the affiliated institute’s high performance computing 
environment.  
5.2.3.) Results 
Developing a BNM and then generating clinical avatars were one of the first 
steps taken in this study. Table 5.1 demonstrates the characteristics of the 
clinical avatar populations generated for both PG and STD simulation arms 
versus the characteristics of the PG and STD arms’ populations in the original 
CoumaGen-I study.  
A few tests were done to show that the clinical avatar populations generated 
based on the BNM were statistically similar to the original CoumaGen-I 
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population. As depicted in Table 5.1, the distribution of the characteristics 
across the PG arms and STD arm are very comparable and statistical test 
shows no significant difference (P >0.05). The variable dependency 
embedded in the BNM of the populations were also tested to see if they also 
persisted in the simulated clinical avatar populations. To do so, a log-linear 
model was fitted to all relevant associations and probability values by using 
the Pearson χ2 statistic were calculated. The test indicated that there were no 
significant differences (P >0.05) between the dependencies in the clinical 
avatar populations and the original CoumaGen-I populations (Table 5.1). In 
addition, it was tested to make sure that the non-embedded dependencies in 
the BNM did not exist in the clinical avatar populations. 
Table 5.1. Characteristics of the subjects in the original CoumaGen-I study 
versus that of Clinical Avatars generated for both PG and STD arms. DVT: 
deep vein thrombosis; PG: pharmacogenetic arm, SD: standard deviation, 
STD: standard clinical arm (Fusaro, 2013). 
Characteristic 
CoumaGen-I Original Clinical Avatars 
PG Arm STD Arm PG Arm STD Arm 
n 101 99 101 99 
Age, y (mean) 63.2 58.9 62.5 58.3 
Male, % 49.5 56.6 51.3 55.1 
Weight, kg, mean±SD 92.1±24.6 94.7±24.2 89.8±24.3 91.9±24.3 
DVT, % 18.8 28.3 18.6 28.6 
White, % 94.1 94.9 94 95 
CYP2C9*2, % 
   CC 
   CT 
   TT 
 
82 
18 
0 
 
76.5 
23.5 
0 
 
82.2 
17.8 
0 
 
76.7 
23.3 
0 
CYP2C9*3, % 
   AA 
   AC 
   CC 
 
89 
10 
1 
 
87.6 
11.3 
1 
 
88.9 
10.2 
1 
 
87.9 
11.1 
1 
VKORC1 1173, % 
   G/G 
   G/A 
   A/A 
 
50.5 
35.4 
14.1 
 
34.7 
50 
15.3 
 
50.5 
35.6 
13.9 
 
34.6 
50.2 
15.2 
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The accuracy of the clinical trial simulator of our in silico PC-CER framework 
was validated by simulating the original CoumaGen-I clinical trial through 
conducting CoumaGen-I Simulation 1 (Figure 5.1 and 5.2A). 
The CoumaGen-I Simulation 1 reproduced the primary TTR outcome of the 
original CoumaGen-I trial (Table 5.2). It predicted a mean TTR of 70.5% and 
72.0% in the STD and PG arms, respectively. Similar to the original 
CoumaGen-I trial, the difference between the mean TTRs was not significant 
(P >0.05). The results of the CoumaGen-I Simulation 1 showed no statistical 
difference between predicted and actual TTRs for CYP2C9 extensive 
metabolizer, intermediate metabolizer, and poor metabolizer subsets (P 
>0.05). Although the original CoumaGen-I showed a significant 9.8% 
reduction in out-of-range INRs for the wild type and multiple variants subgroup 
in the PG arm, CoumaGen-I Simulation 1 indicated a nonsignificant 2.7% 
reduction in out-of-range INRs for the similar groups. 
Through the second simulation, CoumaGen-I Simulation 2, it was tested if a 
modification to PG and STD arms of the original CoumaGen-I dosing 
algorithms would result in a significant change in outcomes of the two arms. 
As depicted in Figure 5.2B, all model and simulation components of the 
CoumaGen-I Simulation 1 (i.e., clinical avatars, initial dosing, PK/PD 
parameters, and TTR outcome calculations) remained the same with the 
exception of the replacement of part of the original CoumaGen-I dosing 
protocol with the Wilson protocol (Wilson, 2007) for days 3 to 90. The 
simulation, CoumaGen-I Simulation 2, was run and the outcome metrics were 
calculated as in the Simulation 1 (Table 5.2).  
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Table 5.2. Percent Time INR in Therapeutic Range (TTR) for some 
subpopulations in 1000 simulated trials of CoumaGen-I Simulations 1 and 2. 
Subpopulation 
CoumaGen-I Simulation 1 CoumaGen-I Simulation 2 
PG Arm STD Arm PG Arm STD Arm 
All Avatars, %, mean±SD 72±26.6 70.5±26.8 78.8±11.9 73.7±13.6 
CYP2C9, %, mean±SD 
     Extensive Metabolizer 
     Intermediate Metabolizer 
     Poor Metabolizer 
 
76±23.6 
72.4±26 
65.6±29.9 
 
73.6±21.8 
72.4±26.2 
65.9±29.6 
 
85.6±10.2 
76.9±10.4 
71.7±11.2 
 
85.6±9.9 
75.4±10 
63.2±12.1 
 
The mean TTR for the PG arm was significantly higher than the STD arm in 
the CoumaGen-I Simulation 2 (78.8% versus 73.7%; P< 0.05, respectively), 
demonstrating that the Wilson protocol, which adjusts dose based on 
percentage change, predicted better management of the clinical avatars and 
was able to achieve a stable TTR for a longer period of time.  
The CoumaGen-I Simulation 2 PG protocol resulted in a higher mean TTR 
across all the genotype subsets than the corresponding CoumaGen-I 
Simulation 1 PG protocol (Table 5.2). For all patients, the difference between 
the STD arms in the CoumaGen-I Simulation 1 and 2 was 3.1%, indicating 
similar TTR results despite different protocols. Conversely, the difference in 
TTR for the PG arm was 6.8% higher, indicating that the Wilson protocol was 
more accurate at maintaining a therapeutic dose within the 90-day clinical trial 
time window. The CoumaGen-I Simulation 2 also exhibited a smaller TTR 
standard deviation for each genotype subset than the CoumaGen-I Simulation 
1, indicating that the INR range was better controlled by the use of the Wilson 
protocol. 
5.2.4.) Conclusion                                                            
This study showed that the clinical trial simulator was useful to study and 
197 
 
 
 
evaluate anticoagulation therapy options and “provide evidence to optimize 
the clinical trial for patient efficacy and reduced risk” (Fusaro, 2013). 
5.3.) CoumaGen-II Clinical Trial Simulation 
5.3.1.) Background and Objective 
In this study, the accuracy of the clinical trial simulator of our in silico PC-CER 
framework was re-examined again by reproducing the CoumaGen-II clinical 
trial outcomes (“CoumaGen-II Simulation 1”), and then the simulator was used 
to evaluate a new dosing protocol (“CoumaGen-II Simulation 2”), to determine 
whether this new study design was significantly more beneficial for the same 
population.  
5.3.2.) Methods 
5.3.2.1) Study Design 
- The original study. The original CoumaGen-II clinical trial (Anderson, 2012) 
comprised 2 prospective clinical trial comparisons: (1) a blinded, randomized 
comparison of 2 refined PG warfarin dosing algorithms and (2) a clinical 
effectiveness comparison of PG-guided therapy with use of either PG 
algorithm with a parallel, standard (STD) dosing (Figure 5.3). The primary end 
points of interest were Percent Time INR in Therapeutic Range (TTR) and 
also percentage of out-of-range (OOR) INRs during up to 90 day treatment 
period. In the original study, the inclusion criteria to recruit subjects were as 
follows: age ≥18 years, and an indication for initiation of warfarin 
anticoagulation. And the subjects with the following characteristics were 
excluded: women who were pregnant, lactating, or of child-bearing potential, 
those taking rifampin within 3 weeks, or patients with comorbidities precluding 
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standard dosing (e.g., creatinine >2.5, hepatic insufficiency, active 
malignancy, advanced physiological age, expected survival <6 months); 
noncompliance risk; and those deemed inappropriate for PG-guided dosing 
for any other reason. 
Based on power calculations, the minimum recruitment target for the 
randomized, PG-guided comparison was set at 500 patients. All qualifying 
parallel control patients were included, anticipated to number >=1000.  
Eventually, 504 qualified subjects were recruited and underwent blind 
randomization to two PG arms; PG-1 and PG-2. The subjects for the 
standard-dosing arm were retrospectively identified by a query to the EMRs of 
3 hospitals. Patients ≥18 years of age initiating warfarin therapy with a 
Figure 5.3. Study design for the original CoumaGen-II clinical trial. 
PG: Pharmacogenetic arm, STD: Standard arm. 
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baseline and at least 1 follow-up INR level between days 3 and 14 were 
selected. The query resulted in identification and extraction of EMR records of 
1911 subjects for the STD arm. Figure 5.3 illustrates the study design of the 
original clinical trial. 
- The simulation study. In this study, the two following simulations were 
designed and conducted: "CoumaGen-II Simulation 1" and "CoumaGen-II 
Simulation 2". For each of these, with the use of a BNM method described in 
section 5.2.1.1, a sufficient number of clinical avatars was created to conduct 
1000 simulations for each of the three arms; PG-1 (n=257000), PG-2 
(n=247000), and STD (n=1900000). For each of the 1000 simulations, 257 
avatars for the PG-1 arm, 247 avatars for the PG-2 arm and 1099 avatars for 
the STD arm were randomly recruited from their associated generated clinical 
avatar populations. Then, following the specific dosing protocol for each arm 
explained in the following sections, daily dose and INR for each avatar for that 
arm for 90 days were predicted. 
CoumaGen-II Simulation 1 followed the dosing protocol as specified in the 
original CoumaGen-II clinical trial (Anderson, 2012; Figure 5.4). For the STD 
arm, it was assumed that retrospectively selected subjects in the original 
CoumaGen-II trial received warfarin standard initial dose of 5mg/day for days 
1 and 2 and then the doses were adjusted using the same standard INR-
based dose-modification algorithm developed and promoted by Intermountain. 
The CoumaGen-II PG-1 and PG-2 arms used modified versions of the IWPC 
(2009) dosing algorithm which required both clinical and genotype (i.e., 
CYP2C9 and VKORC1) information to calculate doses for days 1 and 2. Like 
the original study, the initial doses were followed by (a) a dose adjustment 
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algorithm based on INR according to the Kovacs (2003) protocol for days 3 to 
7 for PG-1 arm and (b) a dose adjustment algorithm based on Lenzini (2010) 
PG-based dosing algorithm for days 3 through 7 for PG-2 arm. For days 8 to 
90 in both PG-1 and PG-2 arms, the Intermountain Healthcare warfarin dosing 
protocol were used. 
The design of the CoumaGen-II Simulation 2 was different from the original 
clinical trial. It was conducted using a third dosing protocol (nomogram) 
offered by Wilson (2007). In this study, the same initial doses for days 1 to 2 
and the same adjustment doses for days 3 through 7 were used as in the 
original CoumaGen-II trial. For days 3 to 90, the Wilson protocol was used to 
Figure 5.4. The study design of the CoumaGen-II Simulation 1. Black text 
represents new features compared to the original CoumaGen-II study, whereas 
gray text represents those features in common with the original study as 
depicted in Figure 5.3. PG: Pharmacogenetic arm, STD: Standard arm. 
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increase or decrease the dose proportionally based on low or high INR 
values, respectively. The following figure (Figure 5.5) illustrates the design of 
the CoumaGen-II Simulation 2. 
5.3.2.2) Clinical Avatar Populations 
Similar to CoumaGen-I clinical trial simulation study (Section 5.2), for the 
BNM used for creating clinical avatars in this study, the same considerations 
were made as the original CoumaGen-II’s individual patients’ information were 
not available. Taking into consideration the subjects’ characteristics required 
for the dosing algorithms used in this study, the prior probabilities used for the 
study’s BNM were based on the statistical characterization of the patient  
Figure 5.5. The study design of the CoumaGen-II Simulation 2. Black text 
represents new features compared to the original CoumaGen-II study, 
whereas gray text represents those features in common with the original study 
as depicted in Figure 5.3. PG: Pharmacogenetic arm, STD: Standard arm. 
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population including age, sex, weight, height, race, body surface area 
(calculated from height and weight), smoking status, deep vein thrombosis 
status, amiodarone use status, and genotypes for CYP2C9*2, CYP2C*3, and 
VKORC1. The CoumaGen-II trial data used age, sex, weight, height, deep 
vein thrombosis, smoking status, and genotypes as their variables.  
In the simulation study, some other required prior probabilities (e.g., 
amiodarone status and genotype distributions) for the BNM were estimated by 
using some sources such as data from the Centers for Disease Control and 
Prevention, the 2000 US Census or some evidence on genotype distributions 
used for STD arm clinical avatar populations (e.g., Scott, 2010). The other 
details which were taken into for development of BNM in CoumaGen-I 
simulation study were also applied to this study too. The BNM was 
implemented in TETRAD IV (Scheines, 1998) to produce the clinical avatar 
populations for the both Simulations 1 and 2. 
5.3.2.3.) Measuring Outcome Metrics 
The primary outcome metric was Percent Time INR in Therapeutic Range 
(“TTR”) and Percent Out-Of-Range INR (“%OOR”). Consistent with the 
original CoumaGen-|I study, TTR was defined as the percentage of time an 
individual avatar had an INR between 1.8 and 3.2 during the 90-day 
simulation. Although our simulator could calculate daily INR values, only INRs 
on those days in which the INR would have been checked in the clinic 
according to the specific protocol were considered. 
5.3.2.4.) Clinical Trial Simulations  
As stated in previous sections, in the original CoumaGen-II randomized 
controlled trial, the 504 recruited subjects were randomly assigned to two PG 
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arms; PG-1 (n=257) and PG-2 (n=247). In addition, in the original study, 1911 
subjects were retrospectively recruited from the EMRs for the STD arm. 
Accordingly, in the Simulation 1 and 2 studies, the three clinical avatar 
populations were randomly sampled to recruit 257, 247 and 1911 avatars for 
the PG-1, the PG-2 and the STD simulation arms. The number of created 
avatars provided the opportunity to create 1000 parallel arms for simulations. 
Then daily dose and INR for each avatar were predicted following a specific 
protocol for that arm for 90 days. The predicted doses, INR, INR-monitoring 
frequency, and population statistics for each clinical trial simulation and 
across all 1000 simulations were recorded to calculate and produce the mean, 
standard deviation, and probability value (unpaired t test) for TTR for each 
study arm and for the aggregated populations from the 1000 clinical trial 
simulations. The simulations produced predictions were then compared with 
the CoumaGen-II results. The simulations were implemented in R (R Core 
Team, 2013) and run on the University of Wisconsin-Milwaukee’s high 
performance computing environment.  
5.3.3.) Results 
Table 5.3 demonstrates the characteristics of the clinical avatar populations 
generated for PG and STD simulation arms along with the characteristics of 
the PG and STD arms’ populations in the original CoumaGen-II study.  
A few tests were done to show that the clinical avatar populations generated 
based on the BNM were statistically similar to the original CoumaGen-II 
population. As depicted in Table 5.3, the distribution of the characteristics 
across the PG arms and STD arm are very comparable and statistical test 
show no significant difference (P >0.05). The variable dependencies 
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embedded in the BNM of the populations were also tested to see if they also 
persisted in the simulated clinical avatar populations. To do so, a log-linear 
model was fitted to all relevant associations and probability values by using 
the Pearson χ2 statistic were calculated. The test indicated that there were no 
significant differences (P >0.05) between the dependencies in the clinical 
avatar populations and the original CoumaGen-II populations (Table 5.3). In 
addition, it was tested to make sure that the non-embedded dependencies in 
the BNM did not exist in the clinical avatar populations. 
Table 5.3. Characteristics of the subjects in the original CoumaGen-II study 
versus that of Clinical Avatars generated for PG and STD arms. DVT: deep 
vein thrombosis; PG: pharmacogenetic arm, SD: standard deviation, STD: 
standard clinical arm. 
Characteristic 
CoumaGen-II Original Clinical Avatars 
PG-1 Arm PG-2 Arm STD Arm PG-1 Arm PG-2 Arm STD Arm 
n 257 247 1911 257 247 1911 
Age, y (mean) 61.3 59.9 51.5 60.9 59.4 51.1 
Male, % 46.3 47.6 48.5 46.9 48.3 49.1 
Weight, kg, mean±SD 93.1±23.9 92.3±24.5 91.3±28 92.1±23.1 92.9±23.5 90.9±27.5 
DVT, % 29.6 29.6 33.7 28.9 29.2 33.9 
White, % 95.3 95.6 91.4 95.6 96.1 91.1 
CYP2C9*2, % 
   CC 
   CT 
   TT 
 
79 
17.9 
2.7 
 
77.6 
20.3 
1.2 
 
NA 
NA 
NA 
 
79.5 
17.7 
2.8 
 
77.2 
20.9 
1.9 
 
78.3 
19.1 
2.6 
CYP2C9*3, % 
   AA 
   AC 
   CC 
 
86.3 
13.3 
0.4 
 
86.1 
13.1 
0.8 
 
NA 
NA 
NA 
 
85.9 
13.7 
0.4 
 
86.6 
13.1 
0.3 
 
86.2 
13.2 
0.6 
VKORC1, % 
   G/G 
   G/A 
   A/A 
 
32 
49.6 
18.4 
 
38.1 
47.5 
14.3 
 
NA 
NA 
NA 
 
31.5 
50.3 
18.2 
 
38.8 
46.7 
14.5 
 
35 
48.6 
16.4 
 
The accuracy of the clinical trial simulator of our in silico PC-CER framework 
was validated again by simulating the original CoumaGen-II clinical trial 
through conducting CoumaGen-II Simulation 1 (Figure 5.3 and 5.4). Similar to 
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the results of the original CoumaGen-II, the CoumaGen-II Simulation 1 study 
showed that the PG-2 dosing algorithm was noninferior compared with the 
PG-1 dosing algorithm at 1 and 3 months (P >0.05, Table 5.4). It also verified 
the same for %OOR INR at 1 and 3 months (P >0.05). 
Through the second simulation, CoumaGen-II Simulation 2, it was tested if a 
modification to PG and STD arms of the original CoumaGen-II dosing 
algorithms would result in a significant change in outcomes of the three arms. 
As depicted in Figure 5.5, all model and simulation components of the 
CoumaGen-II Simulation 1 (i.e., clinical avatars, initial dosing, PK/PD 
parameters, and TTR outcome calculations) remained the same with the 
exception of the replacement of part of the original CoumaGen-II dosing 
protocol with the Wilson protocol (Wilson, 2007) for days 8 to 90. The 
simulation, CoumaGen-II Simulation 2, was run and the outcome metrics were 
calculated as in the Simulation 1 (Table 5.4).  
Table 5.4. Time INR in Therapeutic Range (%TTR) and Out-Of-Range INR 
(%OOR) across the 1000 trials of CoumaGen-II Simulations 1 and 2. 
Outcome Metric 
CoumaGen-II Simulation 1 CoumaGen-II Simulation 2 
PG-1 
Arm 
PG-2 
Arm 
STD 
Arm 
PG-1 
Arm 
PG-2 
Arm 
STD 
Arm 
TTR, %, mean±SD 
1 month 
64.6± 
19.8 
62.9± 
17.6 
41.5± 
13.5 
68.2± 
10.9 
67.4± 
11.2 
55.1± 
13.4 
TTR, %, mean±SD 
3 months 
66.1± 
18.5 
64.5± 
19 
42.3± 
13.8 
70.4± 
9.3 
69.4± 
10.1 
56.5± 
11.8 
OOR, %, mean±SD 
1 month  
35.4± 
11.5 
37.1± 
11.4 
58.5± 
12.2 
31.8± 
8.6 
32.6± 
9.1 
44.9± 
7.8 
OOR, %, mean±SD 
3 months 
33.9± 
10.3 
35.5± 
10.7 
57.7± 
11.1 
29.6± 
6.4 
30.6± 
7.9 
55.1± 
7.8 
 
The 1-month and 3-month mean TTRs for the PG-1 and PG-2 arms were 
significantly higher than the STD arm in the CoumaGen-I Simulation 2 (70.4% 
and 69.4% versus 73.7%; P< 0.05, respectively), demonstrating that the 
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Wilson protocol, which adjusts dose based on percentage change, predicted 
better management of the clinical avatars and was able to achieve a stable 
TTR for a longer period of time.  
The CoumaGen-II Simulation 2 PG protocols resulted in a higher mean TTR 
across all the genotype subsets than the corresponding CoumaGen-II 
Simulation 1 PG protocol. The CoumaGen-II Simulation 2 also exhibited a 
smaller TTR standard deviation across all three arms than the CoumaGen-II 
Simulation 1, indicating that the INR range was better controlled by the use of 
the Wilson protocol. 
5.3.4.) Conclusion  
We have developed a pharmacogenetic clinical trial simulation framework for 
warfarin dosing and validated the framework against the CoumaGen-II clinical 
trial. We also demonstrated the utility of our framework by simulating the 
same clinical trials with the use of a relatively more aggressive dosing 
protocol and predict that the PG arms are likely to perform significantly better 
than the STD arm. The framework provides an opportunity to assess 
alternative strategies such as different dosing protocols, study population, or 
outcome metrics before applying them in real world. 
5.4.) Aurora Health Care Anticoagulation Therapy 
Simulation 
5.4.1.) Background and Objective 
The complexity of anticoagulation therapy and various existing treatment 
options especially the new PG-based dosing protocols create a serious barrier 
to hospitals of identifying and adopting an "optimal" anticoagulation treatment 
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plan for their heterogeneous patient population. To address this challenge, we 
designed a study to take advantage of our pharmacogenetic PC-CER in silico 
framework to simulate a number of anticoagulation therapy scenarios for the 
state-wide AHC patient population. Our approach included extraction of 
representative warfarin patient data from WiAD, collect and codify AHC's 
warfarin dosing protocols, run clinical simulations to compare the predicted 
outcomes of different dosing protocols including the AHC's, and then identify 
the overall best population-wide treatment plan for different subpopulations. 
- AHC warfarin Dosing Protocols 
AHC has an institution-wide standardized warfarin best practice treatment 
protocol that has been in effect for the last decade in different treatment 
facilities of the institute. The AHC protocol called “Aurora Anticoagulation 
Clinic Guideline for Ambulatory Warfarin Management” (AACG–AWM) has 
some special characteristics compared to the other dosing protocols used in 
our previous simulation studies. In the following, some details about the 
protocol are offered.   
AACG-AWM has two dosing protocols where each has three main 
components: initial dose (days 1 and 2), 1st INR in range, and INR-based 
Dose Adjustment. According to the protocol, a fixed dose of warfarin is 
prescribed for days 1 and 2 following the instructions in table 5.5. 
Table 5.5. AHC warfarin dosing protocol - AACG-AWM.  
Initial dosing for days 1 and 2. 
Patients sufficiently healthy to be treated as outpatients = 10mg/day 
Patients 65+ years of age ≤ 5mg/day 
Patients at any age and with multisystem disease, known liver 
disease, taking drugs that are likely to increase warfarin effect, 
have had prior at-goal treatment response with low doses or 
have baseline INR readings above 1.1 
≤ 5mg/day 
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Two days post warfarin initiation, INRs are monitored daily or every other day 
until the INR >= 2.0 or as indicated by referring physician. When this is 
achieved INR testing follows the chronology below (Table 5.6). 
Table 5.6. AHC warfarin dosing protocol - AACG-AWM. 1st INR in range. 
Number of days the INR and warfarin 
dose remain stable and therapeutic 
Days until the proceeding INR test 
2 3-5 
7 7 
14-21 14 
28-35 28 
42 42 
56 56 
84 
84 (absolute max number of days 
between tests) 
 
Based on this protocol, any adjustment of dosage is based on INR records in 
last few days prior to dose adjustment. This aspect makes the AACG-AWM 
different from other doing protocols such as CoumaGen-I and -II (Anderson 
2010a, 2012b) as they take into consideration only the INR value that was 
recorded just prior to dose adjustment. Figure 5.6 provides details on the third 
component of the AACG-AWM protocol which instructions on INR-based dose 
adjustment.  
The AACG-AWM protocol has some other components such as the following 
which were not taken into consideration in the process of codifying the 
protocol as they either were not providing objective measures or the WiAD 
dataset did not provide relevant information on them.  
- Drug Interaction Considerations with Warfarin 
- Herbal/Natural Medicine Interaction Considerations with Warfarin 
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- Other Factors That May Affect INR. 
5.4.2.) Methods 
In this study, our primary hypotheses were as follows:   
(1) Any warfarin dosing algorithm that provides some measure of 
personalization will demonstrate improved predicted clinical outcomes (as 
defined by TTRs and %OOR INRs within 90 day period) compared with 
current AHC ‘best-practice’ dosing algorithm across the entire AHC 
population. We defined personalization as any demographic, clinical or 
genetic variable applied across a medication dosing protocol.  
(2) Predicted clinical outcomes (as defined by TTRs %OOR INR’s within 90 
day period) will improve proportionally to the degree dose personalization 
across the entire AHC population. 
5.4.2.1.) Study Design 
To test these hypotheses, we designed a five-arm simulation study (Figure 
5.7) in which the study arms (AHC, Clinical, PG-1, PG-2, and PG-3 arms) 
Figure 5.6. AHC warfarin dosing protocol - AACG-AWM. INR-
based dose adjustment. Adjusting dosage for patients with INR 
goal of 2.5 (range 2.0 – 3.0). 
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have different levels of personalization depending on required subjects’ 
characteristics for warfarin dose adjustments. As depicted in Figure 5.7, each 
arm’s dosing protocol composed of three components. These components are 
fixed, clinical-based or PG-based. In the first arm (AHC arm), the initial dosing 
was solely based on the age and health condition of the subjects whereas in 
the other arms it was based on either clinical characteristics (i.e., Clinical arm) 
or clinical characteristics along with genotypic profile of the subjects (i.e., PG-
1, PG-2 and PG-3 arms). In the first three arms, the dose adjustment 
algorithm used was the AHC one. For the arms PG-2 and PG-3, the dose 
adjustment algorithm was a PG-based one used in EU_PACT clinical trial 
(Pirmohamed, 2013). Although the maintenance dosing algorithms (days 6 or 
8 through 90) for all of the five arms were non PG-based, the AHC 
maintenance dosing algorithm was used for the first 4 arms and the last arm’s 
maintenance dosing was based on the Intermountain dosing algorithm 
(Anderson, 2012).  
Figure 5.7. Study design for the five simulation trial arms. 
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- Study Population 
Using WiAD-Miner, we identified and extracted the EMR records of all the 
subjects who were under warfarin at AHC and had complete demographic 
and clinical records. This query resulted in 14,206 subjects.  
- Study Power Analysis: 
Taking advantage of our in silico framework, we had the opportunity to test 
our hypotheses against a wide variety of subpopulation such as minority 
subpopulations which had not participated in significant numbers in recent or 
past warfarin clinical trials (e.g., African American). With these subpopulations 
identified, we calculated the statistical characteristics of each subpopulation. 
Accordingly, we found out that the smallest subpopulation of interest was 
African-American male (i.e., 1.9% of whole extracted WiAD warfarin 
population). A power analysis was conducted to calculate the sufficient 
number of avatars to reject our null hypothesis for this subpopulation (African-
American males). Our power analysis showed that we needed to have at least 
250 African American male avatars within each arm (Significance level 0.05 
two-sided, SD 0.2, Power 0.9, INR Improvement [Difference in means] 0.06). 
Consequently, the calculation resulted in a minimum number of 13,015 
avatars for each arm. 
5.4.2.2) Clinical Avatar Populations 
For the purpose of this study, we applied the clinical avatar modeling method 
described in section 3.1.1 to the WiAD warfarin population data to generate 
clinical avatars. As mentioned in chapter 3, our BNM pipeline consists of four 
broad sections: (1) Data preprocessing, and Knowledge aggregation; (2) 
Develop Directed Acyclic Graphs (DAGs) via Ensemble Learning; (3) 
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Estimating conditional probabilities via ensemble learning; (4) Validation of the 
BNM and imposition of variables. In the following section, the application of 
our methodology to the WiAD warfarin population is described in detail. 
Following our clinical avatar model described in chapter 3, clinical avatar 
modeling and generation were done for AHC warfarin patient population (i.e., 
WiAD warfarin cohort). As mentioned in chapter 3, our BNM pipeline consists 
of four broad sections: (1) data and knowledge aggregation and 
preprocessing; (2) semi-supervised Bayesian pattern search to develop a 
Directed Acyclic Graph (DAG); (3) applying the DAG to estimate joint 
conditional probabilities and deriving an instantiated model; (4) the BNM must 
be validated against a subset of data not used in developing the BNM. In the 
following section, our methodology for the WiAD warfarin cohort is described 
in detail. 
Section 1: Data preprocessing, and Knowledge aggregation 
This section has two branches performed in parallel. In Part I we accumulated 
domain knowledge (i.e., expert knowledge or literature-defined knowledge) to 
better understand both the specifics of our data such as the way the data was 
gathered, the semantics of the data dictionary and any measurement error as 
well as the general relationship between the variables as found in literature 
review. In Part II the patient data from WiAD was characterized and prepared 
(i.e., data preprocessing). The data preparation is a multistep process as 
described in Figure 5.8.  Once the data has gone through the data 
preprocessing procedure it is aggregated into a data wrapper.   
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Part I: 
We undertook a complete literature review searching Google scholar and 
PubMed using key words such as “Race and Smoking” and “BMI and Age”, 
similar to those variables found in the Aurora Data. We filtered for articles that 
provide explicit results on populations determined to be similar to the AHC 
patient population. We then filtered for results that linked the same specific 
variables as those found in the WiAD data through an asymmetric conditional 
probabilistic relationship. In Figure 5.9A and 5.9B we demonstrate the results 
of the literature review and then how these relationships are implemented in 
the TETRAD program (Scheines, 1998). Figure 5.9A shows a total of 7 
asymmetric conditional probabilistic relationships discovered through literature 
review. An asymmetric conditional probabilistic relationship is not strictly 
causality nor do we require this strong assumption to be true in the 
development of clinical avatars. Each of the required edges, shown in the 
green directed arrows are each related to evidence cultivated through the 
literature review that were determined to relate direct to the patients in the 
WiAD database (Fiore, 1989; Kuskowska; 1992; Marot, 2011). 
Figure 5.8. Step-by-Step procedure for Section 1 
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In Figure 5.9B we see the description of knowledge tiers within TETRAD. The 
tiers allow use to inform the algorithm that certain relationships are both 
forbidden and/or asymmetric. As implemented for the AHC data, we suggest 
that IF a conditional dependency is discovered between “HEIGHT” and 
“RACE”, Then the relationship must be such that “RACE” given its position in “Tier 
1” is the causal parent of “HEIGHT” given its position in “Tier 2”.  Similarly any 
potential relationship between a higher tier variable must be directed towards a lower 
tier variable and never in the reverse direction.  
Part II: 
Data Discretization and Aggregation: 
Often healthcare data includes a mix of categorical and discrete data, such as 
race and gender, and continuous data such as age and height. The Bayesian 
search algorithms we employ require training data that is either entirely 
continuous and normally distributed or entirely discrete. The WiAD data 
Figure 5.9B. Domain Knowledge 
expressed as causal tiers of hierarchy 
Figure 5.9A. Domain Knowledge 
expressed as required causal 
relationships in green arrows 
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included a combination of both continuous and discrete variables, therefore 
the continuous variables were discretized. The process of discretizing 
continuous data is a ubiquitous data preprocessing technique that must 
balance information loss inherent in the process with the benefits of greater 
processing efficiency. There are numerous discretization methods and the 
choice can impact both the posterior probability estimation as well as the 
discovery of inherent causal structure in the underlying graph. We employed a 
common unsupervised method, EqualWidth that has demonstrated its ability 
to produce accurate data mining results for Bayesian search algorithms when 
compared to other techniques (García-Laencina, 2013).  
Once the data has been fully preprocessed it is loaded into TETRAD the 
program we use to implement the BNM search and relationship discovery.  
The final step before completing the Bayesian search, is to load the 
processed data as a data wrapper. A data wrapper converts the data from a 
flat structural file to a relational file that describes the data as tuples. Data 
wrappers are standard in data mining practices because it allows for 
maximum dimensionality to be passed through the search algorithm. 
Section 2: Directed Acyclic Graphs via Ensemble Learning 
Bayesian search algorithms are based on a number of assumptions that often 
times breakdown when applied to real data. We address the weakness of the 
Bayesian search algorithms, along with certain bias and variance problems 
within the aurora data by eliciting established methods for using ensemble 
learning such as described in Part III section 2. The step-by-step logic of 
section 2 is described in Figure 5.10. We apply an ensemble learning 
technique called, bootstrap aggregation (Bagging) to address the instability of 
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Bayesian classifier searches. From one set of training data, the data is 
resampled at random.  
The choice of bootstrap sampling technique (e.g., Parametric vs. classic 
bootstrap) can ultimately impact the quality of the model. We implemented a 
classic (Unweighted) bootstrap because imputation and missing values were 
non-existent, and there was limited bias within the selected EMR dataset. The 
classic bootstrap is completed from the original data wrapper after it has been 
loaded into TETRAD.  In Figure 5.11, the data is labeled as 
“WiAD_Warfarin_Cohort  Data” before entering the pipeline. This data 
wrapper is then aggregated into five distinct bootstraps and subdivided into 
80% and 20% subsets with 80% used as the training data. The bootstraps are 
labeled as “Training_DATA1… Training_DATA5” in Figure 5.11. The 
bootstraps were resampled to the same size n=14,206 as the original dataset. 
The 80% training data, n=11,365, was used as input into 5 Bayesian 
searches, labeled “Search1…Search5”. Knowledge that was previously 
loaded during the preprocessing phase is also applied evenly across the 
search algorithms to constrain the search space.  
Figure 5.10. Developing a DAG from Training Data 
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Additionally, in experimentation with EMR data we employ a “repeated leave 
one out bootstrap aggregation” method (Clyde, 2004; Jiang, 2007). Holding 
out data for cross validation is considered a data mining ‘best practice’ 
(Belazzi, 2004). However, when the sample size is small and outliers are 
important considerations in the data, holding out any amount of data reduces 
variance in the model. Therefore, it is recommended to perform the bootstrap 
sampling of the original data prior to the dividing the data between training 
and validation subsets.  
Each resampled training data subset was used as input with the previously 
described domain knowledge to a Bayesian search algorithm. The results of 
each search are aggregated and the results are pruned to yield a resultant 
DAG. We employed the Bayesian search algorithm called the Conservative 
PC algorithm (CPC) found within the TETRAD publicly available software. The 
CPC algorithm is a variant of the PC algorithm that has an additional step that 
provides additional autonomous arrow directionality. The PC and CPC 
Figure 5.11. Bootstrapping and performing 
searches constrain by knowledge in TETRAD 
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algorithm perform conditional independence tests between each variable 
except those required or forbidden within the knowledge box.  The conditional 
independence tests are then applied across the data wrapper to discover 
potential causative relationships. Additional details, the pseudo code and 
inherent assumptions of the PC and CPC algorithm can be found in (Sprites, 
2000) and within TETRAD. All searches were completed with an α=0.05.   
We generally recommend using multiple Bayes search algorithms for each 
bootstrap of data to address the inherent instability in the search results.  
However, in application to the WiAD dataset, we determined that the CPC 
algorithm sufficient for the following reasons: There was limited number of 
dimensions (i.e. variables) in the data in proportion to the sample size. Also, 
because all missing values were deleted from the training dataset, a major 
source of algorithm instability was addressed in preprocessing. Lastly, CPC 
was determined to best fit the data, and there was limited variation between 
bootstrapped search results.   
After the 5 CPC pattern searches were performed on the data, the DAGs 
were converted into matrix with the originating state comprising the columns 
and the destination states the rows. Each directed arrows, or edges of the 
DAGs were cataloged in a matrix for comparison. Edges are selected based 
on those that received 50% or more commonality and/or are supported by 
evidence discovered prior to performing the search. The results of the Five 
CPC searches are shown in Figure 5.12. The weight of the arrow corresponds 
to the number of times the search output confirmed an existing edge. The two 
arrows that are dashed from Gender  Tobacco and Race  Weight had 
fewer than 50% search results and therefor were not included in the 
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aggregated DAG. The resultant DAG shown in Figure 5.12 is then used in 
parallel for section three, labeled “AHC_DAG” in Figure 5.14. 
Section 3: Estimating Conditional Probabilities via Ensemble learning 
The step-by-step logic of section 3 is described in Figure 5.13. The dashed 
arrow indicates a final recursive step described at the end of this section. The 
first step in section 3 is to again bootstrap the original data set the same 
number of times as performed in section 2. The bootstraps were resampled to 
the same size n=14,206 as the original dataset. Because the justification for 
selecting a bootstrap procedure is the same in this section as for section 2, 
Figure 5.12. Results from 5 CPC searches.  
Figure 5.13. Developing a DAG from Training Data 
Bootstrap Data: 
Divide Each Bootstrap 
into Training and 
Validation Subsets 
Use DAG(s) to Derive 
Parametric Model (PM) 
for Each Bootstrapped 
Dataset 
Pool Validation Subsets 
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for Modeling 
S
e
c
tio
n
 3
 
Use Ensemble Bayes 
Estimator Algorithms on 
Each Bootstrap  
Generate Equal Amount 
Data (Preliminary 
Avatars) from Each 
Bootstrapped Model 
Pool Preliminary Avatars
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we performed 5 classic bootstraps with replacement holding out 20% of each 
bootstrap for validation in section 4, (identical bootstrap to section 2). The 
bootstraps were performed in TETRAD as seen in Figure 5.14 represented by 
(“Training_Data6… Training_Data10). The DAG derived from section 2, 
“AHC_DAG” was used to develop a parametric model (PM) for each of the 
bootstraps.   
The parameters, or conditional probabilities of the Bayes net were estimated 
for each bootstrap using the ML Bayes estimator for each bootstrap as shown 
in Figure 5.14 noted by the “Estimator1… Estimator5”). At this stage the 
algorithm produced a partial failure. An example of this problem is highlighted 
in Figure 5.15 for particular parameters of “WEIGHT” within the BNM. The 
partial failure of the estimator algorithm is highlighted by the red rectangles 
within the partial estimated Bayes net. In the resultant DAG from section 2, 
“WEIGHT” is a descendent of three Variables, “HIEGHT”, “AGE” and 
“GENDER”. The partial failure is associated with the problem of insufficient 
statistics to provide estimates within those particular parameters highlighted in 
red. In this case, the training data did not provide the estimation algorithm with 
Figure 5.14.  Parameter learning in TETRAD 
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any cases from these particular parameters (e.g, there existed no patients 
with the characteristics “Gender=Female, Age=0, Hieght=0” within the 
bootstrap of the training data).   
To address this situation, and satisfy the parameter learning for this BNM, we 
simplified the model by removing edges related to “WEIGHT” according to the 
four-step logic pattern found in the general description of the method. In this 
case, there were three edges related to “WEIGHT”. Since all three edges 
were retuned every search result performed in section 2, we began by 
increasing α from a value of α=0.05, to a more stringent value of α=0.00001. 
We then used the domain knowledge aggregated in section 2 to delete further 
edges stepwise until sufficient cases existed within training data to calculate 
conditional probabilities. In doing so we increase the number of cases in the 
training data to calculate the conditional probability for all relevant states from 
the parent nodes. The resultant DAG, named “SIMPLIFIED_AHC_DAG” was 
used to derive PM and estimate the conditional probabilities of the simplified 
Bayes Net shown in Figure 5.16.  Figure 5.17 highlights our example of the 
Figure 5.15. Partial failure of Estimator Algorithm for the variable “WEIGHT” 
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variable “WEIGHT”.  We see that the edges “AGE” and “GENDER” were 
removed while the edge between “HEIGHT  WEIGHT” remained.  The 
conditional probability for each discretized category of weight was then 
estimated strictly based on the discretized categories of height. 
The conditional probabilities derived from the simplified model were then used 
as input for the original parametric model. For example, within the more 
complicated Bayes net we experienced a partial failure when the training data 
did not have any counts for patients that have “Gender=Female, Age=0, 
Height=0”. The Estimated conditional probability for this parameter was 
derived from the simplified Bayes net – using weight estimations strictly from 
its probabilistic relationship to Height. This procedure was repeated for 
“Tobacco” and “Height” until all parameters within the original Bayes net were 
satisfied with conditional probabilities for each bootstrap of data.  
Once the parameters of each Bayes net were satisfied within an instantiated 
model (labeled IM within Figure 5.16), 100,000 preliminary avatars were 
generated from each trained model. The preliminary avatars were then pooled 
in equal proportion into a set of “POOLED_PRELIM_AVATARS”.  We elected 
Figure 5.16. Parameter learning with insufficient statistics  
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to use an equal weighting scheme because, similar to the reasons for 
performing a classic bootstrap, the bias was considered minimal. The pooled 
preliminary avatars were then passed through a final round of estimation. The 
resultant “AHC_DAG” developed in section 2 was then used to derive the PM 
that was used as input to the estimator.  Because of outliers within the data 
this second round of estimation again faced the problem of insufficient 
statistics that resulted in partial failure of the estimator algorithm. This, despite 
the large sample size of pooled preliminary avatars passed through the 
Estimator algorithm. We addressed the problem in an identical manner to the 
first round of parameter learning.  We used a simplified DAG to reduce the 
conditional parents and substituting the conditional probabilities for the 
simplified state for those states within the parametric model that suffered from 
the partial failure. We used the same simplified DAG previously developed 
and shown in Figure 5.17.   
 
Figure 5.17. Simplified DAG and subsequent parameter learning  
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The parameters were then aggregated in the “TRAINED_AHC_BNM” shown  
in Figure 5.18.  This BNM was then used to develop 100,000 clinical avatars 
via Monte Carlo simulation techniques that were used as input to section 4 for 
validation purposes.  
 
Section 4: Validation of the BNM and Imposition of Variables 
The first step of this section involves validating the model with some set 
validation data shown in Figure 5.19. We performed a “repeated hold-out 
classic bootstrap” in both section 2 and section 3. A total of 5 classic (i.e., with 
replacement) unweighted bootstraps were performed in section 3. The 
bootstraps were resampled to the same size n=14,206 as the original dataset.  
Each described previously, each bootstrap was randomly divided in 80% and 
20% subsets. Therefore a total of 5 validation data sets each with the same 
size, n=2,841 were aggregated into a data wrapper labeled 
“POOLED_VALIDATION_DATA” in Figure 5.21. This set of validation data 
Figure 5.18. Final round of parameter learning 
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was then used to compare the 100,000 clinical avatars for validation 
purposes. 
There are two types of comparisons used to ensure that the simulated 
population is representative of the original data. The first is univariate  
 
distribution, or the comparative frequency of a single attribute between the 
training data and clinical avatars. The second comparison is the bivariate 
frequency distribution between the training and clinical avatar data sets.  
Variables in which the Bayesian algorithm determined a causal connection 
and are “d-connected” are plotted in frequency histograms. We found no 
significant variance in either the univariate or bivariate distribution, the 
process is refined until there is no significant difference. The comparative table 
is provided in the results section. 
The final step in the development of clinical avatars involves imposing any 
additional characteristics on the BNM validated against the pooled validated 
data. In Figure 5.20, we demonstrate how two genotypes, CYP2C9 and 
VKORC1 are imposed on the BNM derived from the WiAD database.  
 
Figure 5.19. Validating the BNM and generating Clinical Avatars 
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The probabilistic dependent relationship between “RACE  CYP2C9” and 
“RACE  VKORC1” are demonstrated in (Scott, 2010). Additionally, the 
parameters that describe the conditional probability parameters are described 
in (Scott, 2010). The validated structure and parameters that include all 
clinical avatar parameters including genotype are demonstrated in the 
Instantiated BNM titled “AHC_BNM_GENOTYPE” in Figure 5.21. This model 
was then used to generate 1,500,000 clinical avatars via Monte Carlo 
simulation techniques that were entered into the simulation platform.   
 
5.4.2.3.) Measuring Outcome Metrics 
In this study, we calculate a number of outcome metrics. A primary outcome 
metric is Time in Therapeutic Range (TTR) for patient INR. There are two 
methods for calculating TTR, such as INR check points and linear 
Figure 5.20. Final AHC DAG following Genotype Simulation. 
Figure 5.21. Section 4 as implemented in TETRAD 
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interpolation (Rosendaal, 1993). Additional outcome metrics include the 
following: 1&2.) Percent time INR higher than therapeutic range using both 
INR check points and linear interpolation methods, 3&4.) Percent time INR 
lower than therapeutic range using both INR check points and linear 
interpolation methods, 5.) Number of INR predictions, 6.) First day INR higher 
than therapeutic range, 7.) Percent INR in therapeutic range by day 5, 8.) 
Percent INR in therapeutic range by day 9, 10.) number of dose adjustment, 
11.) relative risk of ischemic stroke, and lastly 12.) relative risk of intracranial 
hemorrhage. 
5.4.2.4.) Clinical Trial Simulations  
For each study arm, a 90 day simulation was performed for each Clinical 
Avatar using each of the five PG and non-PG protocols. All results were 
stored in a structured format representing the 100 x 90 day study simulations 
for each clinical avatar in the study subpopulations. Simulation records 
included: clinical avatar record, simulated INRs and dose values (1 per day for 
each of 90 days) and calculated outcome metrics. All simulations were 
implemented in R (R Core Team, 2014) and performed on the UWM’s high 
performance computing research cluster Avi (UWM, 2014). 
5.4.3.) Results 
In the following table we present the statistical characteristics of the clinical 
avatars and the WiAD warfarin study population. The statistical analysis 
indicates no significant difference between these two populations by the 
characteristics. 
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Table 5.7. Characteristics of the WiAD warfarin study population versus WiAD 
warfarin clinical avatar population. SD: standard deviation. 
Characteristic 
WiAD Warfarin 
Population 
WiAD Warfarin  
Clinical Avatar 
Population 
Age, y, mean±SD 67.3 ± 14.43 67.2±14.47 
Weight, lb, mean±SD 199.24 ± 54.71 199.24±54.6 
Height, in, mean±SD 66.78 ± 4.31 66.53±4.32 
Gender, % 
   Female 
   Male 
 
53.14 
46.86 
 
53.10 
46.90 
Race, % 
 White 
 Black or African-American 
 Asian 
 Am. Indian/Alaskan 
 Pacific Islander 
 
95.17 
4.222 
0.3378 
0.1759 
0.0007 
 
95.19 
4.202 
0.4010 
0.1890 
0.0001 
Tobacco, % 
   No 
   Yes 
 
90.33 
9.66 
 
90.67 
9.33 
Amiodarone, % 
   No 
   Yes 
 
88.45 
11.54 
 
88.49 
11.51 
Fluvastatin, % 
   No 
   Yes 
 
99.97 
0.03 
 
99.98 
0.02 
CYP2C9*2, % 
   *1/*1 
   *1/*2 
   *1/*3 
   *2/*3 
   *2/*2 
   *3/*3 
 
NA 
NA 
NA 
NA 
NA 
NA 
 
67.39 
14.86 
9.25 
1.97 
6.51 
0 
VKORC1, % 
   G/G 
   G/A 
   A/A 
 
NA 
NA 
NA 
 
38.36 
44.18 
17.45 
 
The following figure demonstrates the mean predicted TTR of the 100 
simulations for each arm. The comparison of the results of linear interpolated 
TTR across the whole clinical avatar population for all 5 arms is shown in 
Figure 5.22. The PG-1 arm produced the highest mean predicted TTR, at 
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77.43%. The Clinical arm and PG-3 arm produced similar but significantly 
different (p<0.05) mean predicted TTRs at 69.76% and 67.4%, respectively. 
PG-2 and AHC arms produced significantly inferior mean predicted TTRs 
(P<0.05) at 62.99% and 57.16% respectively.   
Gender differences are consistent between all five arms. That is, males 
perform similarly in AHC, Clinical, PG-1, PG-2 and PG-3 when compared to 
females in those same arms. Interestingly, when the genders are also 
segregated by race as shown in Figure 5.23, gender difference remains 
consistent between white and African-American subpopulations. All five arms 
demonstrate significant difference between African-American males versus 
white males and African-American females versus white females (P<0.05). 
For all four subpopulations, PG-1 demonstrated superior predicted percent 
TTR. AHC arm demonstrates the largest difference between race and gender 
groups while PG-3 demonstrates the smallest difference between African-
Figure 5.22. TTR (Rosendaal) across the whole clinical avatar 
population for the 5 simulation arms. 
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American and white racial groups. African-American males and African-
American females demonstrate no significant difference between PG-3 and 
AHC dosing arms. 
 
Results for clinical avatars when segregated by CYP2C9 genotype are shown 
in Figure 5.24. Poor and intermediate metabolizers demonstrate significantly 
lower TTR when compared with the wild type *1/*1 CYP2C9 extensive 
metabolizer. All three PG-based subpopulations produced superior mean 
TTR’s within the PG-1 arm. Similarly, all three produced inferior mean 
predicted TTR’s in the AHC arm. For extensive metabolizers, which are a 
majority of the AHC population, the clinical arm produced the second highest 
mean predicted TTR, followed by the PG-3 arm and the PG-2 arm. For 
intermediate and poor metabolizers, the PG-3 arm produced the second 
highest predicted mean TTR’s and the clinical and PG-2 arm produced similar 
TTR results. 
Figure 5.23. TTR (Rosendaal) across the whole clinical avatar population for the 5 
simulation arms by gender and race. 
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In the final figure (Figure 5.25) we look the percent of time above therapeutic 
range and the percent of time below therapeutic range as calculated by linear 
interpolation. The results are shown for the whole population as well as two 
subpopulations white race and African-American subpopulations. The AHC 
arm produced the highest predicted time above therapeutic range for the 
whole population and white and African-American subpopulations. While PG-
3 arm produced the lowest time above therapeutic range for the whole 
population and white clinical avatars. While the arms PG-1 and PG-3 
produced similar time above therapeutic range specifically for the African-
American subpopulation.   
In contrast, the PG-2 and PG-3 produced the highest mean time, greater than 
20%, with subtherapeutic INR for the whole population and the white and 
African-American subpopulations. The AHC arm and the PG-1 arm produced 
similar predicted times subtherapeutic range for the white population and for 
the white population, but African-American demonstrated greater time below 
Figure 5.24. TTR (Rosendaal) across the whole clinical avatar 
population for the 5 simulation arms by CYP2C9 genotype. 
Extensive Metabolizer: *1/*1, Intermediate Metabolizer: *1/*2, 
*1/*3, *2/*3, Poor Metabolizer: *2/*2, *3/*3.   
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 therapeutic range in the PG-1 arm when compared to the AHC arm. The 
clinical arm produced results that demonstrate slightly greater predicted time 
below therapeutic range when compared to the PG-1 arm. Therefore, white 
subpopulations demonstrate the least time subtherapeutic range in AHC and 
PG-1 arms while African-American subpopulation demonstrates the least time 
in subtherapeutic range specifically in the AHC arm. 
5.4.4.) Conclusion 
We have simulated a total of five clinical trial arms, replicating each arm 100 
times. We simulated 1.5 million clinical avatars for each arm bringing the total 
simulated population to 7.5 million. We found that the PG-1 arm produced 
superior predicted clinical outcomes across the whole AHC population and all 
relevant subpopulations within the study population. When comparing the top 
performing arm (i.e., PG-1) to the current Aurora Health Care best practice 
warfarin dose protocol (i.e., AHC arm), we demonstrate superior TTRs for the 
whole population and all subpopulations. Therefore, we confirm our primary 
Figure 5.25. (a) Percent Time INR higher than therapeutic range across the 
five simulation arms by race. (b) Percent Time INR lower than therapeutic 
range across the five simulation arms by race. 
a b 
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hypothesis that there exists several warfarin dosing algorithms that provide a 
measure of personalization, in this case PG-based and clinically-based, that 
improved clinical outcomes across the entire AHC population.  
The superiority of the PG-1 arm was mirrored in the secondary outcome 
metrics of predicted time above therapeutic range and predicted time below 
therapeutic range. The PG-1 arm produced lower predicted time above 
therapeutic range when compared to the AHC arm for all populations and 
subpopulations, reducing the risk of intracranial hemorrhage and other forms 
of bleeding. The PG-1 arm produced similar predicted time below therapeutic 
range for the white subpopulation, however, the African-American 
subpopulation did experience significantly greater percentage time below 
therapeutic range, thereby diminishing its pharmacological effectiveness.  
We performed a total of four clinical trial arms that included some degree of 
warfarin dose personalization (Clinical, PG1, PG-2 and PG-3). We defined 
personalization as any demographic, clinical or genetic variable applied 
across a medication dosing protocol. The PG-2 and PG-3 clinical trial arms 
included patient specific dose personalization at both the initial dose 
prediction and the adjustment stage of the algorithm. In contrast, PG-1 and 
Clinical arms only included warfarin dose personalization at the initiation stage 
of warfarin therapy. As noted above PG-1 produced superior clinical outcome 
metrics for all subpopulations within the AHC study population. Additionally, 
the clinical arm produced non-inferior clinical outcome metrics to the PG-2 
arm and PG-3 arm for the whole AHC population. However, PG-based 
subpopulations did demonstrate superior outcomes with the PG-2 and PG-3 
arms.  
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Nevertheless we must reject our second hypothesis that predicted clinical 
outcomes improve proportionally to the degree of dose personalization across 
the entire AHC population. While personalization in general provides superior 
outcomes when compared to a “one-size fits all” approach for the AHC best-
practice warfarin management, greater inclusion of personal characteristics 
within the dosing algorithm does not improve clinical outcome metrics across 
the whole AHC population for primary outcome metrics.  
  
235 
 
 
 
5.5.) References: 
Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., 
Nicholas, Z. P., et al. (2007). Randomized trial of genotype-guided versus 
standard warfarin dosing in patients initiating oral anticoagulation. Circulation, 
116(22), 2563-2570. 
 
Anderson, J. L., Horne, B. D., Stevens, S. M., Woller, S. C., Samuelson, K. 
M., Mansfield, J. W., et al. (2012). A randomized and clinical effectiveness 
trial comparing two pharmacogenetic algorithms and standard care for 
individualizing warfarin dosing (CoumaGen-II). Circulation, 125(16), 1997-
2005. 
 
Bellazzi, R., & Zupan, B. (2008). Predictive data mining in clinical medicine: 
current issues and guidelines. International journal of medical informatics, 
77(2), 81-97. 
 
Clyde, M. A., & Lee, H. K. (2001). Bagging and the Bayesian bootstrap. In 
Artificial Intelligence and Statistics (Vol. 169174). 
 
Fiore, M. C., Novotny, T. E., Pierce, J. P., Hatziandreu, E. J., Patel, K. M., & 
Davis, R. M. (1989). Trends in cigarette smoking in the United States: the 
changing influence of gender and race. Jama, 261(1), 49-55. 
 
Fusaro, V. A., Patil, P., Chi, C. L., Contant, C. F., & Tonellato, P. J. (2013). A 
systems approach to designing effective clinical trials using simulations. 
Circulation, 127(4), 517-526. 
 
García-Laencina, P. J., Sancho-Gómez, J. L., & Figueiras-Vidal, A. R. (2010). 
Pattern classification with missing data: a review. Neural Computing and 
Applications, 19, 263-282. 
 
Jiang, W., & Simon, R. (2007). A comparison of bootstrap methods and an 
adjusted bootstrap approach for estimating the prediction error in microarray 
classification. Statistics in medicine, 26(29), 5320-5334. 
 
Kovacs, M. J., Rodger, M., Anderson, D. R., Morrow, B., Kells, G., Kovacs, J., 
et al. (2003). Comparison of 10-mg and 5-mg warfarin initiation nomograms 
together with low-molecular-weight heparin for outpatient treatment of acute 
venous thromboembolism. A randomized, double-blind, controlled trial. Annals 
of internal medicine, 138(9), 714-719. 
 
Kuskowska-Wolk, A., Bergström, R., & Boström, G. (1992). Relationship 
between questionnaire data and medical records of height, weight and body 
236 
 
 
 
mass index. International journal of obesity and related metabolic disorders: 
journal of the International Association for the Study of Obesity, 16(1), 1-9. 
 
 
Marot, A., Morelle, J., Chouinard, V. A., Jadoul, M., Lambert, M., & Demoulin, 
N. (2011). Concomitant use of simvastatin and amiodarone resulting in severe 
rhabdomyolysis: a case report and review of the literature. Acta Clinica 
Belgica, 66(2), 134-136. 
 
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., 
Nicholson, T., et al. (2013). A randomized trial of genotype-guided dosing of 
warfarin. The New England journal of medicine, 369(24), 2294-2303. 
 
R Core Team. (2014). R: A language and environment for statistical 
computing. Vienna, Austria: R Foundation for Statistical Computing. Retrieved 
August 1, 2014, from http://www.R-project.org/ 
 
Rosendaal, F., Cannegieter, S., Van Der Meer, F., & Briet, E. (1993). A 
method to determine the optimal intensity of oral anticoagulant therapy. 
Thrombosis and haemostasis, 69(3), 236-239. 
 
Scheines, R., Spirtes, P., Glymour, C., Richardson, T., & Meek, C. (1998). 
The TETRAD Project : Constraint Based Aids to Model Specification. 
Multivariate Behavioral Research, Vol. 33, N. 1, 65-118, & "Reply to 
Commentary," same issue, 165-180. 
 
Scott, S. A., Khasawneh, R., Peter, I., Kornreich, R., & Desnick, R. J. (2010). 
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and 
ethnic groups. Pharmacogenomics, 11(6), 781-791. 
 
Spirtes, P., Glymour, C. N., & Scheines, R. (2000). Causation, prediction, and 
search. 2nd edition. New York, NY: MIT Press. 
 
University of Wisconsin-Milwaukee. (2014). High Performance Computing 
Research Cluster Avi. Retrieved July 17, 2014 from www.uwm.edu/hpc/ 
 
Wilson, S. E., Costantini, L., & Crowther, M. A. (2007). Paper-based dosing 
algorithms for maintenance of warfarin anticoagulation. Journal of thrombosis 
and thrombolysis, 23(3), 195-198. 
 
 
 
  
237 
 
 
 
Chapter 6: Secondary use of electronic medical records to enhance in silico 
comparative effectiveness research: An application to anticoagulation health 
disparity 
 
6.1.) Background and Significance 
6.2.) Objective 
6.3.) Materials and Methods 
6.3.1.) Secondary Use of Large Diverse Healthcare EMR 
6.3.1.1.) EMR Extraction, Transformation, and Loading 
6.3.2.) WiAD and WiAD-Miner 
6.3.3.) Pharmacogenetic Clinical Trial Simulator (PCTS)  
6.3.4.) Study Population 
6.3.5.) In Silico PC-CER Study Design 
6.3.6.) Statistical Analysis 
6.4.) Results 
6.4.1.) General Characteristics of WiAD Warfarin Cohorts 
6.4.2.) General Characteristics of Clinical Avatar Cohorts  
6.4.3.) WiAD Warfarin Cohorts’ Outcome Metrics 
6.4.4.) Clinical Avatar Cohorts’ Outcome Metrics 
6.4.5.) Comparison between WiAD Warfarin Cohorts and Clinical Avatar 
Cohorts 
6.5.) Discussion 
6.6.) Conclusion 
6.7.) References  
  
238 
 
 
 
6.1.) Background and Significance 
The Patient Protection and Affordable Care Act (PPACA, 2010) established 
Patient-Centered Comparative Effectiveness Research (PC-CER) as a US 
national medical research priority. Under PPACA, the Patient-Centered 
Outcomes Research Institute (PCORI, 2014) was charged to support 
research that investigates effectiveness and outcomes of health care 
treatments, medical services, and clinical care in subpopulations 
(Methodology Committee of PCORI, 2012). Subpopulations may be defined 
by race, ethnicity, gender, age, and medical and physiologic inclusion criteria 
such as disease, comorbidities, genotype or cancer molecular subtype. 
Current PCORI research focus includes secondary use of electronic medical 
records (EMR) to build clinical research databases (Selby, 2012) to conduct a 
spectrum of PC-CER studies including health care disparity in part by seeking 
evidence of treatments’ effectiveness across various populations. 
Socioeconomic status (SES) is one of the most powerful drivers of population-
level health outcomes and lower SES is consistently associated with poorer 
health outcomes (Adler, 1994a, 2008b). Consequently, one such CER area is 
health care outcome disparity observed across SES-based on education and 
income (PCORI, 2014). Another PC-CER area of immense interest to 
biomedical scientists and medical geneticists is the use and value of genetic 
tests, data and information intended to improve public health. No studies to 
date have tested if genetics can reduce SES-based health disparity outcome.   
Warfarin treatment effectiveness studies have potentially high health SES-
based disparity impact when comparisons include genetic-based against 
other “best practice” means of achieving therapeutic dosing. Warfarin’s 
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therapeutic dosing is complicated by a narrow therapeutic index and large 
interindividual dose variability (up to 20-fold depending on genotypes, 
physiology, and compliance (e.g. Anderson, 2007; Momary, 2007; Wu, 
2007)). Compared to controlled clinical trial studies, optimization of warfarin 
dosing in the clinic using a “best” practice protocol is challenging due to 
variances in treatment monitoring (Mega, 2014) and must be balanced to 
prevent thromboembolism while avoiding overdosing that increases risk to 
bleeding events (Flaherty, 2007; Lip, 2011). 
PC-CER human subject studies to improve anticoagulation outcomes by 
optimal selection of warfarin dosing protocols is impractical (too large, 
complex and costly) if designed to test all or even many of the published 
pharmacogenetic-based (PGx) and non-PGx dosing algorithms applied to 
important (and numerous) CER subpopulations.  We have created and 
validated a pharmacogenetic clinical trial modeling and simulation platform 
(Fusaro, 2013) to conduct in silico complex CER simulations to test PGx 
treatment protocols against key patient subpopulations with a goal to predict 
improved treatment outcomes. In this study, we extend the application of the 
platform to include EMR data of a representative large US healthcare system 
with diverse population to conduct a CER study between warfarin treatment 
protocols. In addition to typical CER study design factors, we profile the study 
population by SES and indicate how outcomes may be affected by 
educational and income status as experienced in Milwaukee. 
6.2.) Objective 
We create an anticoagulation patient EMR database from patients treated by 
warfarin at Aurora Health Care system (AHC), a Milwaukee based network, 
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where an institution-wide standardized warfarin best practice treatment 
protocol has been in effect for the last decade. Thereafter, we use the 
database to identify SES outcome disparity and as input to our simulation 
platform that models patient subpopulations, individual patient treatment and 
outcomes, simulates use of multiple anticoagulation protocols, predicts patient 
and population outcomes, and tests those predictions against patient data 
extracted from the database. We then execute an in silico study that tests four 
warfarin dosing protocols against two (simulated) EMR-based SES 
subpopulations to predict if any of the four protocols reduces the outcomes 
disparities. This PC-CER study demonstrates how large comprehensive 
EMRs covering diverse patient populations, coupled with novel modeling and 
computational simulations, provides opportunity to conduct and in part 
validate, in silico CER in diverse populations. 
We first provide a general description of the in silico approach, then describe 
and apply the methods used to test differences between PGx versus non-PGx 
anticoagulation treatment in a diverse Milwaukee population, and finally, 
demonstrate how the results can be used to demonstrate treatment outcomes 
such as “percent Time in Therapeutic Range” (TTR) of International 
Normalized Ratio (INR) and frequency of INR tests (Gouin-Thibault, 2010; 
Koertke, 2003; Sawicki, 1999; White, 1989; Horstkotte, 1998) and validation 
stratified by various factors including SES. 
6.3.) Materials and Methods 
The in silico PC-CER approach starts with extraction of EMR patient data 
pertinent to the objective of the study. In this study, we extract and transform 
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anticoagulation patient records from AHC over the period 2002-2011 (Figure 
6.1 Panel A. AHC EMR). 
 
Next, we uploaded the data into a minable database (Wisconsin 
Anticoagulation Database, WiAD, Figure 6.1, Panel A.) and created a data 
mining application (WiAD-Miner). The in silico approach then requires a study 
design complementary to the objective of the PC-CER and uses our 
previously published Pharmacogenetic Clinical Trial Simulation (PCTS)  
platform (Figure 6.1, Panel B), (Fusaro, 2013) and an iterative PC-CER 
modeling workflow that couples the strength of the EMR database with the 
simulation platform (Figure 6.1.). Testing and validating proposed improved 
treatment protocols against best practice are represented by dotted lines in 
Figure 6.1. Herein, we present the methods for each component of the in 
Figure 6.1. Our two component in silico PC-CER approach consists 
of a process for the secondary use of EMR data (Panel A) and a 
study design and simulation platform (Panel B). The iterative use of 
the two components can be applied to comparative effectiveness 
and healthcare disparity research. 
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silico PC-CER approach when applied to test if genetics can reduce SES-
based outcome disparity in anticoagulation therapy. 
6.3.1.) Secondary Use of Large Diverse Healthcare EMR 
AHC is the largest health care system in Wisconsin serving approximately 1.2 
million unique patients each year through 7.8 million patient encounters per 
year. AHC’s EMR is the most comprehensive (by size, type of health care and 
period of time) digitized health care resource of Southeast Wisconsin’s 
population capturing urban, suburban, and rural constituents of all racial, 
ethnic, and socioeconomic backgrounds. This resource provides a unique 
opportunity to capture data and information vital to conducting retrospective 
and predictive PC-CER studies. However, the same factors that make AHC’s 
EMR extremely valuable (size, scope and longitudinal extent) to PC-CER 
objectives in general, create great difficulty in capturing the targeted data 
important to a particular PC-CER study. Consequently, we have created a 
modular and replicable method to identify, extract, transform and load process 
and tools to mine EMRs and produce a highly enriched PC-CER 
knowledgebase that provides both input to and validation of our CER studies.  
 6.3.1.1.) EMR Extraction, Transformation, and Loading 
The AHC EMR was mined to extract all patients with evidence of prescription 
of: Coumadin (Warfarin), Heparin, Ticlopidine (Ticlid), Clopidogrel (Plavix), 
Dipyridamole (Persantine), Abciximab (ReoPro), Eptifibatide (Integrilin), 
Tirofiban (Aggrastat), or Dabigatran (Pradaxa) over the period of 2002 to 
2011. Patient data was de-identified per IRB approval (allowing zipcode) by 
an AHC honest broker before distribution to the research team. Longitudinal 
data records of 157,450 patients including: gender, race, height, weight, age, 
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day of visit, patient's zipcode, patient's city, provider's zipcode, smoking 
status, INR, medications received (day, dose, frequency), interacting 
medications (Amiodarone, Simvastatin, Fluvastatin, Lovastatin, Atrovastatin, 
Rosuvastatin, Pravastatin, Aspirin), medication indications (by ICD-9 codes: 
Orthopedic surgery-hip or knee, Deep Vein Thrombosis (DVT), Pulmonary 
embolism, Atrial fibrillation, Atrial flutter, Atrial fibrillation and flutter, Stroke, 
Heart valve replacement) and comorbidities (by ICD-9 codes: DVT, 
Pulmonary embolism, Stroke, Myocardial infarction, Bleeding). Subsequent 
data cleaning, quality control and quality assurance include an iterative 
process of data parsing to detect irregularities; statistical analysis designed to 
test population-wide distributions and possible biases; refinement of inclusion 
and extraction data mining codes to address irregularities, possible missing 
data and detected biases; and ultimately, data transformation to produce a 
cohesive set of records capturing all available medical records in a consistent 
format following Weiskopf (2013). Representative of our process was the 
complex method to produce consistent primary and secondary anticoagulation 
outcome metrics such as longitudinal metric TTR in targeted range and 
frequency of INR values. INR frequency is required to assess outcome 
metrics from EMR data since patients seen in the best practice clinical setting 
typically do not experience the same frequency of INR monitoring and 
corresponding dose adjustment as experienced for the controlled clinical trial 
setting (Mega, 2014). 
All extracted INR values and frequency were tested against physiological, 
treatment and compliance consistency criteria such as exclusion criteria:  (a) 
INR values ≤ 1.2 since such values are likely unrelated to warfarin therapy 
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(White, 1989), (b) INR values ≥ 10 consistent with the upper limit of AHC lab's 
reference range and (c) problematic INR values during fixed 5mg/day warfarin 
exposure periods (Sagreiya, 2010). We also profiled patients by defined 
treatment periods (e.g. fixed time or medical procedure periods) during which 
TTR calculations are likely well defined. For example, the warfarin exposure 
period was defined by a combination of time period and frequency of INR 
values (at least two INR values in a 90 day window). For those individuals 
“profiled” by the defined treatment period, the TTR was calculated using the 
linear interpolation method of Rosendaal (1993). This method assumes a 
linear relationship between two consecutive INR results, assigns an INR value 
to each day between successive observed INR values, and determines the 
proportion of time for which the INR is below, within or above the therapeutic 
range (i.e., time in which patient INR values were between 2 and 3). Then, the 
individual warfarin exposure period TTRs and mean TTR ( TTR  ) was 
calculated for each patient.  
6.3.2.) WiAD and WiAD-Miner 
After rigorous data extraction, quality control and transformation, the de-
identified patient record “cleaned” data (157,450 records reference above), 
tagged profiles and related metadata were loaded into WiAD. The WiAD 
patient subpopulation of AHC includes 49.65% female and 50.35% male with 
mean age of 67.99 yo (female) and 65.22 yo (male). WiAD patients are 
geographically distributed across all 72 counties of Wisconsin and WiAD’s 
racial distribution is consistent with that of the state. 47.8%, 10.4% and 1.9% 
of WiAD patients have evidence of only 1, 2, or 3 medications respectively. In 
addition to the AHC patient data, WiAD includes complementary data such as 
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Wisconsin population statistics, demographics, and US census data to 
expand the “knowledgebase” and provide more robust information for the 
subsequent simulations and predictions. An interactive data profiling and 
population “segmentation” tool (WiAD-Miner) includes all the profiling (e.g. 
warfarin only exposure patients), outcome metric (e.g. TTR  based on 
warfarin exposure period) and related data analysis functions described 
above and developed in R (R Core Team, 2013). WiAD-Miner includes a 
cohort selection tool to profile and identify patient subpopulations by any or a 
combination of patients’ characteristics including gender, age group, race, 
patient's residence zipcode, provider's zipcode, medication, medication 
exposure, duration of treatment, number of dose records, frequency of INR 
values, medication indication, and comorbidities. WiAD-Miner allows 
adjustment of various parameters such as the medication exposure period 
definition, triggering a re-profiling and thereafter, re-calculation of outcome 
metrics. 
6.3.3) Pharmacogenetic Clinical Trial Simulator (PCTS)  
Our pharmacogenetic clinical trial simulator (Figure 6.1. Panel B) consists of 
the 5 following adjustable modeling components: 1) A Bayesian network 
model (BNM) derived from a study population to produce the virtual patient 
population (“Clinical Avatars”) consistent with study population, 2) A module 
that sets study conditions such as number of subjects, initial dosing, length of 
study, number of replications, and similar, 3) A circulating medication 
concentration and INR predictor based on appropriate 
pharmacokinetic/pharmacodynamics (PK/PD) model (e.g. Hamberg, 2007), 4) 
A treatment dose algorithm that uses INR or other pertinent physiological 
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variables and invokes a treatment protocol (see details for warfarin treatment 
below), and 5) A study healthcare outcome calculator (e.g., TTR). This five-
component simulator was validated by significant testing against major 
pharmacogenetic anticoagulation clinical trials such as CoumaGen-I and –II 
(Anderson, 2007a, 2012b). The validation included statistically consistent 
clinical simulations and predictions against the published 90 day, multi-
treatment protocol CoumaGen-I results (Fusaro, 2013). All simulations were 
implemented in R (R Core Team, 2013) and performed on the local high 
performance computing research cluster Avi (UWM, 2014). The PCTS 
platform includes the generation of Clinical Avatar populations that mirror the 
study population’s statistical characteristics and are consistent with the EMRs 
of actual patients. Thereafter, the representative synthetic patient populations 
are used to conduct replicated clinical simulations testing multiple 
anticoagulation medication-protocol options.  
6.3.4.) Study Population 
In this study, WiAD-Miner was used to identify all WiAD patients exposed only 
to warfarin from 2002-2011 whose records include complete demographic 
(e.g. race) and geographic data (n=16,900), hereafter this group is called the 
WiAD warfarin population. For the purpose of calculating treatment outcomes 
and identification of SES status in this study, the WiAD warfarin population 
subjectswhose records satisfied the following criteria were selected (a) the 
inclusion criteria: (1) zipcode in Milwaukee, (2) treatment periods between two 
successive INR values of 90 days or less and (b) the exclusion criteria:  (1) 
periods of warfarin exposure interruptions (e.g., hospitalization), and (2) 1 
week before and 3 weeks after warfarin exposure interruptions. With these 
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criteria, WiAD-Miner identified 1085 WiAD warfarin population subjects who 
were then socioeconomically profiled by SES levels across the three 
“Milwaukee SES zipcode” groups as defined in the 2012 Milwaukee Health 
Report (Chen, 2012) resulting in a “lower SES” (n=191), “middle SES” 
(n=716) and “upper SES” (n=178) subpopulations. 
6.3.5.) In Silico PC-CER Study Design 
The PC-CER Study design is based on the comparative effectiveness 
research aim to detect protocols that improve outcomes and minimize 
disparity. The PCTS simulation platform requires three specifics: 
Medication(s) and treatment protocols to be tested; Subpopulation(s) to be 
studied; and the length of the treatment period and the treatment outcomes. 
Warfarin dosing protocols typically include three components - an early (1-2 
day) warfarin loading dose “initial” protocol followed by a relatively short dose 
“adjustment” protocol (typically 3-5 days) followed by the therapeutic dose 
“maintenance” period as needed for treatment. For these simulations, we use 
four three-component warfarin dosing protocols over a fixed 90 day simulation 
period: non-PGx CoumaGen-I Standard (Anderson, 2007) PGx CoumaGen-I 
PG (Anderson, 2008), PGx CoumaGen-II PG-2 Arm (Anderson, 2012) and the 
PGx Wilson as defined in Fusaro (2013) denoted CG-I STD, CG-I PG and 
CG-II PG-2, and “Wilson” respectively (Figure 6.2). 
Clinical Avatars Study Population: The Milwaukee lower SES and the 
Milwaukee upper SES subpopulations as defined above were used in this 
study. A BNM was developed and trained on the WiAD warfarin population. 
The BNM method is described in Fusaro (2013). The Directed Acyclic Graph 
(DAG) produced by fitting the WiAD warfarin population to the optimal BNM 
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was used to produce all clinical avatars used in this study. The BNM's 
conditional probability table ("CPT") was adjusted to reflect the correlation 
structure found in the data of the two subpopulations. CPT prior probabilities 
for the BNM require statistical characterization of the subpopulation including 
age, gender, weight, height, race, body surface area (calculated from height 
and weight), tobacco use status, amiodarone use status, and genotypes for 
CYP2C9 and VKORC1. Statistics of the demographic and clinical information 
for each of the subpopulations were calculated by WiAD-Miner. The genotype 
statistics came from a study which determined individual and combined 
frequencies of important genetic variants associated with warfarin metabolism 
in several racial and ethnic groups (Scott, 2010). Using the BNM and related 
R software, we created a sufficient number of clinical avatars (191 x 1000 
replicates for lower SES and 178 x 1000 replicates for upper SES) to conduct 
one thousand parallel simulations of each arm of the study (Figure 6.2).  
PC-CER Simulation: For each Clinical Avatar study set (191 lower clinical 
avatars and 178 upper clinical avatars), a 90 day simulation was performed 
for each Clinical Avatar using each of the four PGx and non-PG protocols. All 
results were stored in a structured format representing the 1000 x 90 day 
study simulations for each clinical avatar in the study subpopulations. 
Simulation records included: clinical avatar record, simulated INRs and dose 
values (1 per day for each of 90 days) and calculated TTRs using Rosendaal 
method (Navathe, 2011). Statistical analysis was applied across the 1000 
replicated simulations between the two SES groups. 
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6.3.6.) Statistical Analysis  
All statistical analyses were conducted with R (R Core Team, 2013). 
Statistical significance was set at p<0.05, unless otherwise noted. Single 
factor differences between subpopulations were tested using either a 
parametric (unpaired t-test, for normal distributions) or a nonparametric test 
(Wilcoxon-Mann-Whitney, for non-normal distributions). Comparisons 
between the simulated cohorts for TTR were made by using one-way ANOVA 
tests along with the Tukey post-hoc honestly significant difference (HSD) test 
to examine the TTR variances across the SES-based subpopulations. Two 
way ANOVA test was used to detect possible interactions between 
characteristics race and SES on TTR for data corresponding to the WiAD’s 
Figure 6.2. The study’s design with 4 arms. 
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cohorts. Results are expressed as mean ± standard error of the mean (SEM) 
unless otherwise specified. 
6.4.) Results 
6.4.1.) General Characteristics of WiAD Warfarin Cohorts 
A total of 369 warfarin patient were identified across the Milwaukee lower SES 
(n=191) and upper SES (n=178) groups (2nd and 3rd columns of Table 6.1). 
Mean (SD) age of upper and lower SES patients were 73.74 (14.4) and 61.69 
(16.18) respectively. There was no significant difference (p>0.05) in either 
gender or height but average weight and tobacco use of the lower SES was 
higher than the upper SES cohort. The racial profile of the lower SES cohort 
was very different from the upper SES cohort (e.g. 53.9% versus 93.8% 
white).  
6.4.2.) General Characteristics of Clinical Avatar Cohorts  
The statistical characteristics of the clinical avatars simulated to represent the 
study subpopulations, are presented in the 4th and 5th columns of Table 6.1. 
All demographic and clinical characteristics of the clinical avatar cohorts were 
statistically the same as the Milwaukee warfarin lower and upper SES study 
cohorts. Genotype frequencies were matched to those published for 
populations equivalent to the AHC (Scott, 2010).  
6.4.3.) WiAD Warfarin Cohorts’ Outcome Metrics 
The outcome metrics for this study were TTR and number of INR (Figures 6.3 
and 6.4). Lower SES cohort had significantly lower TTR compared to Upper 
SES (39.82%±1.9 vs 48.88%±1.83, P<0.05). Lower SES cohort had 
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Table 6.1. Basic characteristics of the WiAD warfarin and clinical avatars 
cohorts. (1) The WiAD warfarin cohorts’ genotypes were imputed using 
Scott’s distributions, correlations and joint distributions (Scott, 2010). 
Characteristics 
WiAD Warfarin Cohorts Clinical Avatar Cohorts 
Milwaukee 
Lower SES 
Milwaukee 
Upper SES 
Lower SES Upper SES 
Number of Patients 191 178 191 178 
Age, year, mean (SD) 61.6 (16.1) 73.74 (14.4) 61.29 (15.9) 73.38 (14.3) 
Gender, female % 59.1 56.1 59.2 57.4 
Weight, kg, mean 
(SD) 
91.2 (26.2) 84.5 (24.7) 94.4 (25.4) 87.7 (24.6) 
Height, in, mean (SD) 66.13 (4.2) 66.25 (4.9) 66.28 (3.7) 65.78 (3.7) 
Race, % 
   White 
   African American 
   Asian 
 
53.9 
44.5 
1.6 
 
93.8 
5.6 
0.6 
 
53.8 
44.8 
1.3 
 
93.9 
5.4 
0.6 
Tobacco use, % 10.9 5.0 10.7 5.3 
Amiodarone use, % 12.0 12.9 11.4 13.2 
DVT, % 26.1 17.4 29.7 18.4 
VKORC1, % 
   A/A 
   G/A 
   G/G 
(1) 
10.5 
32.5 
56.8 
            (1) 
16.9 
43.5 
39.4 
 
9.7 
33.0 
57.2 
 
16.4 
42.1 
41.2 
CYP2C9, % 
   *1/*1 
   *1/*2 
   *1/*3 
   *2/*2 
   *2/*3 
   *3/*3 
(1) 
70.4 
10.1 
6.5 
3.6 
1.1 
0.7 
(1) 
66.5 
14.4 
9.0 
6.2 
1.8 
0.2 
 
71.1 
8.6 
6.0 
3.0 
1.0 
1.1 
 
67.4 
13.3 
8.5 
5.4 
1.9 
0.3 
 
significantly lower number of INR than Upper SES (7.0 vs 13.0, median, 
respectively, p<0.05). No significant interaction between SES group and race 
on TTR was present (two-way ANOVA, p<0.05). In the absence of interaction 
with race, SES had significant effect on TTR . 
6.4.4.) Clinical Avatar Cohorts’ Outcome Metrics 
Figure 6.3 presents the Milwaukee lower (left panel) and upper (right panel) 
SES clinical avatar cohorts’ TTR computed for CG-I STD, CG-I PG, CG-II PG-
2 and Wilson in order. 
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 For the lower SES cohort, all PGx protocols produced significantly higher 
results than the non-PGx protocol and the Wilson protocol was highest 
(42.41±2.26 vs 52.04±2.24, 56.53±1.93, 73.84±1.52, ANOVA, p<0.05). The 
same result was true for the upper SES cohort (38.85±0.74, 52.58±0.53, 
52.46±0.44, 75.66±0.49, ANOVA, p<0.05). The averaged TTR predicted by 
the Wilson protocol for the two clinical avatar cohorts were not significantly 
different. The average 90 day frequency of INR predicted for each protocol 
was shown in Figure 6.4 (Lower SES, left panel, Upper SES, right panel).  
For the lower SES cohort, the CG-I STD protocol predicted significantly higher 
frequency of INR than either CG-I PG or Wilson protocol (10.2±0.4 vs 
9.4±0.16 and vs 8.7±0.3, ANOVA, p<0.05). Whereas in the upper SES clinical 
avatar cohorts, the predicted frequency of INRs were not different. 
Figure 6.3. Averaged TTR for lower and upper SES clinical avatar cohorts by 
dosing protocol (left and right panel). Capped vertical lines represent standard 
error of the mean. For both cohorts, the Wilson protocol’s TTR was 
significantly higher than any other protocol (ANOVA, p<0.05). 
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 6.4.5.) Comparison between WiAD Warfarin Cohorts and 
Clinical Avatar Cohorts 
Averaged TTR was not significantly different between the Milwaukee lower 
SES cohort (calculated from EMR data) under current AHC non-PGx best 
practice protocol when compared to the equivalent clinical avatar cohort under 
the CG-I STD dosing protocol (39.82%±1.9 vs 42.41±2.26) and was 
significantly less than the three PGx protocol predictions (39.82%±1.9 vs 
52.04±2.24, 56.53±1.93, 73.84±1.52, ANOVA, p<0.05). Averaged TTR for the 
Milwaukee upper SES cohort is significantly more than that predicted for the 
upper SES clinical avatars using CG-I STD (48.88%±1.83 vs 38.85±0.74) and 
significantly less than that predicted using the Wilson protocol (48.88%±1.83 
vs 75.66±0.49). 
Figure 6.4. Averaged frequency of INRs for lower and upper SES clinical 
avatar cohorts by dosing protocol (left and right panel). Capped vertical lines 
represent standard error of the mean. For both cohorts, the Wilson protocol’s 
frequency of INRs was significantly lower than any other protocol (ANOVA, 
p<0.05). 
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6.5.) Discussion 
In this study, we present an in silico pharmacogenetic anticoagulation PC-
CER approach applied to a patient-centered outcomes simulation that 
produced a prediction that was validated with patient data acquired directly 
from a large hospital transaction electronic medical record system. We 
applied this approach to a well-documented health disparity cohort defined by 
a Milwaukee SES index. Upper and lower SES patients treated by warfarin 
using the healthcare system’s best practice dosing protocol were extracted 
from the EMR and simulated to predict treatment outcomes under four 
different warfarin dosing protocols. The approach we used in this study 
includes three key elements (Figure 6.1.):  a) High quality EMR derived data 
set and data mining environment (WiAD) from which clinical-trial like outcome 
metrics are extracted; b) Means to conduct complex multi-factorial 
anticoagulation simulation study designs (PCTS) and predict outcome metrics 
from multiple treatment protocols; and c) Means to test the predicted outcome 
metrics against those derived from the EMR (WiAD-Miner).  
It has been suggested that meaningful patient-centered outcomes research 
need high-quality data, including greater clinical detail, longitudinal follow-up, 
and linkages among data sets (Navathe, 2011). An important result of this 
work is the dynamic collection of anticoagulation treated patient data and 
related information encapsulated in WiAD in support of our PC-CER study. 
WiAD includes over 150,000 Wisconsin resident patients spanning some ten 
years of anticoagulation diagnosis, treatment and outcome data derived from 
the Aurora Health Care EMR and all data was processed using a two-step 
extraction and transformation method including completeness, correctness, 
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and concordance (Weiskopf, 2013). We used WiAD to select the two 
Milwaukee warfarin SES subpopulations and calculate both TTR and number 
of INRs. The lower SES subpopulation’s TTR was significantly less than the 
upper SES subpopulation’s TTR beyond any interaction based on race or 
ethnicity alone. This result is consistent with the Milwaukee Heath Report 
2012, which indicated that dramatic health disparities by SES exist and persist 
within Wisconsin’s largest city (Chen, 2012). Our results demonstrate that this 
disparity is correlated to SES and may be explained by doctor-patient 
relationships as demonstrated in previous studies (Schouten, 2006; Bates, 
2009).  
The 90-day warfarin therapy simulation predicted similar outcome for the 
standard non genotype-based dosing protocol (non-PGx CG-I STD) to those 
calculated for the lower SES subpopulation using the EMRs.  Surprisingly, the 
approach also predicted a similar level of averaged TTR (38.85%) for the 
upper group under the standard protocol as the lower subpopulation even 
though the upper subpopulation’s EMR-calculated averaged TTR was much 
higher (48.88%). This result indicates that the actual outcomes of upper SES 
group in the healthcare system is much higher than one would predict with 
consistent application of the same protocol across all patients independent of 
SES. In addition, the predictions suggest that the warfarin genotype-based 
Wilson protocol would produce the highest averaged TTR across the two SES 
subpopulations while requiring a significantly lower frequency of INR values 
for the lower SES subpopulation. Consistent with our predictions for a revised 
CoumaGen-I trial (Fusaro, 2013). the Wilson protocol produced the best 
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outcomes of all protocols and simultaneously dramatically reduced the health 
disparity between the lower and upper SES subpopulations.   
6.6.) Conclusion 
Multifactorial PC-CER clinical trials designed to test the optimal treatment 
against multiple subpopulations create a complex and costly paradigm whose 
results will guide improved healthcare. Part of this complexity can be 
addressed using judiciously developed and validated mathematical modeling 
and simulations. Herein, we demonstrated the value of using EMRs to extract 
clinical-trial like anticoagulation outcome metrics and detect possible 
disparities within the study population. We applied the approach to a study 
population that includes individuals who historically experience health 
disparity to simulate patient outcomes using one non-PGx and three PGx 
protocols. Our results indicate that the Wilson genotype-based warfarin 
protocol applied systematically to all patients, improves outcomes overall and 
reduces the observed health disparity. If validation studies designed to test 
these predictions prove true, then the optimal warfarin protocol translated into 
the healthcare setting will improve best practice as suggested in Figure 6.1’s 
dotted lines. The combination of in silico studies followed by carefully 
designed targeted validation studies, suggests a powerful approach to 
improve healthcare overall and reduce health disparity in particular. 
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7.1.) Conclusion 
The concept of “translational research” is relatively new. In a commentary in 
JAMA, Woolf has pointed out that “translational research means different 
things to different people” (Woolf, 2008). The newly established NIH’s 
National Center for Advancing Translational Sciences has defined 
“Translation” as “the process of turning observations in the laboratory and 
clinic into interventions that improve the health of individuals and the public - 
from diagnostics and therapeutics to medical procedures and behavioral 
changes” (NCATS, 2014). According to their definition, translational science is 
“the field of investigation focused on understanding the scientific and 
operational principles underlying each step of the translational process” 
(NCATS, 2014). As such, translational research models are designed to 
“translate” discoveries identified through basic science studies (whether 
gained in animal models of human disease or through human studies), to 
knowledge concerning the potential value of the discovery’s application in 
medicine.  
Translational research in genomics, specifically pharmacogenomics as one of 
the first clinical applications of the new genomic era, aims to move promising 
genomic applications to clinical and public health practice for population 
health benefit (Cleeren, 2011). Despite the demonstrable benefits of many 
new genomic discoveries, there have been gaps between the explosive 
growth in scientific discovery and technology and the implementation of this 
new knowledge. It is widely recognized that the current translational process 
is slow, very expensive and often results in an incomplete transfer of research 
findings into practice, and consequently failure of comparative effectiveness 
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studies used to translate the findings into substantial changes in patient care 
and health disparities (Khoury, 2007). A study aiming to evaluate the 
predictors of and time taken for the translation of highly promising basic 
research into clinical applications, over a 15-year period, showed that only 
about 5% of the basic science findings were licensed for clinical use and only 
1% were extensively used for the licensed indications (Contopoulos-Ioannidis, 
2003). 
Although a large number of translational research models have been 
developed over the time, however, no existing model has adequately 
addressed the pressing need to create a process and pragmatic approach 
that will cover the ever expanding collection of high-throughput, individualized 
data that is generated by ever advancing technology. In short, the deluge of 
big data especially in the light of expanding electronic medical record systems 
(EMRs) and genomic era has overwhelmed the antiquated models and 
processes designed to translate important and growing data and evidence to 
the healthcare setting. These models are further weakened when considering 
the important area of patient-centered, comparative effectiveness research 
and the potential disparity of outcomes when coarse applications are applied 
to diverse populations. Given these facts and the need to address many 
complex real-world healthcare questions in short periods of time, it seems that 
alternative research designs and approaches should be considered in 
translational research.  
Taking into consideration these facts, in this dissertation, I have proposed an 
iterative and bidirectional agile translational research model enhanced with an 
in silico knowledge synthesis model (iS-TR) to facilitate pharmacogenomic 
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patient-centered comparative effectiveness research (PC-CER) studies. I 
have hypothesized that retrospective EMR analysis and subsequent 
mathematical modeling and simulation predictions (a) may facilitate and 
accelerate the process of generating and translating pharmacogenomic 
knowledge, (b) may be applied to determine comparative effectiveness of 
anticoagulation treatment plan(s) tailored to well defined target populations, 
and (c) may result in a decrease in overall adverse risk and improve individual 
and population outcomes. 
To test the hypotheses, I have developed an In Silico PC-CER Approach for 
warfarin pharmacogenomics knowledge. The two-component In Silico PC-
CER Approach consists of a process for the secondary use of “Big EMR Data” 
resulting in a unique anticoagulation database, Wisconsin Anticoagulation 
Database (“WiAD”), and also a study design and clinical trial simulation 
platform. Once the simulation platform was validated by replicating and 
reproducing the results of two major warfarin pharmacogenomic clinical trials 
of CoumaGen-I and II (Anderson, 2007a, 2012b), the Approach was applied 
(a) to predict optimal anticoagulation treatment plan for the Aurora Health 
Care’s large heterogeneous patient population, and (b) to an anticoagulation 
therapy outcomes disparity in City of Milwaukee recognized as the most 
segregated metropolitan area in the country with a significant SES-based 
health disparity.   
The studies’ results have demonstrated that the In Silico PC-CER Approach 
taking advantage of retrospective EMR analysis and subsequent 
mathematical modeling and simulation prediction could facilitate and 
accelerate the process of generating and translating pharmacogenomic 
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knowledge on comparative effectiveness of anticoagulation treatment plan(s) 
tailored to well defined target populations (leading to a decrease in overall 
adverse risk and improve individual and population outcomes). Accordingly, 
we have concluded that the combination of in silico studies followed by 
carefully designed targeted validation studies would be a powerful approach 
to conduct PC-CER studies, improve healthcare overall and reduce health 
disparity in particular. 
7.2.) Limitations 
The In Silico PC-CER Approach provides many opportunities and we have 
demonstrated that it could be used as an effective approach to improve and 
facilitate translational research. However, given the complexity of the 
anticoagulation therapy in real clinical settings especially for warfarin, transfer 
of knowledge and evidence produced by the Approach to the real world 
clinical setting requires clinical judgment of the healthcare providers.  
Even though the Approach provides a great opportunity to conduct 
comparative effectiveness studies on heterogeneous study populations; 
however, real world clinical conditions will obviously vary and do not perfectly 
reflect the content or performance of the Approach. For instance, several 
foods and herbal supplements can interact with warfarin and affect its 
effectiveness. The current Approach does not include modules to take into 
consideration this kind of factors in its predictive outcomes. 
7.3.) Future Work 
In next few months, I will focus on improving the In Silico PC-CER Approach. 
One important step will be to expand and enrich WiAD by extracting and 
including more clinical information of the subjects allowing us to take 
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advantage of other predictive models such as CHA2DS2-VASc for risk of 
ischemic stroke (Lip, 2010) and HAS-BLED for risk of bleeding (Pisters, 
2010). The other task will be to design and conduct some validation studies of 
the predicted subpopulation anticoagulation treatment plans produced by the 
In Silico PC-CER Approach.   
I am also interested in applying the In Silico PC-CER Approach to other fields 
such as cancer recurrence and progression. The Approach also has great 
potential to be used as the basis of a Decision Support System for clinicians. 
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